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The Modulation of Non-steroidal Anti-inflammatory Toxicity as a Function of the 
Interplay between Uptake and Efflux Transporters 
Renato J. Scialis, PhD 
University of Connecticut, 2015 
Diclofenac is a commonly used anti-inflammatory drug in the treatment of arthritis and 
pain.  Although mechanisms of injury following diclofenac administration have been 
characterized, the roles that transporters have as modulators of exposure and toxicity 
remain unclear.  To that end, in vivo transporter models were used to assess the 
toxicokinetics of diclofenac and its major metabolites.  Whole body transporter knockout 
mice were administered diclofenac, and the dispositions of parent and metabolites were 
determined in bile, plasma, and liver.  Diclofenac and its reactive acyl glucuronide were 
shown to be substrates for the efflux transporter Bcrp.  Biliary excretion of diclofenac 
and its acyl glucuronide decreased in Bcrp knockout mice while only the plasma levels 
of the glucuronide increased compared to wild-type mice.  Diclofenac acyl glucuronide 
was likewise determined to be a substrate for the basolateral efflux transporter Mrp3 
evidenced by reduced plasma concentrations in Mrp3 knockout mice with no changes in 
biliary excretion.  Toxic challenge by diclofenac resulted in increased intestinal injury in 
Mrp3 knockout mice compared to wild-types.  In vitro assays revealed that human 
MRP3 also can transport diclofenac acyl glucuronide with apparent high affinity 
compared to human MRP2.  The uptake of diclofenac acyl glucuronide was shown to be 
mediated by human OATPs in an in vitro system, specifically OATP2B1 exhibited 
concentration-dependent active uptake kinetics.  As OATP2B1 and mouse Oatp2b1 are 
 
 
expressed along the intestinal tract, the active uptake of the glucuronide metabolite may 
be contributory to the intestinal toxicity observed in animal models and human patients.  
Mechanistic studies indicated that diclofenac acyl glucuronide was able to induce 
oxidative stress through creation of reactive oxygen species and inhibition of superoxide 
dismutase.  Furthermore, diclofenac acyl glucuronide was shown to be an inhibitor of 
both COX-1 and COX-2, which may also have contributed to intestinal injury.  Lastly it 
was demonstrated that diclofenac acyl glucuronide can inhibit human MRP4 that is 
upregulated during oxidative stress.  In summary, the data presented herein 
demonstrate the multifactorial pathways by which diclofenac acyl glucuronide is 
transported and contributes to tissue injury. 
 
 
 
 
 
 
 
 
 
 
i 
 
The Modulation of Non-steroidal Anti-inflammatory Toxicity as a Function of the 
Interplay between Uptake and Efflux Transporters 
Renato J. Scialis 
B.A., Hofstra University, 1996 
 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of 
Doctor of Philosophy 
at the 
University of Connecticut 
 
2015 
ii 
 
Copyright by 
Renato J. Scialis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2015 
iii 
 
APPROVAL PAGE 
Doctor of Philosophy Dissertation 
The Modulation of Non-steroidal Anti-inflammatory Toxicity as a Function of the 
Interplay between Uptake and Efflux Transporters 
Presented by 
Renato J. Scialis, B.A. 
 
Major Advisor             
     Jose E. Manautou, Ph.D. 
 
Associate Advisor             
     Xiao-bo Zhong, Ph.D. 
 
Associate Advisor             
     Christopher L. Shaffer, Ph.D. 
 
University of Connecticut 
2015 
iv 
 
DEDICATION 
 
To my wonderful wife Ayako who gave me endless patience and support while I 
followed my dreams, and for my late father Renato G. Scialis who was so proud of all I 
accomplished. 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
First and foremost my extreme gratitude and eternal thanks go to my lovely wife Ayako 
and my two children, Nanako and Makoto.  Without their love and encouragement, I 
could not have achieved this point in my life.  They sacrificed much, yet they gave me 
much in return.  All the hours toiled away in the lab or on the computer, either doing 
coursework or data analysis, I was able to do by drawing motivation from them.  They 
made it all worthwhile, and I look forward to sharing in their successes as they have 
shared in mine.  I love them dearly them.  And to my parents, Mr. Renato and Emma 
Scialis, my in-laws, Mr. Gunji and Takako Kawamura, and my uncle Walter Pastore who 
shaped my past and gave so much support, I am truly thankful. 
I am deeply grateful for having Dr. Jose Manautou as my advisor.  When I explored 
doctoral graduate programs, Dr. Manautou was quick to reach out and bring me into his 
lab.  I am amazed at his breadth of knowledge, and equally humbled by working under 
such a great person.  His compassion, direction, and guidance were truly remarkable 
during this journey.  I am honored to have studied under him, and thank him for helping 
me become a better scientist. 
My research would not have been possible without the vital contribution of my 
collaborators.  I am deeply appreciative for having worked with Dr. Ivan Csanaky who 
did much of the in vivo studies at the University of Kansas in Dr. Curtiss Klaassen’s 
group.  Dr. Csanaky’s masterful surgeries made our disposition studies truly remarkable.  
I would like to thank Dr. Lauren Aleksunes who conducted the initial studies and gave 
critical feedback over the years.  Dr. Mike Goedken, who provided valuable 
histopathology analysis, was also a key contributor to whom I owe immense gratitude. 
vi 
 
I would like to thank my thesis committee members, both past and present.  Dr. Chris 
Shaffer, who was my former supervisor at Pfizer, was unwavering in his support of me.  
Dr. Shaffer was instrumental in helping me overcome obstacles during my graduate 
studies, and I am in his debt.  My thanks go to Dr. Xiao-bo Zhong who joined my thesis 
committee after the retirement of former member Dr. Urs Boelsterli.  Dr. Zhong’s 
feedback during seminars was engaging and insightful.  And to Dr. Boelsterli who 
helped direct the research by offering his perspectives from his own diclofenac work, I 
am appreciative for his support and contribution to my work and investigative toxicology. 
I would like to recognize the following graduate students, post-docs, and visiting 
scholars from the Pharm/Tox program: Dr. Sarah Campion, Ms. Meeghan O’Connor, Dr. 
Dan Ferreira, Dr. Xinsheng Gu, Mr. Phil Rohrer, Dr. Amy Bataille, Dr. Carolina Ghanem, 
and Mr. Kyle Saitta.  My special thanks go to Dr. Swetha Rudraiah who endlessly 
helped me navigate the labs at UConn.  I also thank Mr. Daniel Albaugh with whom I 
shared much coursework, laughs, and frustrations.  His friendship was truly a blessing. 
My thanks go to Mr. Jonathan Chupka and Ms. Shelly Mireles, my former colleagues at 
Pfizer, who both taught me much about cell culture and transporter studies that became 
critically important during my doctoral research.  I also would like to thank my supervisor 
and managers at Pfizer, Dr. Chester Costales, Dr. Dave Rodrigues, and Dr. Larry 
Tremaine, for supporting my graduate studies while working full-time. 
Lastly I would like to thank Ms. Ione Jackman and Ms. Denise Woodard from the UConn 
Histology group for their technical support.  Ms. Woodard’s expertise was crucial in 
getting the immunohistochemistry assay to yield such robust staining. 
vii 
 
TABLE OF CONTENTS 
APPROVAL PAGE ....................................................................................................... iii 
DEDICATION ...............................................................................................................iv 
ACKNOWLEDGEMENTS ............................................................................................ v 
TABLE OF CONTENTS .............................................................................................. vii 
LIST OF FIGURES....................................................................................................... x 
LIST OF TABLES ....................................................................................................... xiii 
LIST OF ABBREVIATIONS ........................................................................................ xiv 
Chapter 1 REVIEW OF LITERATURE ............................................................................ 1 
1.1 Liver Overview ....................................................................................................... 1 
1.1.1 Structure and Function .................................................................................... 1 
1.1.2 Metabolic Enzymes and Transporters ............................................................. 3 
1.1.3 Gene Regulation ............................................................................................. 6 
1.2 Small Intestine Overview ........................................................................................ 8 
1.2.1 Structure and Function .................................................................................... 8 
1.2.2 Metabolic Enzymes and Transporters ........................................................... 10 
1.3 Transporters ......................................................................................................... 13 
1.3.1 Structure and Function .................................................................................. 13 
1.3.2 Pharmacogenomics ...................................................................................... 17 
1.4 Cyclooxygenases ................................................................................................. 21 
1.4.1 Structure and Function .................................................................................. 21 
1.4.2 COX Inhibition ............................................................................................... 23 
viii 
 
1.4.3 COX Pharmacology ...................................................................................... 25 
1.5 Diclofenac ............................................................................................................ 29 
1.5.1 Pharmacokinetics and Metabolism ................................................................ 29 
1.5.2 Reactive Metabolites ..................................................................................... 31 
1.5.3 Liver Toxicity ................................................................................................. 33 
1.5.3 Intestinal Toxicity ........................................................................................... 39 
1.6 Summary .............................................................................................................. 42 
Chapter 2 IDENTIFICATION AND CHARACTERIZATION OF EFFLUX 
TRANSPORTERS THAT MODULATE THE DISPOSITION OF DICLOFENAC AND ITS 
METABOLITES AT SUBTOXIC DOSES USING WHOLE-BODY TRANSPORTER 
KNOCKOUT MODELS .................................................................................................. 58 
2.1 Abstract ................................................................................................................ 58 
2.2 Introduction .......................................................................................................... 60 
2.3 Materials and Methods ......................................................................................... 63 
2.4 Results ................................................................................................................. 69 
2.5 Discussion .......................................................................................................... 102 
Chapter 3 MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3 (MRP3) PLAYS AN 
IMPORTANT ROLE IN PROTECTION AGAINST ACUTE TOXICITY OF DICLOFENAC
 .................................................................................................................................... 108 
3.1 Abstract .............................................................................................................. 108 
3.2 Introduction ........................................................................................................ 110 
3.3 Materials and Methods ....................................................................................... 113 
3.4 Results ............................................................................................................... 119 
ix 
 
3.5 Discussion .......................................................................................................... 135 
Chapter 4 ELUCIDATION OF THE MECHANISMS THROUGH WHICH THE REACTIVE 
METABOLITE DICLOFENAC ACYL GLUCURONIDE CAN MEDIATE TOXICITY ..... 141 
4.1 Abstract .............................................................................................................. 141 
4.2 Introduction ........................................................................................................ 143 
4.3 Materials and Methods ....................................................................................... 147 
4.4 Results ............................................................................................................... 154 
4.5 Discussion .......................................................................................................... 178 
Chapter 5 THE MODULATION OF TRANSCRIPTIONAL EXPRESSION AND 
INHIBITION OF MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4 (MRP4) BY 
ANALGESICS AND THEIR PRIMARY METABOLITES .............................................. 187 
5.1 Abstract .............................................................................................................. 187 
5.2 Introduction ........................................................................................................ 188 
5.3 Materials and Methods ....................................................................................... 192 
5.4 Results ............................................................................................................... 198 
5.5 Discussion .......................................................................................................... 206 
Chapter 6 SUMMARY ................................................................................................. 210 
Chapter 7 APPENDIX ................................................................................................. 221 
COPYRIGHT PERMISSIONS .................................................................................. 225 
REFERENCES ........................................................................................................ 230 
 
 
 
x 
 
LIST OF FIGURES 
Figure 1.1 Structure and organization of human liver .................................................... 48 
Figure 1.2 Structure and organization of human small intestine .................................... 50 
Figure 2.1 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in C57 WT and C57 Bcrp KO mice after 3 mg/kg DCF dose .......................... 74 
Figure 2.2 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in C57 WT and C57 Bcrp KO mice after 10 mg/kg DCF dose ........................ 76 
Figure 2.3 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in C57 WT and 
C57 Bcrp KO mice after 3 or 10 mg/kg DCF dose ........................................................ 78 
Figure 2.4 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in FVB WT and FVB Mrp3 KO mice after 3 mg/kg DCF dose ......................... 80 
Figure 2.5 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in Mrp3 WT and KO mice after 10 mg/kg DCF dose ...................................... 82 
Figure 2.6 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in FVB WT and 
FVB Mrp3 KO mice after 3 or 10 mg/kg DCF dose ....................................................... 84 
Figure 2.7 Mass spectral identification of major DCF conjugated metabolites excreted in 
bile ................................................................................................................................. 88 
Figure 2.8 Structures of DCF metabolites based on biliary MS/MS infusion data ......... 90 
Figure 2.9 In vitro metabolism of DCF using hepatic S9 fraction from C57 and FVB mice
 ...................................................................................................................................... 92 
Figure 2.10 Time-dependent transport of DCF-AG by MRP2 and MRP3 using inside-out 
vesicles ......................................................................................................................... 96 
xi 
 
Figure 2.11 Determination of the concentration-dependent transporter kinetics of MRP2 
and MRP3 for DCF-AG ................................................................................................. 98 
Figure 3.1 Toxicokinetics of DCF and its metabolites in FVB WT and FVB Mrp3-KO 
mice after a single intraarterial dose of 75 mg/kg DCF ............................................... 123 
Figure 3.2 Hepatic concentrations of DCF, OH-DCF, and DCF-AG in FVB WT and FVB 
Mrp3 KO mice ............................................................................................................. 127 
Figure 3.3 Clinical chemistry of WT and KO mice 24 hours after a single dose of 90 
mg/kg DCF .................................................................................................................. 129 
Figure 3.4 Summary of histopathology of small intestines from C57 WT and C57 Mrp3 
KO mice 24 hours after administration of vehicle or 90 mg/kg DCF ............................ 131 
Figure 3.5 Immunohistochemistry of tissues taken from C57 WT and C57 Mrp3 KO mice 
treated with vehicle or 90 mg/kg DCF ......................................................................... 133 
Figure 4.1 Visual representation of a mechanistic 2-compartmental transporter model
 .................................................................................................................................... 158 
Figure 4.2 Concentration versus time profiles of DCF-AG uptake by OATP2B1 ......... 160 
Figure 4.3 Cytotoxicity of DCF and DCF-AG using HEK cells ..................................... 164 
Figure 4.4 Generation of reactive oxygen species by in HEK cells ............................. 166 
Figure 4.5 Inhibition of superoxide dismutase as an indication of oxidative stress ...... 168 
Figure 4.6 COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG .......................... 170 
Figure 4.7 COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG .......................... 172 
Figure 4.8 Proposed pathways on the disposition and mechanism of intestinal toxicity 
for DCF-AG ................................................................................................................. 176 
Figure 5.1 Structures of APAP, DCF, and their major metabolites .............................. 190 
xii 
 
Figure 5.2 Relationship between ALT values and Mrp4 gene expression following acute 
exposure to APAP ....................................................................................................... 200 
Figure 5.3 Time-dependent and concentration-dependent transporter kinetics of LTC4 
with MRP4 vesicles ..................................................................................................... 202 
Figure 5.4 Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF 
metabolites .................................................................................................................. 204 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF TABLES 
Table 1.1 Protein sequence homology of human efflux and uptake transporters involved 
in xenobiotic disposition ................................................................................................ 52 
Table 1.2 Literature reports for MRP3 substrates using in vitro assays ........................ 55 
Table 1.3 Case studies of hepatotoxicity from diclofenac usage ................................... 56 
Table 1.4 Reported in vitro inhibition of MRP4 using inside-out vesicles ...................... 57 
Table 2.1 Summary of DCF pharmacokinetic parameters in plasma of WT and KO mice 
after a single 3 or 10 mg/kg DCF dose .......................................................................... 86 
Table 2.2 Summary of in vitro DCF metabolism in mouse models ................................ 94 
Table 2.3 Summary of MRP2 and MRP3 vesicle kinetic studies for DCF-AG ............. 100 
Table 3.1 Summary of DCF toxicokinetic parameters in plasma of FVB WT and FVB 
Mrp3 KO after a single 75 mg/kg DCF dose ................................................................ 125 
Table 4.1 Summary of DCF-AG uptake kinetics mediated by OATP2B1 .................... 162 
Table 4.2 Summary of in vitro COX inhibition assays.................................................. 174 
Table 5.1 Primer sequences for quantitative RT-PCR ................................................. 197 
 
 
 
 
 
 
xiv 
 
LIST OF ABBREVIATIONS 
AA   arachidonic acid 
ABCC   ATP-binding cassette transporter family C 
ADR   adverse drug event 
ALT   alanine aminotransferase 
AMP   adenosine monophosphate 
amu   atomic mass units 
APAP   acetaminophen 
APAP-CYS  acetaminophen cysteine 
APAP-GLU  acetaminophen glucuronide 
APAP-GSH  acetaminophen glutathione 
APAP-NAC  acetaminophen N-acetylcysteine 
APAP-SUL  acetaminophen sulfate 
ATP   adenosine triphosphate 
BCRP   breast cancer resistance protein 
BUN   blood urea nitrogen 
CAM   calcein acetomethoxy 
CLint   intrinsic uptake clearance 
COX   cyclooxygenase 
CYP   cytochrome P450 
DCF   diclofenac 
DCF-AG  diclofenac acyl glucuronide 
DCFDA  5-(and-6)-carboxy-2′,7′-dichlorofluorescein diacetate 
DMEM  Dulbecco’s modified Eagle’s medium 
EDTA   ethylenediaminetetraacetic acid 
EthD-1  ethidium homodimer 1 
GI   gastrointestinal 
xv 
 
GSH   glutathione 
GST   glutathione S-transferase 
HBSS   Hank’s balanced salt solution 
HEK   human embryonic kidney 
IA   intra-arterial 
IL   interleukin 
IP   intraperitoneal 
IS   internal standard 
Km   substrate concentration at half the maximal velocity 
KO   knockout 
LC/MS/MS  liquid chromatography tandem mass spectrometry 
LTC4   leukotriene C4 
MOPS  3-(N-morpholino)propanesulfonic acid 
MRP   multidrug resistance-associated protein 
m/z   mass to charge ratio 
NADPH  β-Nicotinamide adenine dinucleotide 2ʹ-phosphate 
NAPQI  N-acetyl-p-benzoquinone imine 
NSAID  non-steroidal anti-inflammatory drug 
OATP   organic anion transporting polypeptide 
OH-DCF  4′-hydroxy diclofenac 
OH-DCF-AG  hydroxy diclofenac acyl glucuronide 
Pdif   passive diffusion 
PGE2   prostaglandin E2 
PO   per os (oral) 
RFU   relative fluorescence units 
RT-PCR  reverse transcription polymerase chain reaction 
SOD   superoxide dismutase 
xvi 
 
SNP   single nucleotide polymorphism 
UDPGA  uridine 5ʹ-diphosphoglucuronic acid 
UGT   uridine 5′-diphospho-glucuronosyltransferase 
Vmax   maximal velocity 
WT   wild-type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter 1 REVIEW OF LITERATURE 
1.1 Liver Overview 
1.1.1 Structure and Function 
The liver is the largest gland in the body and is responsible for a variety of important 
physiological functions.  A depiction of the liver is shown in Figure 1.1.  The human liver 
is divided into a right and left lobe, each of which is further organized into hepatic 
lobules with a hexagonal appearance.  At the core of every lobule is a central vein.  The 
corners of the lobule contain portal triads that are composed of a bile duct, hepatic 
artery, and a portal vein.  About 60 to 70% of the blood supply to the liver originates 
from the portal vein while the remainder is provided by the hepatic artery (Richardson 
and Withrington, 1982).  Blood coming from the portal veins can enter the sinusoids, 
which is an area that bathes the resident hepatic cells.  Arterial blood is mixed with the 
partially deoxygenated portal blood in the sinusoidal space to provide oxygen.  
Sinusoidal blood traverses from the portal triad through the lobule and eventually 
collects into the central vein where it then gathers into the hepatic vein that ultimately 
drains into the inferior vena cava. 
The lobule is divided into subregions referred to as centrilobular, midzonal, and 
periportal.  In terms of functional units, the lobular regions are referred to as an acinus 
consisting of three zones wherein zone 1 is proximal to the portal triad, zone 2 is 
centrally located, and zone 3 is the area closest to the hepatic central vein.  The 
periportal region (zone 1), being much closer to where oxygenated blood enters the 
sinusoids, is exposed to relatively high oxygen content.  Oxygen levels continually 
decline through the midzonal (zone 2) and centrilobular (zone 3) regions.  As a result, 
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the centrilobular zone is prone to hypoxia and injury due to low blood supply (Treinen-
Moslen, 2001). 
There are several cell types that can be found in the liver.  Among the cells residing in 
the sinusoidal space are liver sinusoidal endothelial cells (LSEC) and Kupffer cells (KC).  
LSECs line the sinusoidal lumen and represent about 20% of the total liver cells (Maslak 
et al., 2015).  They possess pores to permit the passing of material from the sinusoids 
into the space of Disse.  KCs are the resident macrophages, making up over 80% of the 
total macrophages in the body.  KCs play an integral role in the overall health of the liver 
as they are an important first line of defense against bacteria (Bilzer et al., 2006).  
Owing to their function as sentinels to hepatic well-being, the majority of KCs are found 
in the periportal region, which is the likely site of entry of microbes from portal blood 
circulation (Bouwens et al., 1986).  KCs can be activated via microorganisms or hepatic 
injury with subsequent release of cytokines.  Within the space of Disse are Ito cells (also 
known as stellate cells) that synthesize collagen and act as storage sites for vitamin A 
and fat (Stanciu et al., 2002). 
The vast majority of hepatic cells are hepatocytes, which are the cells that carry out 
much of the metabolism in the liver.  Hepatocytes take up about 80% of the total liver 
volume and constitute approximately 60% of all the liver cells (Malarkey et al., 2005).  
The liver is one of the primary sites for glycogen storage, which is converted to glucose 
during states of hypoglycemia.  Hepatocytes carry out gluconeogenesis and are 
responsible for the synthesis of albumin, bile, and lipoproteins (Kutchai, 2004b).  There 
is an estimated 139 million cells per gram of human liver yielding an approximate total 
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number of 217 billion hepatocytes in an adult liver (Sohlenius-Sternbeck, 2006; Molina 
and DiMaio, 2012). 
1.1.2 Metabolic Enzymes and Transporters 
Hepatocytes are metabolically active and possess the full array of enzymes that 
participate in Phase I (hydrolysis, reduction, and oxidation) as well as Phase II 
biotransformation (acylation, amino acid conjugation, glucuronidation, glutathione 
conjugation, methylation, and sulfation).  Phase I metabolism occurs predominantly 
through cytochrome (CYP) P450 enzymes of which the main subtypes are CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5.  
In general the CYPs preferentially act upon the following substrates: 1) CYP1A2 – 
planar hydrophobic compounds with high logP that may be basic or neutral (e.g., 
phenacetin and theophylline), 2) CYP2C9 – acidic compounds or neutrals with high 
level of hydrogen bonding that have both hydrophobic and lipophilic regions (e.g., 
diclofenac and warfarin), 3) CYP2D6 – basic amines that are lipophilic and possess a 
nitrogen that is protonated at physiological pH (e.g., atomoxetine and 
dextromethorphan), 4) CYP2E1 – lipophilic compounds that are small with low logP 
(e.g., aniline and chlorzoxazone), and 5) CYP3A4 – basic or neutral compounds that 
are lipophilic (e.g., filodipine and midazolam) (Smith et al., 1998b; Lewis, 1999; Smith, 
2003; Zhou et al., 2009; FDA, 2014). 
Of the Phase II enzymes, uridine 5ʹ-diphospho-glucuronosyltransferases (UGTs) have a 
significant role as an elimination mechanism for non-steroidal anti-inflammatory drugs 
(NSAIDs).  There are three subfamilies, UGT1, UGT2A, and UGT2B with each 
subfamily consisting of multiple enzymes many of which are expressed in the liver 
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(Ohno and Nakajin, 2009; Harbourt et al., 2012).  UGTs catalyze the transfer of uridine 
5ʹ-diphosphoglucuronic acid to a nucleophilic region of substrate thereby facilitating the 
biliary or urinary excretion of the conjugated metabolite (Coughtrie and Fisher, 2003).  A 
review by Williams et al. (2004) indicated that of the top 200 marketed drugs that 
undergo glucuronidation, approximately 35% of the conjugation is mediated by UGT2B7  
while UGT1A4 and UGT1A1 accounted for 20% and 15%, respectively (Williams et al., 
2004).  Glucuronidation does not always result in permanence of conjugation as 
glucuronides can be degraded back to an aglycone parent and glucuronate by the 
actions of β-glucuronidase (Sperker et al., 1997).  UGTs can form an acyl glucuronide 
(R-COO-), ether glucuronide (R-O-), or nitrogen glucuronide (R-N-). 
Returning to the structural layout of the hepatic lobule, work by Jungermann and Katz 
(1989) demonstrated that the periportal region (zone 1) was higher in glutathione (GSH) 
and lower in CYP abundance while the centrilobular region (zone 3) exhibited higher 
CYP levels along with lower intracellular glutathione.  As glutathione has a critical role to 
sequester reactive intermediates, the reduced glutathione supply makes the 
centrilobular region more prone to certain types of injury.  The gradient distribution of 
CYPs and GSH throughout the lobule renders a phenotypic pattern for which the 
periportal region is susceptible to injury from allyl alcohol and cocaine, from different 
mechanisms that involve generation of reactive metabolites (also higher oxygen levels 
may be contributory for oxygen-dependent reactions), while the centrilobular zone is 
sensitive to damage from carbon tetrachloride and acetaminophen as a result of 
depletion of GSH (Harisch and Meyer, 1985; Badr et al., 1986; Powell et al., 1994; Lim 
et al., 1995). 
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Of the aforementioned CYPs, CYP3A4 accounts for roughly 30% of total hepatic CYP 
content, yet CYP3A4 is responsible for nearly 50% of the overall metabolism that occurs 
in the liver (Shimada et al., 1994; Rodrigues, 1999; Williams et al., 2002).  One of the 
reasons for the wide-ranging activity of CYP3A4 is due in part by a large binding pocket 
that can accommodate substrates of different sizes (Beaumont et al., 2010).  Phase I 
metabolism by CYPs is dependent on β-Nicotinamide adenine dinucleotide 2ʹ-
phosphate (NADPH) to provide a source of electrons while Phase II reactions rely on 
cofactors that must be continually replenished.  Generally, biotransformation is thought 
of as a detoxifying process that converts xenobiotics into more water-soluble forms that 
can subsequently excreted via biliary efflux or elimination in urine, however this is not 
always the case.  Hepatocytes in the centrilobular region are responsible for metabolism 
of acetaminophen, making this region more susceptible to injury due to the generation 
of reactive intermediates such as NAPQI that are partially sequestered by GSH 
(Parkinson, 2001; Hinson et al., 2010). 
The hepatocyte, which is essentially cuboidal in nature, is a polarized cell that is 
specifically oriented with respect to functionally active surfaces. The surface exposed to 
sinusoidal blood and the space of Disse is the basolateral membrane while the 
opposing side is the apical membrane.  It is via the apical membrane that the 
hepatocyte excretes substances in the bile canaliculi which coalesce into bile ducts.  
The flow of bile in the lobule runs counter to that of sinusoidal blood flow, going from the 
centrilobular region toward the portal triad.  The bile ducts merge into the common bile 
duct that terminates into the duodenal region of the small intestine.  The basolateral 
membrane of hepatocytes has a number of transporters that facilitate the uptake of 
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substrates from sinusoidal space into the cell.  Among the uptake transporters are 
equilibrative nucleoside transporters (ENTs, SLC29s), organic anion transporters (OATs, 
SLC22As), organic anion transporting polypeptides (OATPs, SLCOs), organic cation 
transporters (OCTs, SLC22As), and sodium-taurocholate co-transporting polypeptide 
(NTCP, SLC10A1) (Giacomini et al., 2010). 
Also on the basolateral membrane are multidrug resistance-associated proteins (MRPs) 
that are efflux transporters from the ATP-binding cassette family C (ABCCs).  A listing of 
the major uptake and efflux transporters along with their corresponding intra-family 
protein homologies is shown in Table 1.1.  The bile canalicular membranes likewise 
host a number of efflux transporters belonging to several different transporter gene 
families (ABCBs, ABCCs, ABCGs, SLC29s, and SLC47As).  Many of the 
aforementioned uptake and efflux transporters are involved in the hepatobiliary 
disposition of endogenous substances as well as xenobiotics and their metabolites 
emphasizing the importance of understanding their roles in modulating the systemic 
exposure and elimination of compounds (Zamek-Gliszczynski et al., 2012).  
Physiologically, the interplay of uptake and efflux transporters is responsible for the 
recirculation of bile as 20% of the total bile pool is eliminated from the body on a daily 
basis (Heaton, 1969).  The recirculation is primarily dependent upon NTCP (basolateral 
uptake) and BSEP (canalicular efflux) along with secondary uptake by the OATPs and 
basolateral as well as canalicular efflux by MRPs (Kullak-Ublick et al., 2000). 
1.1.3 Gene Regulation 
The expression of CYPs, UGTs, and transporters can be modulated via several 
mechanisms.  CYP1A2 for instance is inducible via activation of the aryl hydrocarbon 
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receptor (AhR) (Nebert et al., 2004).  Cigarette smoke has been shown to increase 
CYP1A2 expression via AhR, a result that may be causally linked to the increased 
tumorigenesis due to metabolism of procarcinogens present in cigarette smoke 
(Dertinger et al., 2001).  Activation of the pregnane X receptor (PXR) leads to induction 
multiple genes such as CYP2C9, CYP3A4, and the efflux transporters MDR1 (ABCB1) 
as well as MRP2 (ABCC2).  PXR belongs to a class of orphan nuclear receptors for 
which the endogenous substrate has yet to be identified.  PXR has a ligand binding 
domain as well as a DNA-binding domain, enabling it to both recognize circulating 
substrates and bind to regulatory regions in target genes (Kliewer et al., 1998).  After a 
ligand binds to PXR, the PXR-ligand complex enters the nucleus and forms a 
heterodimer with retinoid X receptor (RXR).  The heterodimer is stabilized by additional 
cofactors allowing the complex to bind to response elements in the target genes and 
promote transcriptional upregulation.  Shukla et al. (2011) reported that out of 2,816 
clinically relevant compounds, 310 (11% of the total) were found to be activators of PXR.  
UGTs are regulated by a wide array of transcriptions factors such as AhR, constitutive 
androstane receptor (CAR), farnesoid X receptor (FXR), nuclear factor erythroid-related 
factor 2 (Nrf2), peroxisome proliferator-activated receptors (PPAR α & γ), PXR, and 
RXR (Hu et al., 2014). 
Activation of PXR has physiological ramifications.  For instance, elevation in bile salts 
stimulates PXR to modulate both CYP activity as well as transporter expression 
resulting in a reduction of toxic bile salts, which if left unchecked could induce 
cholestasis and ultimately lead to hepatic injury (Staudinger et al., 2001; He et al., 2011).  
Induction of the efflux transporter MRP3 (ABCC3) has been demonstrated to occur via 
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pathways involving CAR and PXR while MRP4 (ABCC4) is upregulated by activation of 
CAR (Cherrington et al., 2002; Teng et al., 2003; Zollner et al., 2006).  The induction of 
MRP3 and MRP4 as a compensatory defense mechanism during cholestasis is 
indicative of the important role that basolateral efflux transporters have in attenuating 
cell injury (Claudel et al., 2011).  Aleksunes et al. (2008b) reported induction of Mrp3 
and Mrp4 in mice following toxic challenge by acetaminophen, and the induction was 
mediated through Nrf2.  Further material on transporters will be detailed in subsequent 
sections. 
1.2 Small Intestine Overview 
1.2.1 Structure and Function 
The small intestine is a contiguous structure, with an average length of 6.5 meters in 
adults (Hounnou et al., 2002).  A representation of the small intestine structure is shown 
in Figure 1.2.  The small intestine is functionally separated into three areas: duodenum, 
jejunum, and ileum.  The duodenum represents the first part of the small intestine and is 
physically joined to the pyloric region of the stomach.  The duodenum is the shortest 
region of the small intestine with a length of approximately 25 cm.  The next portion of 
the small intestine is the jejunum, which is about 2.5 meters in length in adults.  The 
ileum is the last section of the small intestine and accounts for the remaining length 
before the gastrointestinal tract transitions into the large intestine. 
It is in the duodenum where gastric chyme is mixed with secretions from the liver, gall 
bladder, pancreas, and small intestine.  Bile, which elmusifies lipids to permit absorption 
of fats, is released into the small intestine though the action of cholecystokinin, a 
hormone that stimulates the gall bladder to release bile through the common bile duct.  
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The duodenum neutralizes the acidic contents emanating from the stomach by 
secreting bicarbonate (Campbell, 1993).  The jejunum also secretes digestive enzymes 
and moves luminal contents via peristaltic contractions to the ileum.  The ileum is the 
segment where nutritional absorption is greatest.  Bile acids are reabsorbed via active 
uptake in the ileum (Kutchai, 2004a). There is a pH gradient along the small intestine 
with a duodenal pH range of 6 to 6.6 while the terminal ileum pH is approximately 7.4 
(Evans et al., 1988; Fallingborg, 1999). 
The structure of the small intestine can be regarded as an elongated tube, and the 
cavity within the small intestine is referred to as the lumen.  Taken as a whole, the small 
intestine has an absorptive surface area of 32 square meters (Helander and Fandriks, 
2014).  The effective surface area exceeds that of a standard cylinder due to the 
presence of plicae circulares, which are folds along the entirety of the small intestine.  
The plicae circulares are comprised of projections called villi, and each villus has a layer 
of enterocytes that are the absorptive cells of the intestinal tract.  The enterocytes have 
microvilli that further increase surface area of the cells.  Goblet cells are also present in 
the villi, though to a far less degree than enterocytes.  The function of goblet cells is to 
secrete mucus.  Within the villus is a network of blood capillaries and lymph vessels 
known as the lacteal.  The capillaries take up amino acids and sugars while lipids are 
absorbed into the lacteal.  The flow of nutrients into the intestinal capillaries is directed 
to the hepatic portal vein that eventually goes to the liver (Campbell, 1993).  In addition 
to nutrients, the small intestine has a role in the absorption of critical electrolytes and 
buffers such as sodium, potassium, chloride, and bicarbonate. 
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1.2.2 Metabolic Enzymes and Transporters 
Similar to the liver, the small intestine possesses both Phase I and Phase II metabolic 
enzymes (Prueksaritanont et al., 1996).  In contrast to the liver for which CYP3A4 
constitutes 30% of the total CYP content, the allotment of CYP3A4 makes up nearly 
82% of all the CYPs expressed in the intestine with CYP2C9 accounting for 14% (Paine 
et al., 2006).  Despite the relatively high expression of intestinal CYP3A, the absolute 
amount of CYP3A4 present in the small intestine is only 1% of the CYP3A amount in 
the liver (Yang et al., 2004).  Nonetheless, the metabolic enzymes in the small intestine 
are able to modulate the overall bioavailability of substances.  In pharmacokinetic terms, 
the extent of bioavailability after oral dosing is determined using the relationship: 
Equation 1.1 
             
where F is the oral bioavailability, Fa is the fraction of dose absorbed from the intestinal 
lumen, Fg is the fraction of dose escaping the intestine (gut), and Fh is the fraction of 
dose escaping the liver.  The sedative agent midazolam is a compound that has high 
passive uptake and can easily enter enterocytes yielding an apparent Fa value of 1.  
Metabolism in the enterocytes diminishes the amount of midazolam presented to the 
intestinal capillaries due to activity of CYP3A4 (Paine et al., 1996) resulting in a Fg of 
0.54.  Furthermore, the loss of midazolam from intestinal metabolism was found to be 
comparable to the liver Fh value of 0.56 (Thummel et al., 1996).  Thus the oral 
bioavailability of midazolam is about 30% given that F = 1 × 0.54 × 0.56 = 0.30, and this 
value was also observed by other researchers (Akabane et al., 2009).  In addition to 
CYP3A4, other major CYPs found along the small intestine are CYP1A1, CYP2C9, 
CYP2C19, and CYP2D6.  The distribution of CYPs is not uniform as expression is 
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relatively high in the duodenum and reaches maximal expression in the proximal 
jejunum followed by sustained decreases through the medial and distal jejunal regions 
with low or non-existent CYP protein in the ileum (Paine and Thummel, 2003).  
Regarding Phase II enzymes, the small intestine has expression of UGTs throughout 
each of the respective intestinal regions (Ritter, 2007).  It was recently shown that of the 
major UGTs, UGT1A1 was present in the jejunum and ileum at levels comparable to 
CYP3A4 (Busch et al., 2015).  Additionally, UGT1A3 and UGT2B7 were detected at 
protein levels greater than or equal to other major Phase I enzymes such as CYP2C9, 
CYP2C19, and CYP2D6.  For the UGTs quantified, protein amounts were highest in the 
jejunum.  Intestinal UGTs can be regulated by the same transcription factors previously 
mentioned as well as caudal-related homeodomain protein 2 (Cdx2), which is specific to 
the intestine and modulates several UGTs (Gregory et al., 2004; Gregory et al., 2006). 
Just as the hepatocyte is polarized, enterocytes too possess a polarized orientation.  
The apical membranes of enterocytes face the intestinal lumen and express a number 
of uptake and efflux transporters.  Recently, proteomic work by Groer et al. (2013) and 
Drozdzik et al. (2014) demonstrated that transporter expression in the small intestine is 
dominated by PEPT1 (SLC15A1), which is involved in the transport of peptides (Adibi, 
2003).  PEPT1 accounted for approximately half of the quantified transporters in a small 
pool of healthy subjects.  Also detected were the sodium dependent bile transporter 
ASBT (SLC10A2), organic cation transporters, OATP2B1 (SLCO2B1), MDR1, MRP2, 
MRP3, and breast cancer resistance protein (BCRP, ABCG2).  MDR1 and CYP3A4 are 
in close proximity to each at the apical membrane, creating a synergistic mechanism by 
which substrates that elude CYP-mediated metabolism are excreted back into the 
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lumen after which reuptake into the cell may eventually result in substrate 
biotransformation (Christians, 2004).  Though the large intestine lies beyond the scope 
of this thesis, a significant finding from Drozdzik’s work was the relatively high MRP3 
expression in the colon, accounting for 36% of the total quantified transporter proteins.  
The extent of MRP3 expression along the intestinal tract, and its role as a protective 
mechanism, is an important concept as it relates to the research detailed in subsequent 
chapters. 
Metabolic enzymes and transporters in the small intestine are regulated via similar 
mechanisms as those present in the liver.  Additionally, Phase I and II enzymes as well 
as transporters are also subjected to modulation by components that are in food.  For 
instance, grapefruit juice has been shown to inhibit the activities of both CYPs and 
transporters (Kantola et al., 1998; Kivisto et al., 1999; Fukazawa et al., 2004; Glaeser et 
al., 2007; Scialis et al., 2011).  It is well known that bergamottin, a component of 
grapefruit juice, incapacitates CYP by a mechanism colloquially referred to as suicide 
inactivation (Eagling et al., 1999; Goosen et al., 2004).  The impact of grapefruit juice on 
small intestine function is multivariate ranging from reduced bioavailability of 
fexofenadine due to inhibition of intestinal OATPs that mediate uptake into enterocytes 
or alternatively increased plasma concentrations of cholesterol lowering 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (henceforth referred to as statins) due 
to blockade of CYP metabolism. 
Analysis of the constituents in grapefruit juice revealed that the contributors of the 
observed inhibition (e.g., bergmamottin, naringin, and quercetin) were present in µM to 
mM concentrations depending on whether the juice or pulp were assayed (Ross et al., 
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2000; De Castro et al., 2006).  Intestinal transporter inhibition was reported to also 
occur with other fruit juices such as apple, grape, and orange (Dresser et al., 2002).  
Owing to the inhibition potential grapefruit juice possesses, clinicians need to be mindful 
of potential drug interactions that may result in toxicity as demonstrated in a patient 
taking verapamil while consuming grapefruit juice (Pillai et al., 2009).  In that case, the 
intake of grapefruit juice along with the recommended dosage of verapamil led to a 
marked increase in plasma verapamil concentrations.  The cause for the increased 
exposure was two-fold: 1) the constituents in grapefruit juice inhibited CYP3A4 that is 
the primary enzyme involved in verapamil metabolism, and 2) the transporter-mediated 
elimination of verapamil via MDR1 was likewise inhibited by grapefruit juice. 
1.3 Transporters 
1.3.1 Structure and Function 
The movement of materials into and out of cells may occur through passive diffusion or 
carrier-mediated transport.  In a carrier-mediated process, transporter proteins function 
to translocate substrates, and this process may or not involve an energy input 
component.  Some gene families are responsible for excretion of substrates from the 
cell to extracellular space while other gene families function as uptake transporters.  Of 
the entirety of transporters in the genome, several families of transporter genes are 
responsible for the disposition of therapeutic agents and/or their metabolites, and three 
of the major subtypes that are relevant to the work presented herein are listed in Table 
1.1 along with their respective intra-family protein sequence homologies. 
The first major class of transporters belongs to the ATP-binding cassette (ABC) family 
which is further divided into seven subfamilies (ABCCA to ABBCG).  Most of the focus 
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of this review will be on members of the ABC subfamily C.  As suggested by their name, 
the ABC transporters use ATP to energize transport activity.  Although the overall 
structure of ABC transporters can vary, there are several conserved features.  ABCC 
proteins, of which there are thirteen identified genes, have the following general 
arrangement: 1) extracellular N-terminus linked to a membrane spanning domain 
(MSD0) with five transmembrane helices followed by a cytoplasmic loop 2) MSD1 with 
six transmembrane helices, 3) cytosolic nucleotide binding domain (NBD1), 4) MSD2 
with six transmembrane helices, and 5) cytosolic NBD2 with C-terminus.  The above 
indicated structure is reflective of the longer ABCCs 1, 2, 3, 6, 8, 9, and 10 whereas the 
shorter ABCCs 4, 5, 7, 11, and 12 have a cytosolic N-terminus-MSD1-NBD1-MSD2-
NBD2 arrangement (Gottesman et al., 2002).  MSD0 is important for trafficking of the 
proteins to their respective locations and for retention of the protein to the plasma 
membrane (Westlake et al., 2005; Bandler et al., 2008).  The NBD regions carry out the 
binding of ATP and subsequent hydrolysis to ADP.  The two MSDs with their twelve 
helices form a channel that closes on the cytoplasmic side upon presentation of 
substrate and ATP.  The substrate is then released into the extracellular space, and 
ATP is hydrolyzed to ADP re-initializing the transporter to accept substrate from the 
cytoplasm (Linton, 2007).  Each transport cycle requires two ATP molecules.  The 
presence of glutathione has been shown to promote the activity of ABCCs in vitro (Qian 
et al., 2001). 
Most of the ABCC proteins are expressed at the basolateral membrane while ABBC2 
(alias MRP2) is unique in that it is exclusively expressed on the apical membrane.  
There is broad overlap of substrates for the various ABCCs.  Common substrates of the 
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longer ABCC proteins are organic anions, glucuronide conjugates, glutathione as well 
as glutathione conjugates, and sulfated compounds (Deeley et al., 2006).  The shorter 
ABCCs transport glucuronide conjugates as well as bile salts, nucleosides, 
prostaglandins, and sulfates.  ABCC7 (alias cystic fibrosis transmembrane conductance 
regulator [CFTR]) is an atypical ABCC in that it functions as a chloride ion channel and 
was identified as being the protein that is defective in cystic fibrosis (Rommens et al., 
1989).  ABCCs 8 and 9 serve as sulfonylurea receptors (alias SURs) and have a role in 
modulating insulin (Thomas et al., 1995; Aguilar-Bryan et al., 1998).  ABCCs 11 and 12 
are thought to be duplicates with closest homology to ABCC5 (Tammur et al., 2001).  
ABCC11 can efflux anions, glucuronides, nucleotides, and is a determinant for ear wax 
type (wet vs. dry) while ABCC12 is expressed in breast cancer (Bera et al., 2002; Chen 
et al., 2005; Yoshiura et al., 2006).  The consequence of the wet ear wax phenotype is 
an increased risk of breast cancer in Japanese but not Caucasian women (Ota et al., 
2010; Lang et al., 2011).  ABCC13 does not appear to be a functional protein as it 
contains only one fully formed NBD, hence it cannot properly bind ATP (Annilo and 
Dean, 2004). 
The members of the ABCG subfamily of transporters are much smaller and consist of a 
cytosolic N-terminus coupled to a NBD and a single MSD with six helices and cytosolic 
C-terminus.  The proteins are considered half-transporters in that they dimerize to form 
a functional unit (Ozvegy et al., 2001).  ABCG1 is the human homologue to a protein in 
Drosophila that produces a white eye color due to the efflux of brown and red pigments 
(Chen et al., 1996).  ABCG1 and ABCG4 are thought to modulate the efflux of sterols 
and have high expression the brain (Wang et al., 2008).  ABCG2 (alias BCRP) has a 
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major role in the disposition of xenobiotics and can mediate the efflux of anti-cancer 
drugs, statins, and Phase II conjugates (Robey et al., 2007).  BCRP is responsible for 
the basolateral efflux of substrates from the central nervous system and is also located 
along the canalicular domains in the hepatocyte and the apical domain of the intestines 
(Berge et al., 2000).  ABCG5 and ABCG8 form a heterodimer and are located at the 
apical membrane in hepatocytes where they excrete cholesterol and other sterols into 
the bile (Lu et al., 2001). 
The last major transporter family that will be covered is the solute-carrier (SLC) that is 
comprised of more than fifty subfamilies.  As it pertains to the research in the thesis, 
focus will be on the SLCO subfamily.  There are thirteen distinct transporter proteins 
encoded by the SLCO genes, and the SLCOs are referred to as organic anion 
transporters or more colloquially as organic anion transporting polypeptides (OATPs).  
The SCLOs have a typical structure of cytosolic N-terminus, a MSD with eight to nine 
helices, an extracellular loop, a second MSD with three helices, and finally a cytosolic 
C-terminus.  In contrast to the ABC transporters, SLCOs are not energized by ATP and 
may use bidirectional transport as a driving mechanism.  The exact mechanism of 
SLCO transport has not been clearly defined, though it is generally thought that the 2 
MSDs form a pore having an internal positive charge with multiple substrate binding 
sites (Han et al., 2010; Niemi et al., 2011).  SLCO2B1 activity can be modulated by 
extracellular pH in that acidic conditions increase the inward transport of substrates, 
however other SLCOs do not necessarily share this trait (Tirona and Kim, 2007). 
The SLCOs are distributed throughout the body and with diverse orientation, i.e. apical 
vs. basolateral localization (Roth et al., 2012).  Among those expressed in the brain are 
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SLCO1A2, SLCO2B1, SLCO1C1, and SCLO3A1.  The liver has SLCO1B1 and 
SLCO1B3, which are hepatoselective, as well as SLCO1A2 and SLCO2B1.  Intestinal 
expression of SLCOs consists of SLCO1A2 and SLCO2B1 that are both facing the 
intestinal lumen.  The kidneys possess SLCO1A2 and SLCO4C1 on opposing 
membranes.  Finally, SLCO2B1 is expressed constitutively in skeletal muscle.  Muscle 
tissue is sensitive to a type of injury called rhabdomyolysis, which is a syndrome 
characterized by muscle pain and myopathy.  During rhabdomyolysis, muscle tissue is 
destroyed, and the degradants are released into the blood potentially leading to renal 
failure as the kidneys become inundated with the muscle protein myoglobin that cannot 
be cleared properly (Sauret et al., 2002; Polderman, 2004).  A causative factor for 
rhabdomyolysis is the accumulation of statins via uptake by SLCO2B1 into muscle 
tissue.  As the intracellular statin concentrations increase beyond the muscle’s ability to 
metabolize the substances, toxicity begins to occur resulting in myopathy of muscle 
(Knauer et al., 2010).  Inhibition of SLCO-mediated statin uptake by the clinically 
relevant antibiotic rifampicin was shown to attenuate statin-induced cytotoxicity using an 
in vitro model (Zhang et al., 2013).  Among the other SLCOs substrates are antibiotics 
(β-lactams), bile salts, glucuronide conjugates, peptides, prostaglandins, sulfated 
compounds, and thyroid hormones (Tirona and Kim, 2007; Roth et al., 2012). 
1.3.2 Pharmacogenomics 
As is the case for many genes, transporters can have a variety of polymorphisms that 
can affect protein functionality with clinical ramifications.  For instance, a SNP for 
ABCC2 in which the amino acid at position 412 changes from an arginine to a glycine 
(R412G) resulted in a loss of methotrexate efflux, as measured in an in vitro system, 
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compared to wild type ABCC2 (Hulot et al., 2005).  The arginine at 412 is conserved in 
the Abcc2 sequence of other animals and is thought to be involved in substrate 
recognition.  Clinically, the R412G mutation was linked to a 3-fold increase in the 
elimination half-life of methotrexate resulting in an overdose that may have contributed 
to nephrotoxicity.  Another SNP for ABCC2, this time in the promoter region hence 
having a no impact on the protein sequence, was correlated with a statistically 
significant 25% increase in the plasma concentrations of mycophenolic acid acyl 
glucuronide (AcMPAG) in healthy subjects compared to homozygous wild-type carriers 
(Levesque et al., 2008).  AcMPAG has immunosuppressive pharmacology similar to its 
parent compound, thus a rise in plasma concentration of the pharmacologically active 
metabolite in carriers of mutant ABCC2 may result in pharmacodynamic effects (Schutz 
et al., 1999; Shipkova et al., 2002). 
Mutations in ABCC2 are associated with pathogenesis of Dubin-Johnson Syndrome 
(DJS) as a result of impaired expression and functionality.  The phenotype of affected 
subjects is characterized by hyperbilirubinemia, jaundice, and darkened livers (Dubin 
and Johnson, 1954; Shani et al., 1970).  The mutations in the ABCC2 gene are a 
combination of alternate deletion, splicing, or substitution (Chen and Tiwari, 2011).  
Several SNPs were shown to have reduced activity suggested to be the result of 
misfolded protein structure (Mor-Cohen et al., 2001).  Other explanations for loss of 
activity were attributed to SNPs in the NBDs that might limit the binding of ATP to 
energize transport (Tsujii et al., 1999).  In addition to functional loss, trafficking of 
ABCC2 was shown to be impaired with localization of protein directed to the 
endoplasmic reticulum rather than the plasma membrane (Arlanov et al., 2012).  The 
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Eisai hyperbilirubinuria rats, which lack Mrp2 as a result of a stop codon insertion, are 
used as a rodent model of DJS (Ito et al., 1997; Johnson et al., 2006). 
To date, there has been little focus on the clinical significance of ABCC3 polymorphisms.  
Nonetheless, research from multiple groups demonstrated that polymorphisms of 
ABCC3 are numerous.  Saito et al. (2002) initially reported 30 ABCC3 SNPs, however 
the functional significances were not investigated.  Work by Lang et al. (2004) 
indentified 51 mutations, and a SNP in the promoter region was correlated with a 
reduction in both hepatic mRNA and protein though only the mRNA reduction was 
statistically significant.  A comprehensive analysis of ABCC3 SNPs was performed by 
Kobayashi et al. (2008) who characterized eleven SNPs with all polymorphisms 
occurring in the protein coding regions.  Eight of the polymorphisms that were found in 
MSD0, NBD1, and NBD2 were determined to have normal function as well as 
expression and had proper localization to the plasma membrane.  A SNP in NBD2, in 
which arginine was changed to serine at position 1381 (R1381S), caused the protein to 
accumulate within the cell and remain bound to the endoplasmic reticulum. 
The remaining two SNPs in Kobayashi’s research were determined to have reduced 
functional activity.  The first of these SNPs is located on the extracellular side of MSD1 
at position 346 where serine is replaced with a phenylalanine (S346F).  The second 
SNP is localized near NBD1 at position 607 and consists of an asparagine substitution 
in place of serine (S607N).  The transport activity was measured using estradiol-17β-
glucuronide as a probe and compared to the wild-type ABCC3 sequence.  Transport 
activity for the two SNPs was between 67 to 77% lower compared to the wild-type.  
Moreover, the previously mentioned eight SNPs yielded transport activity that was 
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greater than or similar to that of wild-type.  The S346F mutation is estimated to occur in 
2.5% of Caucasians while the S607N SNP has a prevalence of approximately 2.8% in 
African-Americans.  More recently, a report by Pussegoda et al. (2013) indicated that a 
SNP near the N-terminus at position 1503 was significantly correlated with ototoxicity in 
children receiving cisplatin during chemotherapy treatment.  Considering that cisplatin is 
a substrate for ABCC3, the correlation may be due to altered protein function, though 
the authors of the study did not investigate ABCC3 protein activity. 
Polymorphisms have likewise been discovered for uptake transporters.  Nozawa et al. 
(2002) reported that 10% of Japanese subjects were homozygous for a SNP at position 
392 where isoleucine is changed to threonine (I392T) for SLCO2B1, and that the 
prevalence of I392T SNP, known colloquially as the *3 allele, occurred in approximately 
31% of the subject pool.  Using an in vitro cell-based system, the I392T SNP was found 
to have reduced transport kinetics compared to homozygous wild-type (*1 allele) of the 
known OATP2B1 substrate estrone-3-sulfate.  Substrate affinity, in terms of Km, was the 
same between *1 and *3 alleles though the *3 Vmax was reduced by over 50%.  Results 
from in vivo studies indicate that the reduction in *3 transport capacity has clinical 
significance.  In a report by Akamine et al. (2010), Japanese subjects with the *3 allele 
had a 51% increase in fexofenadine plasma concentrations compared to *1 carriers.  
Experiments with in vitro cell-based systems indicated that fexofenadine is an 
OATP2B1 substrate (Nozawa et al., 2004; Ming et al., 2011).  However, not all 
OATP2B1 SNPs result in loss of activity as substrates aliskiren and glyburide did not 
have altered activity compared to the wild-type allele (Ieiri et al., 2012; Tapaninen et al., 
2013). 
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Given the importance transporters have in modulating the uptake and efflux of critical 
endogenous substances as well as their respective roles in mediating the clearance of 
xenobiotics, further investigation into transporter loss of function is warranted.  
Transporter knockout models afford a mechanistic means by which dispositional 
changes can be uncovered.  As it applies to the field of toxicology, transporter knockout 
models can serve as surrogates to human polymorphisms whereby the ramifications of 
diminished transporter function can be quantified.  To this end, a major goal of the 
present work is to use animal knockouts to study the disposition of toxicants. 
1.4 Cyclooxygenases 
1.4.1 Structure and Function 
There are two genes that are responsible for the coding of enzymes involved in 
arachidonic acid metabolism, prostaglandin-endoperoxide synthase 1 (COX-1, PTGS1) 
and 2 (COX-2, PTGS2).  Following initial characterization of COX-1 enzyme in sheep 
(DeWitt and Smith, 1988), the structure and sequence of human COX-1 was elucidated 
by Yokoyama and Tanabe (1989) and found to be 599 amino acids in length.  Work by 
Funk et al. (1991) showed that mutation of a serine (Ser) to asparagine at position 529 
abolished activity of the enzyme.  COX-2 was characterized by Hla and Neilson (1992) 
and reported to have 604 total amino acids.  Kim et al. (2005) discovered that mutation 
of a cysteine (Cys) residue at position 555 to a serine eliminated enzyme activity. 
Furthermore, mutation of the Cys526 site to a serine prevented the binding of inducible 
nitrous oxide synthase (iNOS, NOS2).  The binding of iNOS to Cys526 causes it to be 
S-nitrosylated resulting in increased enzymatic activity.  S-nitrosylation is regarded as 
an important post-translational event that can modulate the intrinsic activity of targeted 
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proteins (Hess et al., 2005).  Of the thirteen cysteine residues on COX-2, only Cys526 
can be activated by iNOS. 
The two encoded COX proteins share about 65% identity for their native amino acid 
sequence (Altschul et al., 1997).  Structurally, the two COX enzymes share similar 
features.  The COX protein structure has a membrane bound domain at the amino-
terminus, a proton acceptor site between residues 190 to 210, a substrate recognition 
region is located near position 350, there is a site for cyclooxygenase activity between 
amino acids 370-390, a heme binding motif is located three amino acid residues from 
the catalytic site, and there is a serine site between positions 510 to 530 near the 
carboxyl-terminus that is involved in aspirin pharmacology (Magrane and Consortium, 
2011; UniProt, 2015).  COX-1 has ubiquitous expression in most tissues and is 
constitutively active thus functioning as a housekeeping gene (Dewitt and Meade, 1993; 
Smith and Dewitt, 1996).  COX-2, in contrast, is not detectable under homeostatic 
conditions, though its expression can be inducible and sustained for short durations 
(Evett et al., 1993).  COX proteins are monotopically membrane bound as homodimers 
within the endoplasmic reticulum (Mbonye et al., 2006).  Despite the differences in 
expression and modulation of activity, the two COX enzymes share similar enzyme 
kinetics (Smith et al., 1996). 
Both COX proteins perform the same enzymatic reaction of converting arachidonic acid 
(AA) to prostaglandin G2, which is subsequently converted to prostaglandin H2 by 
hydroperoxidase activity in the COX enzyme.  PGH2, being unstable, is then further 
metabolized into prostacyclins, prostaglandins, or thromboxanes by a number of 
synthases that are tissue specific (Nicolaou et al., 2014).  The products of these 
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reactions have varying pharmacologies ranging from induction of inflammation, 
inhibition of platelet function, immunosuppression, vasodilation, and inhibition of T-cell 
production (Moncada et al., 1976; Sravan Kumar and Das, 1994; Zhou et al., 2007; 
Kalinski, 2011). 
1.4.2 COX Inhibition 
The inhibition of COX enzymes as the pharmacological basis of anti-inflammatory drugs 
was first postulated in 1971 (Ferreira et al., 1971; Vane, 1971).  Compounds that inhibit 
COX are sorted into four structural classes: 1) salicylic acids, 2) anthranilic acids, 3) 
acetic acids, and 4) propionic acids.  Examples of each structural class are aspirin 
(salicylic), mefenamic acid (anthranilic), diclofenac (acetic), and ibuprofen (propionic) 
(Kalgutkar and Daniels, 2010).  Inhibitors of the COX enzymes fall into one of three 
categories: selective 1) COX-1 selective inhibitor, 2) non-selective inhibitor of COX-1/2, 
or 3) COX-2 selective inhibitor. 
Early therapeutic agents were generally non-selective COX inhibitors.  Discovery and 
characterization of the COX-2 protein shifted efforts of medicinal chemists to develop 
therapeutic agents that had greater COX-2 antagonism so as to minimize the 
deleterious effects associated with suppression of COX-1 function (Borne et al., 2013).  
Inhibition of COX occurs as a result of competitive inhibition, tight binding of inhibitors, 
or covalent modification.  Mefenamic acid and ibuprofen are examples of competitive 
inhibitors that interfere with the binding of AA to the COX catalytic site (Catella-Lawson 
et al., 2001). 
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Tight binders are not covalently bound, rather the inhibitor-enzyme complex dissociates 
relatively slowly (Rome and Lands, 1975).  Formation of the tightly bound complex has 
been described as a two step process, initial binding followed by a conformational 
change permitting closer association of inhibitor and enzyme wherein the second step is 
time dependent (Copeland et al., 1994).  Compounds such as indomethacin, a non-
selective COX inhibitor in the same structural category as diclofenac, need to bind to 
one of the COX-2 homodimer units to block AA metabolism.  (Prusakiewicz et al., 2009).  
Ibuprofen and mefenamic acid need to occupy the substrate binding sites in both COX-
2 subunits to inhibit the catalytic conversion of AA into PGH2.  The mechanism of action 
for COX inhibitors has been linked to interaction with the arginine (Arg) residue at 
position 120.  Under normal conditions, Arg120 interacts with the carboxylate moiety of 
arachidonic acid (Marnett et al., 1999).  COX inhibitors occupy the substrate binding site 
with an orientation such that the negatively charged carboxylate region of the inhibitor is 
ion-paired with Arg120 due to the positively charged arginine.  Mutation of Arg120 to 
other amino acids diminished the inhibition potency of diclofenac, indomethacin, 
ketoprofen, and meclofenamic acid (Mancini et al., 1995). 
Selective COX-2 inhibitors do not possess carboxylic acid moieties, rather they contain 
sulfonamides or sulfones.  The mechanism for selective COX-2 inhibition is such that 
the sulfonamide or sulfone of the inhibitor interacts with other regions of the enzyme 
rather than orient towards Arg120 as the traditional COX inhibitors do.  The changes in 
COX-2 amino acids compared to the COX-1 sequence, specifically a valine at positions 
434 and 523, create a larger binding pocket allowing the inhibitor to access a secondary 
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region in the COX-2 enzyme that is otherwise inaccessible in COX-1 (Zarghi and Arfaei, 
2011). 
The final category of COX inhibitors is the covalent modifier.  Despite the long history of 
anti-inflammatory drug research, only one therapeutic agent has been developed and 
subsequently identified as a covalent modifier, aspirin.  The site of covalent modification 
differs for each enzyme with a serine at position 530 and 516 for COX-1 and COX-2, 
respectively, that is acetylated by aspirin (Shimokawa and Smith, 1992; Lecomte et al., 
1994).  The mechanism of action for aspirin relative to other COX inhibitors is distinct in 
that the blockade by competitive inhibitors or tight binders is eventually reversible, 
taking more time for the tight binders, while covalent modification is irreversible.  COX 
enzymes exposed to aspirin must be newly synthesized for cells to regain COX 
metabolism of AA.  The effect of aspirin on COX-1 in platelets is a loss of ability to 
produce thromboxane, a required component in the blood clotting process (Schror, 
1997).  Though aspirin can acetylate both COX enzymes, its potency for COX-1 is far 
greater than that for COX-2 (Awtry and Loscalzo, 2000). 
1.4.3 COX Pharmacology 
The metabolism of AA by the COX enzymes yields a number of prostaglandin 
derivatives.  In the context of the work presented in this thesis, the formation of 
prostaglandin E2 (PGE2) is of significance.  Formation of PGE2 occurs through the 
metabolism of PGH2 by prostaglandin E synthase (PTGES).  PTGES was reported to be 
dependent on glutathione and found to be inducible by the proinflammatory cytokine 
interleukin 1 beta (IL-1β) (Jakobsson et al., 1999).  COX-2 was similarly reported by 
Mitchell et al. (1994) to be inducible by cytokines such as IL-1β and tumor necrosis 
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factor alpha (TNFα).  PGE2 acts as a ligand for several receptors known as EP1, EP2, 
EP3, and EP4 (Coleman et al., 1994).  The rank order affinity of PGE2 for its receptors 
are EP3 > EP4 >> EP2 > EP1 (Abramovitz et al., 2000; Mohan et al., 2012). 
Activation of EP1 and EP3 by PGE2 results in an increase of intracellular calcium, or 
alternatively, for EP3 activation reduces cyclic adenosine monophosphate (cAMP) 
formation.  In contrast, EP2 and EP4 activation stimulates production of cAMP.  
Hoshino et al. (2003) reported the involvement of EP2 and EP4 activation as a 
mechanism for PGE2-mediated protection of the gastrointestinal tract.  Using ethanol as 
a model toxicant, PGE2 was able to inhibit apoptosis of cultured gastric mucosal cells 
(Hoshino et al., 2002).  Use of specific agonists for EP2 and EP4 led to a decrease in 
ethanol-induced toxicity.  Furthermore, EP2 and EP4 agonists also suppressed 
activation of several caspases.  In consideration that caspases are involved in 
mediating apoptosis (McIlwain et al., 2013), suppression of caspase activity via EP2 
and EP4 activation promotes cell viability.  Neither EP1 nor EP3 agonists maintained 
cell viability in gastric cells exposed to ethanol suggesting that EP1 and EP3 do not 
have a role with regards to caspase inhibition and suppression of apoptosis.  
Nonetheless, EP1 activation by PGE2 is a protective mechanism as it results in an 
increase in the release of bicarbonate, a critical buffer for the intestinal tract to 
neutralize the acidity of gastric chyme (Takeuchi et al., 1997). 
Yokotani et al. (1996) published a report detailing the role that EP3 activation has in 
reducing the secretion of gastric acid.  Using a gastric epithelial cell line that expressed 
EP4, but not EP1 or EP3, the addition of PGE2 to the cells resulted in production of 
hexosamine (Hassan et al., 1996).  The formation of hexosamine occurs during 
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synthesis of gastric mucous (Gindzienski et al., 2003), hence EP4 activation represents 
yet another pathway by which PGE2 maintains the overall health and integrity of the 
gastrointestinal tract.  Overall, the outcome of PGE2 synthesis and subsequent binding 
to its native receptors is an apparent resistance to damage from toxicants through 
several distinct but physiologically relevant and complementary pathways. 
The role that COX-1 has in maintaining health of the gastrointestinal tract was 
demonstrated using mice that were exposed to radiation.  Cox-1 but not Cox-2 was 
induced in mice exposed to radiation (Cohn et al., 1997).  In that same study, mice were 
then challenged with indomethacin which has greater potency against COX-1 compared 
to COX-2 (Blanco et al., 1999).  The administration of indomethacin reduced both PGE2 
synthesis as well as the number of surviving intestinal stem cells.  Treatment with a 
PGE2 analogue was able to counter the indomethacin effect on the stem cells.  The 
authors conclude that PGE2 generated from Cox-1 had a protective effect in their 
mouse model. 
The cytoprotective effects of COX-2 are evidenced by its apparent induction in 
neoplastic tissue (Eberhart et al., 1994).  As an example, PGE2 stimulated colon tumors 
in a rat model wherein PGE2 was administered over multiple weeks (Kawamori et al., 
2003).  The authors of that study reported transcriptional expression of all EP receptors.  
PGE2 administration also decreased the level of apoptosis compared to control.  The 
authors concluded that PGE2 stimulated cellular proliferation in addition to inhibiting 
apoptosis.  The potential for PGE2 to induce cellular growth in models of tumor growth 
created interest in pursuing COX-2 inhibition as a potential treatment for metastases of 
the colon (Ferrandez et al., 2003; Koehne and Dubois, 2004; Fujimura et al., 2007). 
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As mentioned previously, COX-2 is inducible, and its expression increases during 
inflammation or injury (Mizuno et al., 1997).  A rat model was used to demonstrate that 
inhibition of COX-2 was associated with a delay in repair of ulcers as well as reduction 
of angiogenesis (Ma et al., 2002).  A separate study reported that activation of EP4 but 
not EP1, EP2, or EP3 accelerated wound healing in a rodent model of intestinal 
ulceration (Hatazawa et al., 2007).  Ulceration in the animals was induced by application 
of heat that led to a marked increase of intestinal PGE2.  The involvement of EP4 in 
wound repair was confirmed by administration of an EP4 agonist.  Administration of a 
selective EP4 antagonist caused a delay in healing.  Furthermore, rats and mice that 
received indomethacin and rofecoxib (a selective COX-2 inhibitor), experienced delays 
in ulcer repair in contrast to animals given SC-560 (a selective COX-1 inhibitor).  
Furthermore, the latency in healing was observed in Cox-2 knockout mice but not Cox-1 
knockout mice.  Thus it can be inferred from the Hatazawa study that COX-2 was 
operative in healing of ulcers through generation of PGE2 that acted on EP4 receptors. 
Given the importance of COX-1 and COX-2 for protection of the gastrointestinal tract as 
well as involvement on cellular regeneration, inhibition of both pathways would be 
contributory toward exacerbation of gastrointestinal injury.  One of the critical 
components of COX inhibition is the production of PGE2 from AA metabolism.  In this 
framework, the research presented in subsequent chapters will focus on the role that 
DCF and its metabolites have in causing injury to the intestinal tract. 
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1.5 Diclofenac 
1.5.1 Pharmacokinetics and Metabolism 
Diclofenac is an NSAID that was developed by Ciba Geigy and patented in Europe and 
the United States in 1965 and 1971, respectively (Sallmann and Pfister, 1971).  In the 
United States, diclofenac is available only by prescription and is commonly given in 100 
mg doses though its therapeutic benefit can be achieved with dosing of 50 to 200 mg 
per day (Novartis, 2011; Depomed, 2014).  Diclofenac is also prescribed as a gel for 
topical applications.  Low dose diclofenac was made available as an over-the-counter 
(OTC) remedy in a number of countries (Hinz et al., 2005).  As recently as 2015, 
diclofenac was removed from OTC status by the Medicines and Healthcare products 
Regulatory Agency (MHRA) in the United Kingdom due to concerns of cardiac toxicity 
(MHRA, 2015).  Consequently, diclofenac became available as a prescription only 
medicine similar to its status in the United States. 
The pharmacokinetics of diclofenac has been characterized in animals and man.  
Approximately 60% of diclofenac is eliminated in feces in the dog and rat with the 
remaining 40% excreted in the urine (Riess et al., 1978).  The elimination pathway is 
reversed in monkey whereby approximately 80% of the dose is eliminated in urine with 
20% excretion in feces.  Similar to monkey, 60% of the dose was excreted in the urine 
of healthy human subjects with the remainder directed to biliary excretion (Stierlin and 
Faigle, 1979).  The bioavailability of diclofenac in human subjects given a single 50 mg 
dose was reported to be 54% (Willis et al., 1979).  In healthy human subjects receiving 
an oral dose, the maximum plasma concentration (Cmax) was calculated to be 2.0 µg/mL 
(6.75 µM) occurring approximately 2.5 hours after dosing with a terminal half-life of 1.8 
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hours.  A food effect was observed in humans in that the time to maximum plasma 
concentration was increased however the overall exposure of diclofenac, as measured 
by integration of plasma-concentration time profiles, was similar between fasting and 
non-fasting subjects (Willis et al., 1981). 
Diclofenac undergoes extensive metabolism, and less than 1% of the dose is excreted 
in the urine as parent compound.  Major Phase I metabolites are 3ʹ-hydroxy-, 4ʹ-
hydroxy-, 5-hydroxy, 3ʹ,4ʹ-dihydroxy-, and 4ʹ,5-dyhyroxy-diclofenac as the result of 
catalysis by CYP2C8, CYP2C9 (for 4ʹ-hydroxy), and CYP3A4 (for 5-hydroxy) (Riess et 
al., 1978; Stierlin and Faigle, 1979; Bort et al., 1999a).  Approximately 30% of the total 
diclofenac dose is excreted in urine as the 4ʹ-hydroxy metabolite while biliary excretion 
of 4ʹ-hydroxy accounts for up to 20% of the dose (Davies and Anderson, 1997).  Phase 
II metabolites are taurine and acyl glucuronide conjugates of diclofenac (Pickup et al., 
2012; Sarda et al., 2012).  Glucuronide conjugates can subsequently be hydroxylated.  
Regarding glucuronide formation, the predominant enzyme is UGT2B7 (UGT2B7).  In 
addition to UGT2B1, Nakamori et al. (2012) reported that diclofenac can be 
glucuronidated by UGT2B15, UGT2B17, and UGT1A9. 
Diclofenac has excellent absorption as characterized in the Caco-2 colorectal 
adenocarcinoma cell line.  Caco-2 cells are often used to test compound permeability 
and determine if there is transport by MDR1 as the cells express this efflux transporter 
(Marino et al., 2005).  Owing to the polarization of Caco-2 cells, test compounds are 
assayed in an Apical→Basolateral (A→B) and Basolateral→Apical (B→A) format, and 
the flux or movement of compound is reported as a two dimensional parameter with 
units of cm/sec.  The A→B and B→A values for diclofenac are 20 and 21 × 10-6 cm/sec, 
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respectively (Yazdanian et al., 2004).  The B→A/A→B ratio of 1.1 signifies diclofenac is 
not a MDR1 substrate as ratios > 2 indicate MDR1 efflux.  The cell assay was confirmed 
with a parallel artificial membrane permeability assay (PAMPA), which is a non-cell 
based assay that uses lipids to mimic a physiologic barrier (Nakamori et al., 2012).  
Diclofenac’s permeability classifies it as highly permeable and similar to compounds 
such as caffeine, midazolam, and verapamil.  Using Equation 1.1, the bioavailability of 
diclofenac can be broken down as follows: 
                                  
The above relationship indicates that: 1) absorption of diclofenac is complete as a 
consequence of high permeability, 2) intestinal enzymes significantly contribute to 
overall diclofenac metabolism, and 3) hepatic metabolism is less than intestinal 
metabolism following an oral dose (Varma et al., 2010). 
1.5.2 Reactive Metabolites 
The metabolism of diclofenac results in reactive metabolites.  Both the 4ʹ- and 5-hydroxy 
metabolites (refer to Figure 2.8) can form quinone imines due to the hydroxy groups 
being para to nitrogen (Shen et al., 1999).  A simplified reaction is shown below: 
H
R
OH N
R
O N
 
Exposure to diclofenac has been linked to bone marrow toxicity.  Studies with 
neutrophils provided evidence that a quinone imine derivative of diclofenac was 
detected in neutrophils (Miyamoto et al., 1997).  Neutrophils are white blood cells that 
protect the body against microorganisms. 
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One the ways in which neutrophils carry out their antimicrobial function is to generate 
reactive oxygen species from the release of myeloperoxidase (Monteseirin et al., 2001).  
Myeloperoxidase (MPO) generates hypochlorous acid (HOCl) from chloride ions using 
hydrogen peroxide, which is reduced to water (Arnhold, 2004).  HOCl then reacts with a 
number of agents to produce reactive oxygen and nitrogen species.  Regarding 
diclofenac-associated bone marrow toxicity, Miyamoto and colleagues demonstrated 
that myeloperoxidase, through the synthesis of HOCl, generated diclofenac quinone 
imine reactive species.  Though the authors admit that quinone imine formation by MPO 
is slow, they argue that such a reaction could occur in vivo and be a contributory factor 
to the bone marrow toxicity that can occur during treatment with diclofenac (Sell et al., 
1999; Aydogdu et al., 2006). 
In addition to diclofenac, a number of marketed agents are metabolized into acyl 
glucuronides including clofibric acid, diflunisal, fenoprofen, furosemide, ibuprofen, 
ketoprofen, mycophenolic acid, suprofen, tolmetin, valproic acid, and zomepirac (Bailey 
and Dickinson, 1996; Bolze et al., 2002).  Ferosemide acyl glucuronide has very low 
reactivity as a result of its benzoic acid structure providing a stabilizing force through 
resonance of the aryl π bonds (Sawamura et al., 2010).  Though ibuprofen is converted 
to an acyl glucuronide that can covalently bind albumin, it has an excellent safety profile 
in that reports of adverse drug reactions (ADRs) were less than or equal to placebo 
(Fries et al., 1991; Kellstein et al., 1999).  In the case of ketoprofen, its reactive 
glucuronide was shown to covalently bind to the UGT enzyme that generated it (Terrier 
et al., 1999).  Despite the UGT modification by ketoprofen acyl glucuronide, ketoprofen 
usage for pain relief did not result in any ADRs during an 18 month study designed to 
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test its overall safety in 402 patients (Kneer et al., 2009).  Valproic acid was found to 
form covalent adducts, via its acyl glucuronide, in patients taking the drug for epilepsy 
treatment.  Yet in those patients that tested positive for valproic acid antibodies, the 
antibody titer was reportedly low (Williams et al., 1992).  Factoring the incidence of 
covalent adduct formation and antibody generation in response to the adducts, valproic 
acid usage is not likely to result in hypersensitivity reactions.  That said, valproic acid 
itself has been linked to nonalcoholic fatty liver disease that is characterized by mixed 
hepatocellular injury thought to have an immune component (Farinelli et al., 2015).  Of 
the more reactive acyl glucuronides listed above, the rank order of reactivity is tolmetin 
> zomepirac > diclofenac.  Zomepirac was withdrawn from marketed status due to fatal 
hypersensitivity reactions (FDA, 1998).  Interestingly, Cannell et al. (2001) reported that 
incubation of colon cancer cells with the acyl glucuronides of diclofenac, diflunisal, and 
zomepirac attenuated the cellular division of the cells perhaps as a result of their 
covalent adduction to factors involved in proliferation. 
1.5.3 Liver Toxicity 
Liver injury can be determined through the use of serum markers, specifically alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 
(ALkP), and bilirubin.  ALT and AST are indicators of hepatocellular damage while ALkP 
and bilirubin are used to indicate biliary obstruction or cholestasis (Green and Flamm, 
2002).  ALT is more exclusive to the liver cells and is found in the cytosol while AST is 
localized in both in the cytosol and mitochondria.  Elevations of ALT and AST in the 
blood may indicate that a degree of liver injury or necrosis has occurred.  ALkP is useful 
as an indicator of cholestasis due to its localization along the bile canalicular domain.  
34 
 
Bilirubin is formed during the breakdown of heme, and its elimination is dependent upon 
glucuronidation before excretion into the bile.  The pattern of liver injury is contingent 
upon the extent of elevations in the serum markers.  For reference, the upper limit of 
normal (ULN) for ALT, ALkP, and bilirubin are 40 U/L, 115 U/L, and 1.2 mg/dL, 
respectively (livertox.nih.gov).  A comparative score, R value, is used to categorize the 
type of injury and is determined as follows: 
Equation 1.2 
                              
As a general guideline, an R value > 5 indicates hepatocellular injury, an R of <2 
represents cholestatic injury, and R values between 2 to 5 signify a mixture of 
cholestatic and hepatocellular injury (Chalasani et al., 2014). 
According to diclofenac prescribing information, hepatotoxicity from diclofenac can 
manifest within one to two months of therapeutic use (Novartis, 2011).  A composite of 
reported diclofenac hepatotoxicity cases is shown in Table 1.3.  The calculated R values 
for the cases cited appear to indicate that the liver injury attributable to diclofenac usage 
exhibited a pattern of hepatocellular damage while one of the cited cases seems to 
have been a mixed cholestatic and hepatocellular phenotype.  Presentation of jaundice, 
which can occur during cholestasis, was positively correlated with severe liver injury 
though several subjects with jaundice recovered once diclofenac treatment was stopped.  
Manifestation of high ALT values did not reliably predict that mortality would necessarily 
follow.  As an example, Chalasani et al. (2015) followed 899 subjects for drug-induced 
liver injury for which twelve subjects were identified as taking diclofenac.  Of the twelve 
subjects, one exhibited a peak ALT of 1,895 U/L before ultimately dying.  The diclofenac 
group as a whole had a mean ALT of 1,266 ± 680 U/L, a value that is approximately 30-
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fold greater than the ALT ULN.  Five of the diclofenac subjects were classified as having 
mild injury (increased ALTs & bilirubin <2.5 mg/dL) while six were deemed to have 
severe injury (bilirubin >2.5 mg/dL, hospitalization, jaundice, and organ failure).  Liver 
injury from diclofenac accounted for nearly 36% of the entire cohort of subjects taking 
analgesics (12 of 33 total subjects) suggesting that diclofenac usage carries greater risk 
of hepatic injury compared to other anti-inflammatory drugs. 
One key feature of diclofenac patients who develop liver injury is the dosing regimen.  
When liver injuries do occur, more often than not the patients are adherent to the 
prescribed dosage indicating that the liver injury is likely not a function of diclofenac 
overdose.  This is in stark contrast to acetaminophen for which overdose is more 
common.  An analysis by Larson et al. (2005) revealed that acetaminophen accidental 
overdoses and suicide attempts accounted for 133 and 122 cases, respectively, out of 
662 acute liver failures over a six year period.  The majority of subjects overdosing on 
acetaminophen survived, however 27% died and 8% needed liver transplants for which 
29% of transplant patients did not survive beyond three weeks after surgery.  Lastly, the 
median acetaminophen dose was 24 g despite product labeling warnings not to exceed 
4 g per day.  The high incidence of acetaminophen is linked to ease of access as an 
over-the-counter medication (Sheen et al., 2002). 
Reports of diclofenac overdose are rare, however once such case was published by 
Netter et al. (1984) in which a 19-year old man intentionally overdosed on 1.5 g of 
diclofenac, which is 7.5-fold greater than the maximum recommended therapeutic dose 
(MRTD).  Diclofenac plasma concentration seven hours after ingestion was 60.1 µg/mL 
(189 µM), which is 30-fold higher than the plasma Cmax after a 50 mg therapeutic dose.  
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Despite the overdose and subsequent high diclofenac plasma concentrations, the 
subject recovered after two days with no apparent injury to liver or kidneys.  Diclofenac 
overdose has been associated with renal dysfunction after an accidental overdose 
(Kulling et al., 1995).  In that case a 29-year old man consumed 2 g of diclofenac (10-
fold MRTD) and survived.  No information regarding liver injury was given, however 
renal function was affected as evidenced by peak serum creatinine levels of 2.6 mg/dL 
compared to the normal range of 0.7 to 1.5 mg/dL (Lee, 2013).  Tolerance of diclofenac 
during an overdose is not consistent as seen in a case whereby a 30-year old woman 
took 1 g of diclofenac (5-fold MRTD) and died two weeks after the overdose (Montiel et 
al., 2010).  Hepatic and renal injury were apparent, leading to organ failures for both, 
with maximal ALT and serum creatinine levels of 4,710 U/L and 3.7 mg/dL, respectively.  
The role that diclofenac may have had in that case is unclear due to ingestion of several 
other medications including 8 g ibuprofen.  In a study of 1,572 German subjects taking 
analgesics, approximately 25% were found to be using diclofenac with ibuprofen usage 
second-most at 21% (Freytag et al., 2014).  In 426 subjects taking multiple analgesics, 
diclofenac was consumed with ibuprofen in 8.9% of the cases with polypharmacy also 
observed with acetaminophen (6.6%), metamizole (6.3%), and tramadol (4.9%).  
Despite the fact that subjects took more than the recommended dosage of diclofenac or 
consumed multiple analgesics, the most common risk was gastrointestinal bleeding. 
The exact mechanisms of liver injury following diclofenac usage are not wholly clear.  In 
the examples cited above and Table 1.3, injury ranged from mild to severe/fatal without 
clear distinction of the injury phenotype.  For instance, all fatalities presented with 
jaundice, yet not all patients who developed jaundice died.  Additionally, ALT values 
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were minimally 20-fold higher than ULN in the cases where fatality was reported.  
Subjects that eventually recovered had ALTs that were comparable to the fatalities.  
Several of the cases showed evidence of hypersensitivity that was determined by the 
presence of antinuclear antibodies.  Furthermore, accumulation of eosinophils was 
found in livers of diclofenac subjects with hepatotoxicity supporting the hypersensitivity 
hypothesis.  Eosinophils are part of the immune system and are involved in the 
development of delayed-type hypersensitivity reactions (Akahira-Azuma et al., 2004). 
Dunk et al. (1982) reported their finding of a 52-year old man who had been taking 
diclofenac for the treatment of pain.  After four months of usage, the individual 
developed jaundice with AST and bilirubin levels of 1,375 U/L and 7.4 mg/dL, 
respectively.  Upon cessation of diclofenac treatment, the jaundice gradually subsided 
during the following week.  The patient subsequently continued diclofenac treatment a 
month later, and within several weeks the jaundice reappeared.  A liver biopsy was 
performed, and the presence of eosinophils as well as Kupffer cell proliferation was 
detected in the liver signifying activation of the immune system.  Such activation may 
also result in production of anti-diclofenac antibodies, a point illustrated by Aithal et al. 
(2004) who reported that subjects with hepatotoxicity due to diclofenac treatment had 
anti-diclofenac antibodies. 
Further evidence for immune modulation is provided by the work of Yano et al. (2012) 
for which plasma IL-17 was induced in mice given an 80 mg/kg dose of diclofenac.  
Hepatotoxicity in the mice was diminished when IL-17 was sequestered by an anti-IL-17 
antibody indicating that IL-17 may have promoted injury through pro-inflammatory 
pathways (Jin and Dong, 2013).  A recently published study characterized immune 
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activation by diclofenac in an in vitro assay with human hepatoma cell lines wherein the 
pro-inflammatory mediators IL-1, IL-8, and TNF as well as monocyte chemoattractant 
protein and immune mediator S100 calcium-binding protein A9 were upregulated by 50 
µM diclofenac (Oda et al., 2015).  Yet antibody presence does not appear to be a 
specific indicator of liver injury as antibodies were detected in 60% of subjects on 
diclofenac who did not have liver injury.  Presumably, the anti-diclofenac antibodies are 
likely directed against the covalent adducts that were described in the preceding section.  
Nonetheless, hypersensitivity to diclofenac is cause for concern in that there is the 
possibility of adverse reaction to other structurally similar anti-inflammatory drugs (del 
Pozo et al., 2000; Picaud et al., 2014). 
Non-immune hepatotoxicity may be linked to formation of metabolites and blockade of 
critical organelle function.  For example, research by Castell et al. (1997) demonstrated 
that generation of N,5-dihyroxy diclofenac was associated with hepatocellular injury.  
Base on the results in a follow-up study, the authors postulated that continual 
generation of the N,5-dihydroxy diclofenac from 5-hydroxy diclofenac by CYPs depletes 
the cell of NADPH (Bort et al., 1999b).  Furthermore, both diclofenac and N,5-dihydroxy 
diclofenac were shown to deplete ATP.  The loss of both ATP and NADPH is 
detrimental to the cell since ATP is needed to generate NADPH as well as to drive a 
number of cellular functions.  Under normal conditions, cells can replenish ATP in the 
mitochondria, however diclofenac disrupts mitochondrial function.  It has been shown 
that diclofenac interferes with the mitochondrial permeability transition pore, allowing the 
pore to remain open for a longer duration leading to mitochondrial swelling and cell 
death (Gomez-Lechon et al., 2003b; Lim et al., 2006). 
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1.5.3 Intestinal Toxicity 
It has been well established that therapeutic usage of NSAIDs is correlated with 
gastrointestinal injury.  In a study of 1,800 subjects being treated for arthritis, ulceration 
and gastrointestinal lesions occurred in 24% and 37%, respectively, of the patient 
population (Geis et al., 1991).  Just as for other NSAIDs, treatment with diclofenac is 
associated with gastrointestinal ADRs such as abdominal pain, bleeding, perforation, 
and ulceration (Novartis, 2011).  Thomas et al. (2012) monitored 943 patients receiving 
diclofenac by prescription and noted that of the 561 ADRs, 267 (48%) were 
gastrointestinal in nature.  Abdominal pain accounted for 19% with ulceration making up 
6% of reported ADRs. 
As a consequence of intestinal injury and to promote patient compliance, diclofenac can 
be prescribed as a combination treatment with misoprostol (Pfizer, 2014).  Misoprostol 
is a synthetic PGE1 analogue, and its therapeutic benefit is a result of activating EP 
receptors to stimulate the gastrointestinal secretion of bicarbonate and mucous (Karim 
and Gels, 1995).  Administration of 0.2 mg misoprostol one to three times daily was 
effective in reducing the incidence of gastrointestinal ulcers after a twelve week 
treatment period (ulceration in 4.4% of patients receiving combination therapy vs. 
ulceration in 11% of subjects receiving diclofenac monotherapy (Verdickt et al., 1992).  
Another therapeutic benefit of misoprostol co-administration with diclofenac was a 
marked reduction in the number of patients experiencing abdominal pain, 19% vs. 70% 
for monotherapy (Agrawal et al., 1995).  Thus, as a PGE1 analogue, misoprostol is able 
to partially restore the prostaglandin-mediated protection that is otherwise attenuated 
following exposure to diclofenac. 
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The intestinal injury during diclofenac treatment is linked to the inhibition of COX 
enzymes by diclofenac.  That diclofenac inhibits both COX enzymes is part of the 
pathogenesis in gastrointestinal ulcers (Tanaka et al., 2001; Sigthorsson et al., 2002).  
Emery et al. (1999) conducted a study in which patients with arthritis received either 
diclofenac or the selective COX-2 inhibitor celecoxib.  Patients were followed for six 
months, and a subset was analyzed for gastrointestinal injury via endoscopy.  
Pharmacologically, both agents were effective in ameliorating inflammation and pain.  A 
higher percentage of patients taking diclofenac experienced abdominal pain (21%) and 
developed gastrointestinal ulcers and/or erosions (45%) compared to the celecoxib 
group (11% for pain and 23% for ulcers/erosions).  The higher incidence of diclofenac-
induced gastrointestinal injury resulted in a withdrawal rate from therapy that was more 
than twice the withdrawal for celebrex (16% vs. 6%, respectively).  Reanalysis of a 
separate study was somewhat contradictory in that celecoxib and diclofenac appeared 
to be comparable with respect to gastrointestinal injury (Silverstein et al., 2000; Juni et 
al., 2002).  A possible explanation for the parity may be attributable to a higher dosage 
of celecoxib (800 mg) in the report by Silverstein et al. relative to the dose used in the 
study by Emery and colleagues (200 mg twice a day). 
The degree of intestinal injury following exposure to diclofenac is partially dependent on 
the route of administration.  For instance, in a study wherein diclofenac was 
administered either orally or via application to skin by gel, oral dosing resulted in 39% of 
subjects developing gastrointestinal ADRs whereas 25% of patients with topical skin 
application manifested gastrointestinal injury (Roth and Fuller, 2011).  The withdrawal 
rate in the oral dosing group was 2.5-fold greater than the rate observed in the skin 
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application group.  That gastrointestinal injury also occurred during topical application of 
diclofenac is indicative of a systemic effect for which the magnitude was enhanced after 
oral dosing due to the higher systemic concentration of diclofenac.  As per the 
prescribing information for diclofenac topical gel, standard application of the gel (4 g gel, 
4 times/day) results in a total daily dose of 160 mg with an average maximum plasma 
concentration of 0.015 ng/mL (0.051 µM) while an oral daily regimen of 150 mg (50 mg, 
3 times/day) yields an average maximum plasma concentration of 2.27 µg/mL (7.67 µM) 
(Novartis, 2014).  The lower maximum plasma concentration from topical application is 
consistent with what was determined for ketoprofen for which plasma concentrations 
following topical administration were 1% of the plasma concentrations following the 
nominal oral dose of 200 mg (Kneer et al., 2009). 
Gastrointestinal injury following diclofenac administration has been demonstrated to 
occur in animal models of acute exposure.  Rats given a single dose of diclofenac 
developed intestinal ulcers within 24 hours of administration (Atchison et al., 2000a; 
Atchison et al., 2000b).  Sequestration of diclofenac with cholestryramine, which is 
therapeutically used to reduce bile reabsorption, decreased the incidence of gastric 
injury but not intestinal damage compared to diclofenac monotherapy in rats (Ramírez-
Alcántara et al., 2005).  It has been suggested that the reactive metabolites of 
diclofenac, specifically the acyl glucuronide, may be linked to induction of intestinal 
ulceration (Seitz and Boelsterli, 1998; Ware et al., 1998).  The theory is that the 
glucuronide conjugate may compromise the integrity of the intestinal tract via covalent 
modification to enterocytes.  An alternate hypothesis is that the acyl glucuronide 
undergoes cleavage to the aglycone parent compound, which is then able to induce 
42 
 
enteropathy.  LoGuidice et al. (2012) demonstrated that chemical inhibition of β-
glucuronidase decreased the number and size of ulcers in mice treated with diclofenac 
and inhibitor compared to mice that received only diclofenac.  The intestinal injury 
observed both in animal models and human patients most likely involves contribution 
from both diclofenac and its acyl glucuronide.  As such, one of the key themes of the 
research presented in this thesis is to further expand the probable mechanisms causing 
intestinal injury. 
1.6 Summary 
The work presented throughout this thesis focuses on the roles that BCRP, MRP3, and 
OATP2B1 may have in modulating the exposure of diclofenac and its primary 
metabolites.  BCRP, OATP2B1, and MRP2 have been extensively studied for 
substrates evidenced by 247, 84, and 141 studies, respectively, as listed in the 
University of Washington (UW) in vitro Drug Interaction Database (UW, 1999-2015).  In 
comparison, MRP3 is underrepresented with respect to literature reports having 23 
unique citations in that same database (see Table 1.2).  Though the UW repository may 
not contain all reported studies, its frequent update and breadth of data capture help to 
underscore the relative obscurity of MRP3 findings.  In consideration of the lack of data 
regarding DCF elimination by transporters other than Mrp2, our initial investigations 
included Bcrp and Mrp3 as potential canalicular and basolateral mediators of DCF 
transporter-mediated clearance. 
Our hypothesis was that deletion of Bcrp or Mrp3 would result in altered disposition of 
DCF or its metabolites.  To assess the contribution of efflux transporters in DCF 
disposition, we utilized whole-body in vivo transporter knockout animal models and 
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administered a single low dose to mice.  The doses used were presumed to be below 
the threshold that would induce tissue damage.  Regardless of dose selection, a 
potential consequence of gene deletion is an upregulation of other genes as a 
compensatory response, a condition that may have potential ramifications for the overall 
design and anticipated outcome of our studies. For instance, rats that are missing Mrp2 
via a spontaneous mutation were demonstrated to have induction of Mdr1 in brain but 
not liver (Hoffmann and Loscher, 2007).  A similar situation can occur in humans.  For 
example, in a subset of patients with acute myeloid leukemia there is deletion of one or 
both copies of MRP1, yet the overall MRP activity was found to be comparable to 
normal hematopoietic cells taken from healthy patients (van Der Kolk et al., 2000).  The 
authors of that study speculate that upregulation of other efflux transporters was the 
reason.  As it pertains to our study design, the mice used in our studies were not 
reported to have alterations in other efflux transporters such as Mrp2 (Manautou et al., 
2005; Zelcer et al., 2005).  Thus the results detailed in Chapter 2 reflect bona fide 
hepatic canalicular efflux of DCF and DCF-AG by Bcrp as well as basolateral efflux of 
DCF-AG by Mrp3. 
Based on the results observed in Chapter 2, we focused our efforts on Mrp3 and further 
hypothesized that loss of Mrp3 would have a deleterious effect such that mice lacking 
Mrp3 would be more susceptible to liver and/or intestinal injury after a single toxic 
administration of DCF.  The data in Chapter 3 support the claim that Mrp3 functions as 
an important protective mechanism against injury.  Indeed, the presence of Mrp3 was 
able to attenuate the extent of intestinal injury after an acute toxic dose of DCF.  Mice 
that lacked Mrp3 exhibited an increase in the incidence of injury, in terms of number of 
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erosions and ulcers, as well as severity of damage compared to wild-type mice.  
Strikingly, there was no evidence of hepatic injury in either wild-type mice or Mrp3 
knockout mice.  Although DCF is implicated in liver injury in humans, the potential for 
DCF-mediated hepatotoxicity was not readily apparent on an acute basis with the 
mouse models implemented in our studies.  It is possible that hepatotoxicity caused by 
diclofenac manifests only after repeated dosing.  Despite the null finding in liver, the 
intestinal toxicity was unequivocal and emphasizes the importance of Mrp3 as a vital 
clearance mechanism in the intestine. 
Acyl glucuronides have low passive uptake (Zhou et al., 2005; Shackleford et al., 2006; 
Patel et al., 2013; Kimoto et al., 2015), therefore the uptake of DCF-AG into enterocytes 
would likely occur through active transport.  Since glucuronide conjugates have been 
reported to be substrates of OATP2B1, a major intestinal uptake transporter, the uptake 
of DCF-AG was postulated to occur via OATP2B1.  To test this theory, an in vitro 
system wherein OATP2B1 was stably transfected into human embryonic kidney (HEK) 
cells was utilized.  HEK cells provide an advantage to study transporter activity in an 
overexpressed system as these cells have low to non-existent expression of many of 
the uptake and efflux transporters shown in Table 1.1 (Ahlin et al., 2009).  The uptake of 
DCF-AG via OATP2B1 was quantified and determined to be saturable.  A mouse 
homologue, Oatp2b1 (Slco2b1), likewise is expressed along the intestinal tract allowing 
for a reasonable argument that DCF-AG intestinal uptake in the mouse studies was 
mediated by Oatp2b1. 
In prior sections, the intrinsic toxicity of DCF was detailed as was the reactivity of DCF-
AG.  Given the high biliary DCF-AG concentrations detected in the acute toxicokinetic 
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study, along with the apparent injury characterized in the Mrp3 knockout mice in the 
toxicodynamic study, it seemed plausible that DCF-AG was a direct mediator of the 
observed toxicity.  Nonetheless, the manner by which DCF-AG causes toxicity is not 
wholly clear.  Rather than focus on immunologic pathways, as suggested by those 
supporting a hapten hypothesis, that may or may not manifest in a mouse model, 
investigation into other causal mechanisms was considered.  Furthermore, immune 
hypersensitivity would require multiple doses, which is not the case in our acute injury 
model. 
We theorized that DCF-AG was cytotoxic, and used HEK cells to measure the extent of 
DCF-AG has on cell viability.  The data in Chapter 4 provide evidence that DCF-AG is 
indeed cytotoxic, and that DCF-AG can induce cell death more so than DCF.  The 
mechanism of the cytotoxicity was thought to occur through oxidative stress.  Rationale 
for the oxidative stress hypothesis stems from the report that suprofen acyl glucuronide 
inhibited superoxide dismutase, an important component of antioxidant defense (Kakkar 
et al., 1984; Chiou et al., 1999; Fukui and Zhu, 2010).  Subsequently, DCF-AG was 
analyzed for induction of oxidative stress by means of two distinct pathways.  Not only 
was DCF-AG able to generate reactive oxygen species, but it also exhibited a dose-
dependent inhibition of superoxide dismutase.  Furthermore, DCF-AG was tested for 
inhibition of cyclooxygenase enzymes and found to inhibit both COX-1 and COX-2.  As 
mentioned in the prior section, perturbation of COX metabolism of arachidonic acid 
renders the intestinal tract more susceptible to injury and diminishes the capacity for 
regeneration. 
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Inhibition of efflux of either cytoprotective or danger signals from stressed cells can 
interfere with cellular signaling and limit adaptive response to toxicants.  PGE2 is an 
important cytoprotective agent that was reported to be a substrate for MRP4 in addition 
to other MRP4 cellular signaling substrates such as cyclic nucleotides and steroid 
hormones (Reid et al., 2003b; Russel et al., 2008).  Thus the final objective of current 
work was to assess the effect of analgesics and their respective metabolites on the 
function of MRP4.  Further impetus for conducting MRP4 inhibition stems from two 
findings: 1) MRP4 protein expression is inducible following challenge by hepatotoxicants, 
and 2) the high concentrations of parent compound and metabolites after a toxic 
challenge.  A listing of reported inhibitors of MRP4 can be found in Table 1.4 (Morrissey 
et al., 2012).  Inhibition of MRP4, using leukotriene C4 as the substrate, was detected 
for DCF, DC-OH, and DCF-AG.  Inhibition failed to surpass 50% up to 300 µM, 
therefore IC50 values could not be determined.  Whereas DCF had low inhibition 
potency for MRP4 efflux of methotrexate, its inhibition potency for MRP4 efflux of 
leukotriene was decidedly weaker.  The full significance of MRP4 inhibition as it pertains 
to a clinical setting remains to be determined. 
In summary, the research presented throughout the thesis provides evidence on the 
complex interaction between efflux and uptake transporters.  Specifically, OATP2B1 
mediates the uptake of DCF-AG in an in vitro system, while the efflux of DCF-AG was 
characterized both in vitro using MRP3 vesicles as well as in vivo with a Mrp3 knockout 
mouse model.  Perturbation of transporter activity, in the form of Mrp3 deletion, results 
in increased susceptibility to intestinal injury following a toxic DCF dose.  In vitro assays 
showed that DCF-AG may have directly contributed to the intestinal enteropathy by 
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causing a state of oxidative stress vis-à-vis induction of reaction oxygen species in 
addition to inhibition of superoxide dismutase.  Furthermore the pharmacological activity 
of DCF-AG against COX-1 and COX-2 may have promoted injury by attenuating the 
levels of cytoprotective prostaglandins.  As it relates to the human condition, patients 
taking DCF who possess polymorphic MRP3 may be at risk for greater intestinal injury.  
At the very least, these data justify investigation of human MRP3 polymorphisms during 
the course of treatment with DCF or similar therapeutic agents that have reactive acyl 
glucuronides. 
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Figure 1.1 Structure and organization of human liver 
 
Source: Howard M. Reisner: Pathology: A Modern Case Study.  2015.  McGraw-Hill 
Education.  Reproduced with permission of McGraw-Hill Education. 
Copyright © McGraw-Hill Education.  All rights reserved. 
 
 
 
 
 
 
49 
 
Figure 1.1 Structure and organization of human liver. 
Each lobe of the liver consists of lobules with a hexagonal appearance.  The lobules are 
anatomically structured such that blood flows from portal triads at the periphery of the 
lobule toward the central vein in the middle of the lobule.  In contrast bile flows from the 
central vein towards bile ducts in the portal triad.  The majority of the lobule is populated 
with hepatocytes that are metabolically active. 
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Figure 1.2 Structure and organization of human small intestine 
 
"small intestine: regions and structures". Art. Encyclopædia Britannica Online. Web. 27 Oct. 2015. 
http://www.britannica.com/science/duodenum/images-videos/Structures-of-the-small-intestine-The-inner-wall-of-the/68637 
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Figure 1.2 Structure and organization of human small intestine. 
The small intestine consists of three physically contiguous segments.  Each segment 
has a hallow cavity called the lumen.  The effective surface area within the lumen and 
magnified by folds termed plicae circulars that have fingerlike protrusions denoted as 
villi.  The villi are comprised of a single layer of enterocytes.  Substances that are taken 
up by the enterocytes from the lumen can be metabolized, transported back into the 
lumen, or excreted into the villus. 
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Table 1.1 Protein sequence homology of human efflux and uptake transporters involved in xenobiotic disposition 
Gene 
(alias) 
ABCC1 
(MRP1) 
ABCC2 
(MRP2) 
ABCC3 
(MRP3) 
ABCC4 
(MRP4) 
ABCC5 
(MRP5) 
ABCC6 
(MRP6) 
ABCC7 
(CFTR) 
ABCC8 
(SUR1) 
ABCC9 
(SUR2) 
ABCC10 
(MRP7) 
ABCC11 
(MRP8) 
ABCC12 
(MRP9) 
ABCC13 
(MRP10) 
ABCC1 100 48 57 38 42 45 31 33 34 35 33 33 35 
ABCC2  100 46 36 43 38 31 31 32 34 33 34 32 
ABCC3   100 35 39 43 30 33 34 36 33 32 34 
ABCC4    100 42 33 37 32 32 33 34 34 25 
ABCC5     100 37 30 31 31 39 41 45 - 
ABCC6      100 31 31 30 33 30 31 30 
ABCC7       100 32 31 30 28 30 - 
ABCC8        100 67 31 29 29 - 
ABCC9         100 31 29 28 - 
ABCC10          100 31 34 - 
ABCC11           100 48 - 
ABCC12            100 - 
ABCC13             100 
 
Gene 
(alias) 
ABCG1 
(WHITE1) 
ABCG2 
(BCRP) 
ABCG4 
(WHITE2) 
ABCG5 
(Sterolin-1) 
ABCG8 
(Sterolin-2) 
ABCG1 100 31 72 26 25 
ABCG2  100 30 30 29 
ABCG4   100 27 25 
ABCG5    100 32 
ABCG8     100 
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Gene 
(alias) 
SLCO1A2 
(OATP1A2) 
SLCO1B1 
(OATP1B1) 
SLCO1B3 
(OATP1B3) 
SLCO1B7 
(LST-3) 
SLCO1C1 
(OATP-F) 
SLCO2A1 
(PGT) 
SLCO2B1 
(OATP2B1) 
SLCO3A1 
(OATP-D) 
SLCO4A1 
(OATP-E) 
SLCO4C1 
(OATP-H) 
SLCO5A1 
(OATP-J) 
SLCO6A1 
(GST) 
SLCO1A2 100 42 41 41 46 36 30 34 30 29 31 22 
SLCO1B1  100 80 73 45 34 31 34 29 30 33 25 
SLCO1B3   100 78 47 33 32 35 30 30 33 24 
SLCO1B7    100 42 34 32 34 29 28 33 24 
SLCO1C1     100 33 31 34 31 28 30 23 
SLCO2A1      100 42 36 31 32 32 26 
SLCO2B1       100 34 29 30 32 24 
SLCO3A1        100 35 35 35 26 
SLCO4A1         100 44 37 33 
SLCO4C1          100 34 44 
SLCO5A1           100 27 
SLCO6A1            100 
 
54 
 
Table 1.1 Protein sequence homology of human efflux and uptake transporters involved 
in xenobiotic disposition.  Homology of transporter proteins for each gene was 
determined with the online basic local alignment search tool (BLAST) using the wild-
type amino acid sequence for every gene (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  Each 
number reflects the percentage of positive identification between two amino acid 
sequences.  A “-” indicates homology could not be determined by the BLAST algorithm. 
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Table 1.2 Literature reports for MRP3 substrates using in vitro assays 
Substrate 
Therapeutic 
Category 
Km 
(µM) 
Vmax 
(pmol/min/mg) 
Vmax/Km 
(µL/min/mg) 
Comments 
PubMed 
ID 
7-hydroxycoumarin 
glucuronide 
None (natural 
product) 
187 460 2.46 - 22415933 
Cefadroxil Antibiotics 2500 600 0.24 - 22166395 
Dehydroepiandrosterone 
sulfate 
Androgens 46.3 281 6.07 
MRP3 
wild-type 
15083066 
Dehydroepiandrosterone 
sulfate 
Androgens 34.6 269 7.77 
MRP3 
R1297H 
15083066 
E3040 glucuronide 
None (metabolite 
of thromboxane 
inhibitor) 
- - - Substrate 19628752 
Erythromycin Antibiotics - - - Substrate 21451505 
Estradiol-17β-
glucuronide (E17βG) 
Estrogens 9.1 116 12.7 - 24154606 
E17βG Estrogens - - - - 18698235 
E17βG Estrogens 24.2 71.5 2.95 
MRP3 
wild-type 
15083066 
E17βG Estrogens 16 72.3 4.52 
MRP3 
R1297H 
15083066 
E17βG Estrogens - - - Substrate 19628752 
E17βG Estrogens - - - Substrate 18245269 
E17βG Estrogens - - - Substrate 20360302 
E17βG Estrogens 56 2,220 39.6 - 21511945 
Fexofenadine 
H-1 Receptor 
Antagonists 
- - - Substrate 18245269 
Gadolinium-
ethoxybenzyl-
diethylenetriamine 
pentaacetic acid 
Diagnostic Agents 1800 116 0.1 - 24056116 
Gemfibrozil glucuronide 
Fibric Acid 
Derivatives 
- - - Substrate 19628752 
Glutathione 
methylfluorescein 
None (dye) - - - Substrate 17172311 
Isoscutellarin Food Products - - - Substrate 22822035 
Leucovorin Antidotes - - - Substrate 12874005 
Leukotriene C4 
None (metabolite 
of arachidonic 
acid) 
- - - 
MRP3 
wild-type 
15083066 
Scutellarin 
Herbal 
Medications 
- - - Substrate 22822035 
Troglitazone glucuronide Thiazolidinediones - - - Substrate 19628752 
R1297H: arginine substituted for histidine at amino acid position 1297 
Table adapted from http://didb.druginteractioninfo.org 
56 
 
Table 1.3 Case studies of hepatotoxicity from diclofenac usage 
Gender 
Age 
(years) 
Dose 
Regimen 
Duration 
ALT 
(U/L) 
ALkP 
(U/L) 
R value Status Reference 
F 55 
N/A 
N/A 
2 weeks 
937 466 6 
Jaundice, 
Death 
(Lascar et 
al., 1984) 
M 56 
100 mg 
QD 
5 weeks 
2,110 321 20 
Jaundice, 
Death 
(Breen et 
al., 1986) 
F 21 
200 mg 
QD 
14 days 
1,113 269 12 
Jaundice, 
Death 
(Snijder et 
al., 1987) 
M 45 
75 mg 
BID 
3 months 
922 213 12 
Recovery 
(DCF 
stopped) 
(Helfgott et 
al., 1990) 
F 54 
75 mg 
BID 
6 weeks 
763 186 12 
Recovery 
(DCF 
stopped) 
(Helfgott et 
al., 1990) 
F 83 
50 mg 
TID 
9 days 
314 230 4 
Jaundice, 
Recovery 
(DCF 
stopped) 
(Nezic et 
al., 2012) 
F 60 
50 mg 
TID 
88 days 
1,829 168 31 
Jaundice, 
Recovery 
(DCF 
stopped) 
(LiverTox, 
2015) 
F 60 
N/A 
N/A 
46 days 
1,895 303 18 
Jaundice, 
Death¹ 
(Chalasani 
et al., 2015) 
10F/2M 50 (15) 
N/A 
N/A 
83 days 
1,266 (680) 222 (100) 16 est. 
11 
recoveries, 
1 death¹ 
Chalasani 
et al., 2015) 
Abbreviations: BID – two times a day, est – estimate, F – female, M – male, N/A – not available, QD – 
once a day, TID – three times a day. Values in parentheses represent standard deviation 
¹: indicates same subject 
 
 
 
 
 
57 
 
Table 1.4 Reported in vitro inhibition of MRP4 using inside-out vesicles 
Inhibitor Substrate 
IC50 
(µM) 
PubMed 
ID 
Benzbromarone 
9-(2-
phosphonomethoxyethyl)adeni
ne (PMEA) 
150 12695538 
Candesartan Uric acid 16 17674156 
Celecoxib Methotrexate 35 17005917 
Diclofenac Methotrexate 0.006 17005917 
Dilazep PMEA 20 12695538 
Dipyridamole PMEA 2 12695538 
Dipyridamole Cholyltaurine <20 12883481 
Indomethacin Methotrexate 6.1 17005917 
Ketoprofen Methotrexate 11.9 17005917 
Losartan Uric acid 1.5 17674156 
MK-571 PMEA 10 12695538 
MK-571 Cholyltaurine ~2 12695538 
Nitrobenzylmercaptopurine 
riboside 
PMEA 75 12695538 
Probenecid PMEA 2,300 12695538 
Probenecid Cholyltaurine ~100 12695538 
Probenecid Cyclic GMP <100 11856762 
Sildenafil PMEA 20 12695538 
Sulfinpyrazone PMEA 420 12695538 
Sulindac Methotrexate 2.11 17005917 
Telmisartan Uric acid 11 17674156 
Trequinsin PMEA 10 12695538 
Zaprinast PMEA 250 12695538 
Table adapted from http://dbts.ucsf.edu/fdatransportal 
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Chapter 2 IDENTIFICATION AND CHARACTERIZATION OF EFFLUX 
TRANSPORTERS THAT MODULATE THE DISPOSITION OF DICLOFENAC AND ITS 
METABOLITES AT SUBTOXIC DOSES USING WHOLE-BODY TRANSPORTER 
KNOCKOUT MODELS 
2.1 Abstract 
In the present work, in vivo transporter knockout (KO) mouse models were used to 
characterize the pharmacokinetics of diclofenac (DCF) and the disposition of its primary 
metabolites following a single sub-toxic dose.  Mice that were lacking breast cancer 
resistance protein (Bcrp) or multidrug resistance-associated protein (Mrp)3 were 
administered 3 or 10 mg DCF by intraarterial injection and compared to a wild-type 
(WT) strain of similar background.  The results indicated that Bcrp acts a canalicular 
efflux mediator for DCF as WT mice had biliary excretion values that were 2.2- to 2.6-
fold greater than Bcrp KO mice.  Bcrp deletion did not affect the basolateral efflux of 
DCF.  Furthermore, diclofenac acyl glucuronide (DCF-AG) was found to be a substrate 
of Bcrp, and the loss of Bcrp caused DCF-AG plasma levels to increase 1.8- to 3.2-fold 
in KO animals compared to WT.  In addition, the biliary excretion of DCF-AG increased 
by 1.4-fold in WT versus KO.  Furthermore, Mrp3 was found to mediate the basolateral 
transport of DCF-AG, but not DCF nor 4ʹ-hydroxy diclofenac (OH-DCF).  WT mice had 
DCF-AG plasma concentrations that were 7.0- to 8.6-fold greater compared to Mrp3 KO 
animals, however no change in DCF-AG biliary excretion was observed.  The in vivo 
mouse data were further supported by in vitro studies.  Vesicular transport experiments 
with human MRP3 demonstrated that MRP3 is able to transport DCF-AG.  The data 
suggest that MRP3 has both a low and high affinity binding site.  The low affinity MRP3 
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transport had a Vmax and Km of 170 pmol/min/mg and 98.2 µM, respectively.  The high 
affinity MRP3 Vmax and Km parameters were estimated to be 71.9 pmol/min/mg and 1.78 
µM, respectively.  In summary, we offer evidence that the disposition of DCF-AG can be 
affected by both Bcrp and Mrp3, and these findings may be applicable to humans. 
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2.2 Introduction 
The non-steroidal anti-inflammatory drug diclofenac (DCF) has been used for a number 
of years to treat arthritis and for pain management.  Its primary mechanism of action is 
to block the metabolism of arachidonic acid by cyclooxygenase enzymes (COX) into 
pro-inflammatory mediators, and it is known that DCF can inhibit both COX-1 and COX-
2 (Menasse et al., 1978).  The pharmacokinetics of DCF has been extensively 
characterized in animal and human models.  In humans receiving either an intravenous 
or oral dose, DCF administration resulted in 65% of dosage excretion in the urine with 
the remaining 35% eliminated in feces (Riess et al., 1978).  Conversely, elimination of 
DCF in dogs and rats was reversed with 65% elimination in feces and 35% in urine.  
The percentage contributions were determined using radiometric analysis, a sensitive 
method that permits accurate mass balance assessment. 
The metabolic profile of DCF has likewise been carefully profiled, and only a small 
portion of DCF is eliminated as unchanged parent compound (Stierlin and Faigle, 1979; 
Stierlin et al., 1979).  DCF is metabolized in vivo into a variety of hydroxylated and 
conjugated metabolites (Bort et al., 1999a; Tang et al., 1999; King et al., 2001; Kenny et 
al., 2004).  Using in vitro assays, a multitude of major and minor metabolites have also 
been detected, and most of their structures have been elucidated (Pickup et al., 2012; 
Sarda et al., 2012).  Though DCF is normally given orally, it has excellent 
physicochemical qualities resulting in nearly 100% dose absorption.  This is due in part 
to the high passive uptake that DCF possess, categorizing it as an ECCS class 1B 
compound (Varma et al., 2015).  The complete absorption leads to a large fraction of 
the dose entering portal circulation from which there is extensive partitioning of DCF into 
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the liver.  Upon entering hepatic cells, primarily hepatocytes, DCF is subjected to 
multiple clearance pathways.  Since the Phase I and Phase II enzymes that metabolize 
DCF have been characterized, there is a need to better understand which transporters 
contribute to DCF clearance. 
The liver is host to a variety uptake and efflux transporters, many of which are 
exclusively localized to either the basolateral membrane or the (apical) canalicular 
domain (Giacomini et al., 2010).  Uptake transporters are expressed on the basolateral 
membrane and modulate the transport of endogenous as well as xenobiotic compounds 
from blood into the liver.  Furthermore, the basolateral membrane is host to an array of 
efflux transporters that translocate intracellular substrates into hepatic sinusoidal space.  
Efflux transporters are also expressed on the canalicular domains and serve to excrete 
their substrates into the bile canaliculi whereupon biliary flow carries the substrates into 
the common bile duct, which ultimately terminates into the duodenal region of the small 
intestine.  The interplay of these transporters can result in extensive elimination and 
reuptake of substances, prolonging their residence time in the body (Roberts et al., 
2002). 
The efflux transporters have broad substrate affinity.  The multidrug resistance-
associated proteins (MRPs, encoded by ABCC genes) transport endogenous 
substances such as organic anions, bile salts, glutathione, and steroids as well as 
xenobiotics and their conjugated metabolites.  For example, MRP3 (ABCC3) was 
observed to transport acetaminophen glucuronide, estradiol-17β-glucuronide, 
leukotriene C4, and morphine-3-glucuronide (Hirohashi et al., 1999; Manautou et al., 
2005; Zelcer et al., 2005).  BCRP (ABCG2) has substrates such as estrone-3-sulfate, 
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methotrexate, and SN-38 that is the pharmacologically active metabolite of irinotecan 
(Kawabata et al., 2001; Vlaming et al., 2009a).  MRP2 (ABCC2) overlaps with the 
aforementioned transporters and can mediate the excretion of pravastatin, 
carboxydichlorofluorescein as well as 4-methylumbelliferone conjugated metabolites 
(Zamek-Gliszczynski et al., 2006a; Elsby et al., 2011). 
The rat homologue of MRP2 was determined, using mutant rats that lack Mrp2, to 
modulate the elimination of DCF-AG from the liver into bile (Seitz et al., 1998).  The 
finding was particularly impactful as it was one of the first reports to ascribe the 
importance of transporters in mediating toxicity from DCF exposure.  In that study, rats 
lacking Mrp2 had significantly lower intestinal injury compared to rats with functional 
Mrp2.  Thus, exploration of other efflux transporters that may have affinity for DCF or its 
metabolites is warranted in order to enhance understanding of how transporter 
clearance can modulate toxicity after DCF administration. 
The purpose of the current work was to identify other efflux transporters that are 
responsible for mediating the disposition of either DCF or its primary metabolites.  To 
accomplish this goal, mouse transporter knockout models in which either Bcrp or Mrp3 
were genetically deleted were utilized.  The selection of Bcrp and Mrp3 would allow 
insight into how a major canalicular (in addition to Mrp2) or basolateral transporter, 
respectively, can potentially impact the dispositional profile of DCF or its conjugated 
metabolites.  Furthermore, the affinity of DCF and its metabolites for human MRP3 was 
also investigated via in vitro assays with commercial vesicles. 
 
63 
 
2.3 Materials and Methods 
Chemicals and Reagents.  Alamethecin, AMP, ATP, DCF, formic acid, indomethacin 
(used as the IS), KCl, MgCl2, MOPS, NADPH, OH-DCF, Tris-HCl, and UDPGA were 
purchased from Sigma-Aldrich Corporation (St. Louis, MO).  DCF-AG was purchased 
from Toronto Research Chemicals Incorporated (Toronto, Canada).  Solutol® HS 15 
was provided by the BASF Corporation (Florham Park, NJ).  MRP2 and MRP3 vesicles 
were purchased from GenoMembrane Corporation (Kanazawa, Japan).  All LC/MS/MS 
solvents were of high analytical grade and were purchased from Burdick & Jackson 
(Muskegon, MI). 
Animals.  Mrp3-null mice of FVB 129/Ola background were provided by Dr. Piet Borst 
(Netherlands Cancer Institute, Amsterdam, Netherlands).  Bcrp-null mice having 
C57BL/6 background were generated at the University of Kansas Medical Center.  Mice 
were housed in an American Animal Associations Laboratory Animal Care accredited 
facility of University of Kansas Medical Center under a standard temperature-, light-, 
and humidity-controlled environment.  Mice had free access to Laboratory Rodent Chow 
8604 (Harlan, Madison, WI) and drinking water.  All animal studies were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals using protocols 
reviewed and approved by the local Institutional Animal Care and Use Committee of 
University of Kansas Medical Center (Kansas City, KS). 
In Vivo Studies.  Male 2-4 month old FVB 129/Ola WT, FVB 129/Ola Mrp3 KO, 
C57BL/6 WT, and C57BL/6 Bcrp KO mice were anesthetized intraperitoneally with a 
ketamine/midazolam mixture (100 and 5 mg/kg, respectively), and both the right carotid 
artery and the common bile duct were cannulated for sample collection.  The mice 
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received a single intraarterial dose of 3 or 10 mg/kg DCF in 10:90 (v/v) Solutol HS 
15:0.9% saline at a dosing volume of 10 mL/kg.  Bile flow was monitored, and bile 
fractions were collected in fifteen minute intervals from -15 to 0, 0 to 15, 15 to 30, 30 to 
45, 45 to 60, 60 to 75, and 75 to 90 minutes post administration.  Blood samples were 
collected into heparinized tubes at 2, 7.5, 22.5, 37.5, 52.5, 67.5, and 90 minutes after 
administration, and the blood was subsequently centrifuged to yield plasma.  The 
volumes of bile were determined gravimetrically, using 1.0 for specific gravity.  Both bile 
and plasma were stored at -20 °C until analysis.  At the conclusion of the study (90 min 
post-administration), animals were sacrificed by overdose with ketamine and midazolam.  
Livers were harvested and quickly frozen in liquid nitrogen prior to storage at -80 °C. 
Bioanalytical Analysis.  Bile and plasma were diluted with 0.1% formic acid in water 
(Solvent A) for LC/MS/MS detection as well as to stabilize DCF-AG.  Liver samples 
were homogenized by bead milling using Solvent A.  A 50 µL aliquot of diluted biological 
matrix was then precipitated with 400 µL of 0.1% formic acid in acetonitrile (Solvent B) 
containing IS.  Standard curves using naïve matrices were prepared in a similar fashion.  
Samples and standards were vigorously vortex-mixed and centrifuged at 1000 × g for 
15 min and 5 °C.  A 200 µL aliquot of supernatant was removed and evaporated under 
Nitrogen gas at 45 °C.  The resulting residue was reconstituted with 200 µL of 90:10 
(v/v) A:B, vigorously vortex-mixed, and centrifuged prior to injection onto LC/MS/MS.  
The injection volume for all sample types was 10 µL. 
In Vitro Metabolism.  Untreated livers from three male FVB (WT & KO) and C57 (WT & 
KO) mice were homogenized using a Dounce Teflon homogenizer in ice-cold Tris-HCL 
buffer (50 mM Tris, 15.4 mM KCl, 2 mM EDTA) in a ratio of 4 parts buffer to 1 part liver.  
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The homogenate was centrifuged at 9,000 × g for 30 min and 4 °C, and the S9 
supernatant fraction was removed, separated into aliquots, and kept frozen at -80°C.  
The S9 fraction was analyzed for protein content using a Pierce BCA kit (Thermo Fisher 
Scientific Inc., Grand Island, NY) following the manufacturer’s recommendations.  
Incubation reactions were conducted in duplicate in the presence of increasing DCF 
concentrations.  The reaction mixture consisted of DCF, 0.1 M phosphate buffer pH 7.4 
at 37 °C, 1 mg/mL S9 protein, 10 µg/mL Alamethacin, 1 mM GSH, 5 mM MgCl2, 1 mM 
NADPH, and 1 mM UDPGA.  Incubations without cofactors (MgCl2, NADPH, UDPGA) 
served as the control.  The total incubation volume was 300 µL, and the reaction 
mixture was open to air.  Aliquots of 50 µL were taken at 0, 7.5, 15, 30, and 45 min, 
immediately quenched with 200 µL ice-cold Solvent B, and kept on ice.  At the end of 
the experiment, samples were mixed with 50 µL IS, and 200 µL of the mixture was 
removed to be evaporated to dryness under N2 at 40 °C.  The resulting residue was 
reconstituted in 200 µL of 90:10 (v/v) solvents A:B, vigorously vortex-mixed, and 
injected onto the LC/MS/MS.  The samples were monitored for the disappearance of 
DCF.  The LC/MS/MS response (DCF peak area/IS peak area) was converted to 
percentage remaining with 0 min serving as 100%.  All percentage values were log 
transformed and plotted against incubation time to yield an elimination rate (k) that was 
derived from the slope of the resulting line.  The elimination rate was converted into an 
apparent half-life using the formula: 
Equation 2.1 
     
     
  
 
The initial enzyme velocity was calculated using the equation: 
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Equation 2.2 
         
 
         
     
             
                
 
where v0 is expressed as pmol/min/min and [S] is the DCF substrate concentration in 
µM.  The kinetic parameters of Km and Vmax were then calculated by plotting v0 as a 
function of [S]. 
In Vitro Transport.  Commercially available MRP2 and MRP3 inside-out vesicles were 
quickly thawed from storage and placed on ice.  Incubation reactions consisted of 
uptake buffer at pH 7.0 (50 mM MOPS-Tris, 70 mM KCl, and 7.5 mM MgCl2), 25 µg 
vesicle protein, 5 mm of AMP or ATP, and 2.5 mM GSH.  After a 5 min pre-incubation 
period of reaction mixture, incubations were commenced by addition of increasing 
concentrations of DCF-AG.  Incubations were conducted at 37 °C in a total volume of 75 
µL.  Reactions were quenched by the addition of 100 µL ice-cold stopping buffer (40 
mM MOPS-Tris and 70 mM KCl), and the quenched mixtures were quickly transferred 
to a 96-well glass-fiber filter plate (EMD Millipore, Billerica, MA).  The filter plate was 
subjected to vacuum filtration followed by 5 rapid washes of 100 µL/well ice-cold 
stopping buffer.  The filter plate was allowed to completely dry before extraction of 
samples.  DCF-AG was extracted by filling each well of the filter plate with 200 µL of 
80:20 (v/v) methanol:0.1% formic acid in water.  Plates were shaken for 15 min on ice, 
and the filtrate was collected via centrifugation at 3,000 × g for 10 min and 4 °C.  The 
filtrate was evaporated to dryness under warm N2 at 40 °C.  The resulting residue was 
reconstituted with 200 µL of 90:10 (v/v) solvents A:B, vigorously vortex-mixed, and 
injected onto the LC/MS/MS.  The accumulation of DCF-AG was quantified against a 
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standard curve, and the uptake data were expressed as pmol normalized to mg vesicle 
protein. 
LC/MS/MS Method.  Chromatographic separation of analytes was performed on a 
Synergi™ 4 µm Max-RP 50 × 2 mm column (Phenomenex Incorporated, Torrance, CA).  
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies 
Incorporated, Carrboro, NC), a SCL-10Avp system controller, two LC10ADvp pumps, 
and a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD).  Analytes 
of interest were eluted using a gradient profile that began with 10% solvent B for the first 
1.0 min, which was then increased to 90% solvent B at 3.5 min using a linear gradient 
and held at this mixture for 0.5 min before reverting back to initial solvent conditions for 
1.0 min to re-equilibrate the column.  The flow rate was 0.4 mL/min, and the column 
effluent was directed to waste for the initial 1.5 min before switching to the mass 
spectrometer.  Analytes were detected using an AB Sciex API™ 4000 LC/MS/MS triple 
quad mass-spectrometer with a TurboIonSpray® probe and Analyst version 1.4.2 
software (AB Sciex, Framingham, MA) that was operated in multiple reaction monitoring 
mode.  Ion spray voltage was -4250 V, and the source temperature was set to 400 °C.  
The mass transitions in negative ion mode for monitoring DCF, OH-DCF, DCF-AG, and 
indomethacin were m/z 294.0→249.9, 309.9→265.9, 470.1→192.9, and 356.0→311.8, 
respectively.  The retention times of DCF, OH-DCF, DCF-AG, and indomethacin were 
3.25, 2.84, 2.69, and 3.20 min, respectively.  Concentrations of analytes in the samples 
were determined by comparing the peak area ratios (analyte/IS) to those in the standard 
curve using a linear regression model.  The criterion of acceptance for standards was 
defined to be ±20% of nominal concentration. 
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Statistical Analysis.  Data are expressed as mean ± standard error of the mean.  P 
values < 0.05 were considered as statistically significant.  Statistical analysis of data 
was performed using R version 3.2.1 (R Core Team, 2015).  Two groups were 
compared by Student’s t test, and multiple groups were compared by an analysis of 
variance followed by Tukey’s post hoc test.  GraphPad Prism version 6.0 (GraphPad 
Software Incorporated, La Jolla, CA) was used to calculate kinetic parameters (Vmax and 
Km). 
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2.4 Results 
In Vivo Studies.  Plasma concentrations of DCF and OH-DCF in C57 WT and C57 
Bcrp KO mice receiving 3 mg/kg DCF were nearly equal (Figure 2.1A-B), whereas KO 
animals had on average 1.8-fold higher DCF-AG plasma levels compared to WT (Figure 
2.1C).  Biliary excretion for DCF was 2.2-fold higher in WT animals relative to KO 
(Figure 2.1D) with statistical significance observed at each time interval.  OH-DCF 
biliary levels were relatively unchanged between WT and KO (Figure 2.1E) though 
DCF-AG biliary WT concentrations were 1.4-fold greater than KO at 90 min, and the 
difference was statistically significant (Figure 2.1F).  The trends observed at the 3 mg/kg 
dose were also evident following 10 mg/kg DCF administration.  DCF and OH-DCF 
plasma concentrations were approximately equal in WT and KO (Figure 2.2A-B), while 
DCF-AG KO plasma levels were increased 3.2-fold compared to WT (Figure 2.3C).  
DCF WT biliary excretion was higher by 2.6-fold compared to KO (Figure 2.2D).  From 
60 min and beyond, biliary OH-DCF and DCF-AG WT levels were elevated by 1.3- and 
1.4-fold, respectively, versus KO animals.  Analysis of whole liver collected 90 min after 
3 or 10 mg/kg DCF showed no significant differences between WT and KO for DCF or 
OH-DCF while DCF-AG was not detected in the samples (Figure 2.3A-C). 
The plasma concentrations of DCF and its metabolites in FVB WT and FVB Mrp3 KO 
animals are shown in Figure 2.4 and Figure 2.5.  At the 3 mg/kg dose, the overall data 
showed little statistical significance between WT and KO plasma concentrations for 
DCF and OH-DCF (Figure 2.4A-B).  Strikingly, there was nearly an 8.6-fold increase in 
DCF-AG WT plasma levels versus that of KO animals (Figure 2.4C).  With regards to 
biliary excretion, all three analytes had similar concentrations between WT and KO 
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subjects (Figure 2.4D-F).  The 10 mg/kg data for the FVB mice exhibited comparable 
trends for the plasma profiles of DCF and OH-DCF (Figure 2.4A-B).  WT plasma DCF-
AG was greater than KO by 7.0-fold (Figure 2.4C).  Biliary levels of DCF, OH-DCF, and 
DCF-AG were unremarkable between WT and KO after a 10 mg/kg dose (Figure 2.4D-
F) though OH-DF began to show a slight increase in KO biliary output relative to WT.  
Liver concentrations were determined 90 min post-administration and were not found to 
be statistically different between genotypes for each analyte, which was true for both the 
3 mg/kg and 10 mg/kg doses (Figure 2.5A-B). 
The pharmacokinetics of DCF at each dose for all genotypes is summarized in Table 
2.1.  The parameters listed in the table were calculated using non-compartmental 
analysis.  The data show that the relative half-lives of DCF at each dose for each 
genotype were comparable with the exception of the 10 mg/kg Mrp3 KO mice that had a 
t1/2 of 52.9 ± 9.8 min, which was slightly elevated compared to the rest of the dosing 
groups.  The overall exposure of DCF, as assessed by AUC0-tlast normalized by dose, 
further demonstrated that the absorption and distribution of DCF were fairly alike. 
Metabolite Identification.  In order to account for metabolism of DCF that extended 
beyond generation of OH-DCF and DCF-AG, WT and Mrp3 KO bile were pooled from a 
number of animals, extracted with organic solvent, and infused onto the LC/MS.  
Spectra from 100 amu to 1000 amu were acquired in both positive ion and negative ion 
mode and compared between genotypes.  The WT spectra were subtracted from KO 
spectra, and the resulting signals were analyzed for traces of DCF metabolites.  As 
shown in Figure 2.7, several metabolites possessing an isotopic distribution similar to 
DCF were identified (for reference, DCF-AG is shown in Figure 2.7C).  The masses of 
71 
 
the primary peaks were compared using MetabolitePilot software (Framingham, MA, 
CA).  Structures of the proposed biliary metabolites are shown in Figure 2.8.  M1 and 
M2 are the hydroxylated metabolites, while M3 is DCF-AG.  M4 is positively identified, 
based on product ion fragmentation, as OH-DCF-AG (Figure 2.7D).  M6, a taurine 
conjugate, corresponds to the peak shown in Figure 2.7A.  M7, an S-cysteine conjugate, 
matches the profile observed in Figure 2.7B.  M9, a dihydroxylated glutathione adduct, 
is putatively identified as the peak shown in Figure 2.7F.  The structure of M9, for which 
the profile is indicated by Figure 2.7E, is uncertain as its mass does not match up to 
typical combinations. 
In Vitro Metabolism.  To determine if the different strains of mice have similar 
metabolic capacity, S9 fraction was generated by pooling naïve liver homogenates from 
several WT or KO mice.  S9 was chosen for metabolic studies to afford a system 
capable of multiple biotransformation pathways (Wu and McKown, 2004).  The range of 
DCF was selected to cover the plasma concentrations that were observed in the in vivo 
studies.  Conditions for the assay were based on the work by Fisher et al. (2000) in 
order to promote Phase II metabolism.  Incubations conducted in the presence of 
cofactors (e.g., GSH and UPDGA) required for Phase II metabolism showed that the 
background-matched strains (e.g., C57 WT and C57 Bcrp KO) had indistinguishable 
profiles (Figure 2.9A-B).  The metabolic data were analyzed to determine relevant 
kinetic parameters, and these values are summarized in Table 2.2.  C57 WT and Bcrp 
KO mice had apparent Vmax values of 846 ± 31 and 882 ± 26 pmol/min/mg, respectively, 
while the Km values were 69.3 ± 4.3 and 82.4 ± 1.1 µM, respectively.  Likewise, the Vmax 
data for FVB WT and Mrp3 KO mice were 734 ± 32 and 696 ± 79 pmol/min/mg, 
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respectively, and the Km parameters were determined to be 44.3 ± 3.5 and 43.3 ± 9.0 
µM, respectively.  From the Vmax and Km data, the intrinsic metabolic clearances were 
calculated with the equation: 
Equation 2.3 
      
    
  
 
The resulting CLint for C57 WT and Bcrp KO were 12.2 and 10.7 µL/min/kg, respectively, 
while those for FVB WT and Mrp3 KO were 16.7 and 16.4 µL/min/mg, respectively. 
In Vitro Transport.  With the mouse models showing evidence that Mrp3 can mediate 
the efflux of DCF-AG in vivo, the next objective was to determine the extent by which 
DCF-AG interacts with human MRP3.  As rodent Mrp2 was previously shown to 
modulate DCF-AG toxicity (Seitz et al., 1998), human MRP2 was also examined for 
DCF-AG affinity.  MRP2 and MRP3 inside-out vesicles were assessed for DCF-AG 
transport, and it was determined that uptake was linear for several minutes before 
reaching an apparent plateau (Figure 2.10A-B).  The uptake of DCF-AG with MRP2 and 
MRP3 was found to be ATP- and time-dependent.  Having established an optimal 
incubation time for further studies, vesicles were incubated for 5 min in the presence of 
increasing DCF-AG concentrations.  The concentration-dependent uptake by MRP2 and 
MRP3 was determined to be saturable (Figure 2.11A-B).  The Eadie-Hofstee plot for 
MRP2 uptake suggests an allosteric sigmoidal interaction, hence the ATP-dependent 
data were fit using this model.  MRP3 uptake of DCF-AG, when graphed using an 
Eadie-Hofstee plot, indicated a biphasic profile.  Therefore, MRP3 data was fit using a 
two Km model.  The results of the model outputs for MRP2 and MRP3 are summarized 
in Table 2.3.  The Vmax and Km for MRP2 vesicular uptake of DCF-AG were determined 
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to be 130 pmol/min/mg and 50.5 µM, respectively, yielding a transporter intrinsic 
clearance (using Equation 2.3) of 2.58 µL/min/mg.  Analysis of MRP3 kinetics led to 
identification of a possible low affinity and high affinity binding site for DCF-AG transport.  
The low affinity Vmax and Km for MRP3 were 170 pmol/min/mg and 98.2 µM, respectively, 
with a transporter clearance of 2.37 µL/min/mg for the low affinity site.  The high affinity 
Vmax and Km parameters were estimated to be 71.9 pmol/min/mg and 1.78 µM, 
respectively, and the high affinity transporter clearance was calculated to be 40.3 
µL/min/mg. 
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Figure 2.1 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, 
and DCF-AG in C57 WT and C57 Bcrp KO mice after 3 mg/kg DCF dose 
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Figure 2.1 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in C57 WT and C57 Bcrp KO mice after 3 mg/kg DCF dose.  Pharmacokinetics 
of DCF and its metabolites in WT (○) and Bcrp KO (●) mice after a single intraarterial 
dose of 3 mg/kg DCF.  (A-C) Plasma concentration profiles for (A) DCF, (B) OH-DCF, 
and (C) DCF-AG at discrete time points.  (D-F) Biliary excretion profiles for (D) DCF, (E) 
OH-DCF, and (F) DCF-AG.  Time points represent accumulation of biliary flow during 
successive 15 min intervals (0-15, 15-30, 30-45, 45-60, 60-75, and 75-90 min).  All data 
are expressed as mean ± standard error of the mean for 5-6 subjects/group.  * P < 0.05; 
** P < 0.01; *** P < 0.001 versus WT. 
 
 
 
 
 
 
 
 
 
 
76 
 
Figure 2.2 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, 
and DCF-AG in C57 WT and C57 Bcrp KO mice after 10 mg/kg DCF dose 
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Figure 2.2 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in C57 WT and C57 Bcrp KO mice after 10 mg/kg DCF dose.  
Pharmacokinetics of DCF and its metabolites in WT (○) and Bcrp KO (●) mice after a 
single intraarterial dose of 10 mg/kg DCF.  (A-C) Plasma concentration profiles for (A) 
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points.  (D-F) Biliary excretion 
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.  Time points represent 
accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 45-
60, 60-75, and 75-90 min).  All data are expressed as mean ± standard error of the 
mean for 5-6 subjects/group.  * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT. 
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Figure 2.3 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in C57 WT 
and C57 Bcrp KO mice after 3 or 10 mg/kg DCF dose 
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Figure 2.3 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in C57 WT and 
C57 Bcrp KO mice after 3 or 10 mg/kg DCF dose.  Hepatic concentrations of DCF, OH-
DCF, and DCF-AG in WT (□) and KO (■) mice were determined 90 min after DCF 
administration.  Data are expressed as mean ± standard error of the mean for 5-6 
subjects/group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
Figure 2.4 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, 
and DCF-AG in FVB WT and FVB Mrp3 KO mice after 3 mg/kg DCF dose 
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Figure 2.4 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in FVB WT and FVB Mrp3 KO mice after 3 mg/kg DCF dose.  
Pharmacokinetics of DCF and its metabolites in WT (○) and Mrp3 KO (●) mice after a 
single intraarterial dose of 3 mg/kg DCF.  (A-C) Plasma concentration profiles for (A) 
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points.  (D-F) Biliary excretion 
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.  Time points represent 
accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 45-
60, 60-75, and 75-90 min).  All data are expressed as mean ± standard error of the 
mean for 7 subjects/group.  * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT. 
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Figure 2.5 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, 
and DCF-AG in Mrp3 WT and KO mice after 10 mg/kg DCF dose 
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Figure 2.5 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and 
DCF-AG in FVB WT and FVB Mrp3 KO mice after 10 mg/kg DCF dose.  
Pharmacokinetics of DCF and its metabolites in WT (○) and Mrp3 KO (●) mice after a 
single intraarterial dose of 10 mg/kg DCF.  (A-C) Plasma concentration profiles for (A) 
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points.  (D-F) Biliary excretion 
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.  Time points represent 
accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 45-
60, 60-75, and 75-90 min).  All data are expressed as mean ± standard error of the 
mean for 7 subjects/group.  * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT. 
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Figure 2.6 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in FVB WT 
and FVB Mrp3 KO mice after 3 or 10 mg/kg DCF dose 
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Figure 2.6 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in FVB WT 
and FVB Mrp3 KO mice after 3 or 10 mg/kg DCF dose.  Hepatic concentrations of DCF, 
OH-DCF, and DCF-AG in WT (□) and KO (■) mice were determined 90 min after DCF 
administration.  Data are expressed as mean ± standard error of the mean for 6-7 
subjects/group. 
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Table 2.1 Summary of DCF pharmacokinetic parameters in plasma of WT and KO 
mice after a single 3 or 10 mg/kg DCF dose 
Dose Genotype 
C0 
(µM) 
t1/2 
(min) 
AUC0-tlast 
(µM × min) 
3 mg/kg C57 WT 57.8 ± 6.0 31.2 ± 4.0 1,050 ± 50 
 C57 BCRP KO 46.0 ± 5.1 27.8 ± 3.6 1,020 ± 80 
10 mg/kg C57 WT 132 ± 8 30.5 ± 3.1 3,420 ± 290 
 C57 BCRP KO 201 ± 44 33.5 ± 2.5 3,570 ± 340 
3 mg/kg FVB WT 51.4 ± 5.1 24.0 ± 4.1 862 ± 86 
 FVB Mrp3 KO 41.2 ± 3.3 37.5 ± 9.2 1,110 ± 130 
10 mg/kg FVB WT 178 ± 16 37.8 ± 5.6 4,220 ± 420 
 FVB Mrp3 KO 172 ± 13 52.9 ± 9.8 4,770 ± 280 
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Table 2.1 Summary of DCF pharmacokinetic parameters in plasma of WT and KO mice 
after a single 3 or 10 mg/kg DCF dose.  C0 indicates the estimated DCF plasma 
concentration at time zero, t1/2 is the DCF elimination half-life, and AUC0-tlast is the area 
under the plasma concentration versus time curve for DCF from time zero to the last 
collected time point.  Parameters were calculated using non-compartmental analysis.  
Each value represents the mean ± standard error of the mean of 5-7subjects/group. 
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Figure 2.7 Mass spectral identification of major DCF conjugated metabolites 
excreted in bile 
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Figure 2.7 Mass spectral identification of major DCF conjugated metabolites excreted in 
bile.  Bile from WT and Mrp3 KO mice were pooled, extracted with organic solvent, and 
infused onto a mass spectrometer.  The infusion was then scanned across a range of 
masses for which multiple acquisitions were made to determine masses of putative 
metabolites.  The WT spectral profile was subtracted from the KO profile resulting in a 
range of masses (i.e., metabolites) that can be considered to be in excess in KO 
compared to WT.  (A) DCF taurine conjugate, (B) DCF cysteine conjugate, (C) DCF-AG, 
(D) either 4ʹ- or 5-OH-DCF-AG, (E) unknown DCF conjugate, and (F) di-hydroxy-DCF 
glutathione. 
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Figure 2.8 Structures of DCF metabolites based on biliary MS/MS infusion data 
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Figure 2.8 Structures of DCF metabolites based on biliary MS/MS infusion data.  M1 
and M2 are hydroxylated metabolites (OH-DCF) that have the same parental mass as 
do M4 and M5 (OH-DCF-AG) which can be generated from M1, M2, or M3 (DCF-AG).  
DCF can also be conjugated to M6 (taurine conjugate), M7 (cysteine conjugate), and 
M9 (di-hydroxy glutathione conjugate) which were identified in spectral scans.  The 
structure of M8 has not been elucidated, however is appears to have a negative ion 
mode mass (m/z) of 572. 
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Figure 2.9 In vitro metabolism of DCF using hepatic S9 fraction from C57 and FVB 
mice 
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Figure 2.9 In vitro metabolism of DCF using hepatic S9 fraction from C57 and FVB 
mice.  Pooled S9 fraction was prepared from (A) C57 WT and C57 Bcrp KO and (B) 
FVB WT and FVB Mrp3 KO mice.  Incubations consisted of 1 mg/mL S9 protein and 
were conducted at 37 °C.  Cofactors (e.g., GSH and UDPGA) were added to permit 
Phase II metabolism.  Initial incubations were conducted in duplicate at 0, 7.5, 15, 30, 
and 45 min, and the responses at each concentration were used to generate a velocity 
for the corresponding concentration.  The results indicate the two WT and KO pairings 
(i.e., FVB and C57) have nearly equal intrinsic metabolic capacity.  Each data point 
represents the velocity for a given concentration from 2 separate studies. 
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Table 2.2 Summary of in vitro DCF metabolism in mouse models 
Genotype 
Vmax 
(pmol/min/mg) 
Km 
(µM) 
Metabolic CLint 
(µL/min/mg) 
C57 WT 846 ± 31 69.3 ± 4.3 12.2 
C57 KO 882 ± 26 82.4 ± 1.1 10.7 
FVB WT 734 ± 32 44.3 ± 3.5 16.7 
FVB KO 696 ± 79 43.3 ± 9.0 16.4 
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Table 2.2 Summary of in vitro DCF metabolism in mouse models.  Metabolic 
parameters were determined using S9 fraction from FVB and C57 strains of mice that 
were WT or KO for Bcrp or Mrp3.  Data represent the mean ± standard error of the 
mean from 2 separate studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
96 
 
Figure 2.10 Time-dependent transport of DCF-AG by MRP2 and MRP3 using 
inside-out vesicles 
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Figure 2.10 Time-dependent transport of DCF-AG by MRP2 and MRP3 using inside-out 
vesicles.  DCF-AG was incubated with vesicles in the presence of 5 mM AMP (○) or 5 
mM ATP (●) at 37 °C.  (A) Uptake of 10 µM DCF-AG by MRP2.  (B) Uptake of 1 µM 
DCF-AG by MRP3.  The dotted lines in both plots represent the nonlinear fit of DCF-AG 
active uptake and were determined by subtracting the AMP values (background and 
passive uptake) from the ATP response.  Each data point reflects the mean ± the 
standard error of the mean for n=3 measurements per time point. 
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Figure 2.11 Determination of the concentration-dependent transporter kinetics of 
MRP2 and MRP3 for DCF-AG 
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Figure 2.11 Determination of the concentration-dependent transporter kinetics of MRP2 
and MRP3 for DCF-AG.  MRP2 and MRP3 vesicles were incubated with increasing 
concentrations of DCF-AG in the presence of 5 mM AMP or ATP for 5 min at 37 °C. 
AMP response was subtracted from ATP, and the resulting data was fit to determine 
kinetic parameters.  (A) MRP2 data was fit according to an allosteric sigmoidal model 
that yielded an apparent Hill slope of 2.2. Insert: Eadie-Hofstee plot.  (B) MRP3 data 
was fit according to a two-Km indicating the presence of high affinity and low affinity 
binding sites.  Insert: Eadie-Hofstee plot.  Each data point reflects the mean ± the 
standard error of the mean for n=3 measurements per concentration. 
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Table 2.3 Summary of MRP2 and MRP3 vesicle kinetic studies for DCF-AG 
Transporter 
Vmax 
(pmol/min/mg) 
Km 
(µM) 
Transport CLint 
(µL/min/mg) 
MRP2 130 50.5 2.58 
MRP3 (low affinity) 170 98.2 2.37 
MRP3 (high affinity) 71.9 1.78 40.3 
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Table 2.3 Summary of MRP2 and MRP3 vesicle kinetic studies for DCF-AG.  MRP2 
had single Km transport affinity for DCF-AG whereas MRP3 demonstrated biphasic 
kinetics.  Intrinsic transporter clearance (Vmax/Km) for MRP2 and the low affinity MRP3 
clearance were comparable.  In contrast, the high affinity MRP3 efflux clearance was 
over an order of magnitude greater than that of MRP2. 
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2.5 Discussion 
Currently, more is known about which transporters are inhibited by DCF rather than 
which transporters mediate the disposition of DCF and its primary metabolites.  Thus 
the intention of the present work was to investigate the impact of efflux transporters on 
DCF disposition.  Studies in TR- rats, which are of a Wistar background and have a 
spontaneous mutation for the Abcc2 gene thereby lacking functional expression of Mrp2 
(Kitamura et al., 1990), demonstrated that the those mutants are resistant to intestinal 
injury compared to non-mutant Wistar rats (Seitz et al., 1998).  Though intestinal injury 
in the TR- rats was significantly lower compared to non-mutants, GI damage was not 
completely abolished.  The mechanism of the decreased injury stems from the reduced 
biliary translocation of reactive intermediates, such as DCF-AG, from the hepatocyte 
into the bile canaliculi.  That seminal work laid the foundation for further investigation 
into transporter-mediated modulation of DCF-associated toxicity. 
The results presented herein demonstrate the involvement of other efflux transporters to 
modulate disposition of not only reactive metabolites, but also of DCF itself.  Data from 
two subtoxic doses of DCF indicate that Bcrp, which is expressed on the canalicular 
domain along with Mrp2, is partially responsible for the active transport of DCF.  This 
discovery was supported by the observations that C57 Bcrp WT animals had statistically 
higher DCF biliary excretion compared to KO after a dose of 3 or 10 mg/kg DCF (Figure 
2.1D and Figure 2.2D).  The reduction in DCF biliary output in the KO did not result in 
any increase in the KO DCF plasma concentration.  KO mice exhibited a statistically 
significant increase in DCF-AG plasma concentrations compared to WT (Figure 2.1C 
and Figure 2.2C), and this increase was paralleled in KO by a decrease in DCF-AG 
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biliary excretion (Figure 2.1F and Figure 2.2F).  Taken together the results indicate that 
Bcrp is operative, in vivo, with respect to modulation of DCF and DCF-AG transport 
activity. 
Lagas et al. (2009) reported the involvement of Bcrp to transport DCF, though this was 
conducted using a transfected cell system with polarized MDCK cells in a transwell 
format.  For that study, murine Bcrp exhibited greater transport of DCF compared to 
human BCRP (transport was assessed by comparing A→B to B→A vectorial transport).  
Curiously, a follow-up study by Lagas et al. (2010) with an in vivo Bcrp knockout mouse 
model from a FVB background contradicted their earlier findings.  Whereas we report 
that C57 WT had DCF biliary excretion 2.2- to 2.6-fold greater compared to that of C57 
Bcrp KO, the Lagas Bcrp KO mice had 1.2-fold more biliary DCF compared to WT 
though this difference was not statistically significant.  The authors acknowledge the 
disconnect between their in vitro and in vivo data, yet there was no rationale given for 
the divergent results.  DCF-AG WT plasma levels in the Lagas in vivo study were 
modestly higher without statistical significance in contrast to the present data that reflect 
1.8- and 3.2-fold greater KO plasma concentrations relative to WT (Figure 2.1C and 
Figure 2.2C).  That said, the Lagas study did indicate biliary DCF-AG levels were 2.1-
fold greater in WT compared to KO.  There is some limitation to the Lagas report, 
primarily the selection of a single time point, 60 min post-administration, from which to 
make comparisons between genotypes.  In contrast, we report plasma and bile profiles 
over a span of time giving greater power to make dispositional characterizations.  We 
also assessed the pharmacokinetics from two doses compared to a single 5 mg/kg IV 
dose for the Lagas work. 
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In addition to demonstrating the interplay of Bcrp activity, we also report that Mrp3 is 
responsible for the in vivo translocation of DCF-AG.  This key outcome was observed in 
the plasma profiles at each sub-toxic dose for which C57 WT mice had 7.0- to 8.6-fold 
greater DCF-AG plasma concentrations compared to C57 Mrp3 KO (Figure 2.4C and 
Figure 2.5D).  In the same 2010 Lagas publication referenced previously, FVB WT mice 
had approximately 2-fold greater DCF-AG plasma concentrations (at 60 min) compared 
to FVB Mrp3 KO, hence our data are confirmatory.  Considering the degree of 
separation between WT and KO, it is evident Mrp3 plays a major role in the disposition 
of DCF-AG.  Whereas Bcrp deletion led to altered disposition of plasma and biliary 
profiles for DCF and DCF-AG, deletion of Mrp3 only affected basolateral excretion of 
DCF-AG.  There were no changes to DCF-AG biliary output (Figure 2.4F and Figure 
2.5F) nor were there changes in hepatic levels of DCF-AG (Figure 2.6A-B).  The lack of 
elevated biliary DCF-AG was unexpected given the published reports of increased 
biliary excretion of 4-methylumbelliferyl glucuronide and acetaminophen glucuronide in 
Mrp3 KO mice (Manautou et al., 2005; Zamek-Gliszczynski et al., 2006b). 
All mouse strains were evaluated for their intrinsic metabolic capacity using S9 fraction.  
S9 was chosen as the modality for this assessment due to the presence of an array of 
metabolic enzymes (Lu, 2014).  The results from in vitro metabolism studies suggest 
that mice of C57 and FVB backgrounds have similar metabolic capacity (Figure 2.9A-B).  
From these data, it can be inferred that deletion of transporters did not result in any 
compensatory changes to enzymatic (Phase I and Phase II) expression or activity.  
Therefore, changes in the biliary excretion or plasma dispositional profiles are reflective 
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of diminished transporter capacity, due to selective genetic deletion, rather than innate 
differences in metabolic competency. 
Upon consideration that the FVB strain of mice had such a large differential regarding 
WT and KO plasma DCF-AG concentrations without concomitant changes in biliary 
output, the bile from WT and KO were infused into a LC/MS/MS system to permit 
rudimentary metabolite identification.  The WT spectra was subtracted from the KO 
spectra and analyzed for likely candidates that could account for the fraction of DCF-AG 
not present in KO plasma.  The spectral scans revealed several important findings.  
Firstly, of the three quantified analytes, DCF-AG biliary levels were 10-fold greater than 
DCF and OH-DCF, and the DCF-AG excreted in bile accounted for nearly 12% of the 
total DCF dose.  Secondly, a diclofenac taurine conjugate (designated as M6 in Figure 
2.8) was also detected and found to have a signal intensity (Figure 2.7A) nearly equal to 
DCF-AG (Figure 2.7C).  The DCF-TAU response is suggestive that taurine conjugation 
may be as dominant of a metabolic process as glucuronidation.  Taurine conjugates of 
DCF in mice were likewise reported by Sarda et al. (2012) and Pickup et al. (2012).  In 
fact, both Sarda’s and Pickup’s respective works provided evidence that multiple taurine 
conjugates were detectable furthering the notion that taurine conjugation constitutes a 
significant clearance mechanism.  Taurine conjugation is an important detoxification 
step since the amide that is formed results in less reactive compared to the ester bond 
that is present in DCF-AG (Montalbetti and Falque, 2005).  The significance of the 
spectral scans and identification of other conjugated metabolites implies that the portion 
of DCF-AG which was not excreted into plasma was putatively converted into other 
metabolites that were ultimately transported into bile.  Another biliary metabolite of high 
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intensity observed at m/z of 572 was categorized as M7 (Figure 2.8).  The structure of 
M7 remains to be elucidated, however it may be similar to a metabolite, which was 
detected using human liver microsomes, that was described as being 4ʹ-OH-2ʹ-
glutathion-deschloro-diclofenac (Yu et al., 2005). 
Bearing in mind that these data and that of the TR- rat study provided conclusive 
evidence of DCF-AG in vivo transport, the last component of the work was to assess the 
affinity of DCF-AG to be transported by human MRP2 and MRP3.  The purpose of the 
investigation was to gauge if human MRPs had similar potential to interact with DCF-AG.  
To that end, studies with commercial inside-out vesicles were carried out.  In keeping 
with the TR- rat data, our results indicated that DCF-AG is a substrate of MRP2 (Figure 
2.10A) and that transport by MRP2 was saturable (Figure 2.11A).  The affinity of DCF-
AG for MRP2 was relatively weak in that the ATP incubation responses ranged from 
1.5- to 2.0-fold greater than the AMP responses.  Furthermore, the activity of MRP2 for 
DCF-AG appears to have an element of allosteric modulation, evident by a Hill slope 
estimate of 2.2.  The Eadie-Hofstee plot for MRP2 is in agreement with an allosteric 
effect (Hutzler and Tracy, 2002).  The allosterism is a function of MRP2 having multiple 
binding sites (Zelcer et al., 2003a).  Like DCF-AG, estradiol-17β-glucuronide was 
demonstrated to be transported with cooperative binding by human MRP2 vesicles as it 
had a Hill slope of 2.4 (Elsby et al., 2011; Li et al., 2011).  MRP3-mediated transport of 
DCF-AG was determined be biphasic with a high affinity and low affinity binding site 
(Figure 2.11B).  Whereas the dynamic response by MRP2 was low, MRP3 had a 
maximal fold-ratio (ATP/AMP) of 37 at the low end of the concentration range while the 
minimal ratio was 1.5-fold at the highest tested concentration.  The intrinsic transporter 
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clearance of the high affinity site indicated that DCF-AG can be transported by MRP3 to 
a greater degree at low DCF-AG concentrations compared to MRP2 (Table 2.3). 
Overall these data offer insight on the disposition of DCF and its metabolites.  We offer 
proof that Bcrp can mediate DCF translocation from the hepatocyte into bile, and that 
DCF-AG can also be transported by Bcrp.  The deletion of Bcrp not only diminished 
biliary DCF-AG efflux, but it also resulted in an increase in plasma DCF-AG 
concentrations.  In contrast, Mrp3 was involved in the basolateral excretion of DCF-AG 
from the liver into blood.  Despite the profound differences between WT and KO for 
DCF-AF levels, there was no effect on DCF-AG biliary excretion suggesting only 
basolateral disposition was affected.  Finally, we report that human MRP3, through the 
means of an in vitro assay, appeared able to transport DCF-AG.  Based on the in vitro 
MRP3 vesicle assay and the in vivo Mrp3 KO study, it is highly likely that MRP3 is an 
operative transporter of DCF-AG in vivo for humans.  As such investigations into human 
MRP3 polymorphisms are warranted to ascertain the extent to which patients may 
experience dispositional changes to MRP3 substrates. 
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Chapter 3 MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3 (MRP3) PLAYS 
AN IMPORTANT ROLE IN PROTECTION AGAINST ACUTE TOXICITY OF 
DICLOFENAC 
3.1 Abstract 
Diclofenac (DCF) is a non-steroidal anti-inflammatory drug commonly prescribed to 
reduce pain in acute and chronic inflammatory diseases.  One of the main DCF 
metabolites is a reactive diclofenac acyl glucuronide (DCF-AG) that covalently binds to 
biological targets and may contribute to adverse drug reactions arising from DCF use.  
Cellular efflux of DCF-AG is partially mediated by multidrug resistance-associated 
proteins (Mrp).  The importance of Mrp2 during DCF-induced toxicity has been 
established, yet the role of Mrp3 remains largely unexplored.  In the present work, Mrp3 
knockout (KO) mice were used to study the toxicokinetics and toxicodynamics of DCF 
and its metabolites.  DCF-AG plasma concentrations were 90% lower in KO mice than 
in wild-type (WT) mice, indicating that Mrp3 mediates DCF-AG basolateral efflux.  In 
contrast, there were no differences in DCF-AG biliary excretion between WT and KO 
suggesting that only DCF-AG basolateral efflux is compromised by Mrp3 deletion.   
Susceptibility to toxicity was also evaluated after a single high DCF dose.  No signs of 
injury were detected in livers and kidneys, however ulcers were found in the small 
intestines.  Furthermore, the observed intestinal injuries were consistently more severe 
in KO compared to WT.  DCF covalent adducts were observed in liver and small 
intestines, however staining intensity did not correlate with the severity of injuries 
implying that tissues respond differently to covalent modification.  Overall, the data 
provides strong evidence that (1) in vivo Mrp3 plays an important role in DCF-AG 
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disposition and (2) compromised Mrp3 function can enhance injury in the 
gastrointestinal tract after DCF treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission of the American Society for Pharmacology and Experimental 
Therapeutics. All rights reserved. 
Copyright © 2015 by The American Society for Pharmacology and Experimental 
Therapeutics 
110 
 
3.2 Introduction 
Diclofenac (DCF) is a non-steroidal anti-inflammatory drug (NSAID) that is prescribed to 
alleviate symptoms associated with ankylosing spondylitis, osteoarthritis, rheumatoid 
arthritis, and migraine (McNeely and Goa, 1999; Novartis, 2011; Depomed, 2014).  DCF 
is generally well tolerated although long term usage has been implicated with a variety 
of adverse drug events (ADR) in a subset of patients.  The most common side effects of 
DCF are discomfort, ulceration, and bleeding in the gastrointestinal (GI) tract.  These 
ADRs are related to DCF pharmacodynamics, namely chronic inhibition of 
cyclooxygenase (COX) enzymes causing a decrease of prostaglandins that protect the 
GI mucosa (Menasse et al., 1978; Wallace, 2008).  NSAIDs as a group have a mean 
liver injury rate of 1 per 100,000 users.  However, chronic DCF administration increases 
the risk of liver injury to 6 per 100,000 users (de Abajo et al., 2004).  More recently, a 
meta-analysis of cardiovascular safety implicated DCF with a higher risk of 
cardiovascular death and stroke among a group of seven NSAIDs (Trelle et al., 2011). 
DCF undergoes extensive first-pass metabolism in humans, and approximately 50% of 
the dose is systemically available (Willis et al., 1979).  The majority of DCF is converted 
into metabolites of which 65% are eliminated in urine with the remainder excreted in bile 
(Riess et al., 1978; Novartis, 2011).  Among the main products are hydroxylated 
metabolites, the predominant being 4′-hydroxy diclofenac (OH-DCF), that can form 
reactive quinone imines that adduct and deplete glutathione causing a state of oxidative 
stress (Tang et al., 1999).  Another key metabolite is the highly reactive diclofenac acyl 
glucuronide (DCF-AG), which is primarily catalyzed in humans by uridine 5′-diphospho-
glucuronosyltransferase (UGT) 2B7 (King et al., 2001).  It has been shown that 
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inheritance of one or two copies of the UGT2B7*2 allele was associated with an 
increased risk of DCF-induced hepatotoxicity compared to UGT2B7*1 homozygotes as 
the *2 variant possesses higher catalytic activity (Daly et al., 2007). 
DCF-AG is initially formed as a β-1-O-acyl glucuronide (β-anomer) which can be 
cleaved by β-glucuronidase into DCF and glucuronic acid.  β-anomers spontaneously 
isomerize into β-glucuronidase-resistant 2-, 3-, and 4-O-acyl isomers (Sallustio et al., 
2000).  DCF-AG undergoes these rearrangements as the pH changes from acidic to 
physiologic conditions such as those that occur in the GI tract (Ebner et al., 1999; 
Kenny et al., 2004).  DCF-AG can form adducts with multiple proteins in the liver and GI 
tract, and dipeptidyl peptidase IV was identified as a DCF-AG target in rat liver where 
adduction resulted in decreased activity (Hargus et al., 1995).  Furthermore, it was 
found that broad-acting UGT inhibitors can significantly diminish the covalent binding of 
DCF metabolite to hepatocellular proteins in vitro (Kretz-Rommel and Boelsterli, 1993).  
There is consensus that repeated exposure to DCF-AG contributes to the idiosyncratic 
drug reaction seen with clinical usage, however the exact nature of how DCF-AG 
contributes to the etiology of these reactions remains unclear. 
The potential for DCF-AG to cause extrahepatic covalent binding modifications is 
contingent upon active transport.  For instance, DCF-AG was not detected in the bile of 
rats lacking canalicular multidrug resistance-associated protein 2 (Mrp2, Abcc2) (Seitz 
et al., 1998).  A follow-up study revealed that Mrp2 mutant rats also had reduced 
intestinal ulceration compared to wild-type (WT) rats (Seitz and Boelsterli, 1998).  These 
findings are important as they suggest that Mrp2 is at least partially responsible for 
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DCF-AG excretion from hepatocytes into bile.  The mechanism by which DCF-AG is 
transported from hepatocytes into blood remains less understood. 
Among the MRPs that are expressed along the basolateral membrane, MRP3 (ABCC3) 
has been demonstrated to export glucuronide conjugates of other compounds (Zelcer et 
al., 2001; Zelcer et al., 2006).  In a Caucasian sample pool, fifty-one single nucleotide 
polymorphisms (SNP) in MRP3 were found (Lang et al., 2004).  A pharmacogenomic 
study of healthy Japanese subjects identified twenty-one novel SNPs, with two resulting 
in immature transcript due to insertion of a stop codon (Fukushima-Uesaka et al., 2007).  
Functional significance of MRP3 SNPs was demonstrated whereby several MRP3 
SNPs expressed in an in vitro system had impaired transporter function either by 
reductions in transporter activity or disruption of intracellular transporter trafficking to the 
cell membrane (Kobayashi et al., 2008). 
Because MRP3 has been shown to transport both endogenous and exogenous 
glucuronide conjugates, it can be hypothesized that perturbation of MRP3 expression or 
function may affect the disposition and toxicity of DCF-AG in vivo.  To investigate the 
role of MRP3 in the disposition and toxicity of DCF, a mouse Mrp3 knockout (KO) model 
is used to assess the disposition of DCF-AG and whether Mrp3 deletion increases 
likelihood of injury. 
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3.3 Materials and Methods 
Chemicals and Reagents.  DCF, OH-DCF, Dulbecco’s phosphate buffered saline 
(DPBS), formic acid, indomethacin (as the IS), and sodium citrate were purchased from 
Sigma-Aldrich Corporation. (St. Louis, MO).  DCF-AG was purchased from Toronto 
Research Chemicals Incorporated (Toronto, ON, Canada).  Solutol® HS 15 was 
provided by the BASF Corporation (Florham Park, NJ).  DCF antiserum was graciously 
donated by Dr. Dietmar Knopp (Technische Universität München, München, Germany). 
Animals.  Mrp3-null mice of FVB 129/Ola background were provided by Dr. Piet Borst 
(Netherlands Cancer Institute, Amsterdam, Netherlands).  An additional set of Mrp3 KO 
mice having C57BL/6J background were generated at the University of Kansas Medical 
Center.  Mice were housed in an American Animal Associations Laboratory Animal Care 
accredited facility of University of Kansas Medical Center under a standard 
temperature-, light-, and humidity-controlled environment.  Mice had free access to 
Laboratory Rodent Chow 8604 (Harlan, Madison, WI) and drinking water.  All animal 
studies were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals using protocols reviewed and approved by the local Institutional 
Animal Care and Use Committee of University of Kansas Medical Center (Kansas City, 
KS). 
In Vivo Studies.  Toxicokinetics.  Male 2-3 month old FVB 129/Ola WT and FVB 
129/Ola KO mice were anesthetized intraperitoneally with a ketamine/midazolam 
mixture (100 and 5 mg/kg, respectively), and both the right carotid artery and the 
common bile duct were cannulated for sample collection.  The mice received a single 
intraarterial dose of 75 mg/kg DCF in 10:90 (v/v) Solutol HS 15:DPBS at a dosing 
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volume of 5 mL/kg.  Bile flow was monitored, and bile fractions were collected in fifteen 
minute intervals from -15 to 0, 0 to 15, 15 to 30, 30 to 45, 45 to 60, 60 to 75, and 75 to 
90 minutes post administration.  Blood samples were collected into heparinized tubes at 
2, 7.5, 22.5, 37.5, 52.5, 67.5, and 90 minutes after administration, and the blood was 
subsequently centrifuged to yield plasma.  The volumes of bile were determined 
gravimetrically, using 1.0 for specific gravity.  Both bile and plasma were stored at -
20 °C until analysis.  At the conclusion of the study (90 min post-administration), 
animals were sacrificed by overdose with ketamine and midazolam.  Livers were 
harvested and quickly frozen in liquid nitrogen prior to storage at -80 °C. 
Toxicodynamics.  2-3 month old male WT and KO (C57BL/6 background) were injected 
a single intraperitoneal dose of either vehicle, 10:90 (v/v) Solutol HS15: DPBS, or 90 
mg/kg DCF in vehicle at a dosing volume of 5 mL/kg.  The mice were then allowed 
access to food and water ad libitum.  Twenty four hours after dosing, the mice were 
anesthetized for sacrifice with an intraperitoneal injection of 50 to 70 mg/kg 
pentobarbital.  Blood was collected and centrifuged to yield plasma and kept frozen at -
20 °C.  Kidneys, liver, and small intestines were harvested, fixed in buffered formalin for 
24 hours with gentle shaking at room temperature, and then transferred into 70% 
ethanol.  Tissues were subsequently paraffin embedded and sectioned onto glass slides 
for histopathology and immunohistochemistry. 
Bioanalytical Analysis.  Bile and plasma were diluted with 0.1% formic acid in water 
(Solvent A) for LC/MS/MS detection as well as to stabilize DCF-AG.  Liver samples 
were homogenized by bead milling using Solvent A.  A 50 µL aliquot of diluted biological 
matrix was then precipitated with 450 µL of 0.1% formic acid in acetonitrile (Solvent B) 
115 
 
containing IS.  Standard curves using naïve matrices were prepared in a similar fashion.  
Samples and standards were vigorously vortex-mixed and centrifuged at 1350 × g for 
10 min and 4 °C.  A 200 µL aliquot of supernatant was removed and evaporated under 
Nitrogen gas at 45 °C.  The resulting residue was reconstituted with 200 µL of 90:10 
(v/v) A:B, vigorously vortex-mixed, and centrifuged prior to injection onto LC/MS/MS.  
The injection volume for all sample types was 10 µL. 
LC/MS/MS Method.  Chromatographic separation of analytes was performed on a 
Synergi™ 4 µm Max-RP 50 × 2 mm column (Phenomenex Incorporated, Torrance, CA).  
The system front end consisted of a HTC PAL Autosampler outfitted with a Coolstack 
set to 4 °C (LEAP Technologies Incorporated, Carrboro, NC), a SCL-10Avp system 
controller, two LC10ADvp pumps, and a DGU-14A degasser (Shimadzu Scientific 
Instruments, Columbia, MD).  Analytes of interest were eluted using a gradient profile 
that began with 10% solvent B for the first 1.0 min, which was then increased to 90% 
solvent B at 3.5 min using a linear gradient and held at this mixture for 0.5 min before 
reverting back to initial solvent conditions for 1.0 min to re-equilibrate the column.  The 
flow rate was 0.4 mL/min, and the column effluent was directed to waste for the initial 
1.5 min before switching to the mass spectrometer.  Analytes were detected using an 
AB Sciex API™ 4000 LC/MS/MS triple quad mass-spectrometer with a TurboIonSpray® 
probe and Analyst version 1.4.2 software (AB Sciex, Framingham, MA) that was 
operated in multiple reaction monitoring mode.  Ion spray voltage was -4250 V, and the 
source temperature was set to 400 °C.  The mass transitions in negative ion mode for 
monitoring DCF, OH-DCF, DCF-AG, and indomethacin were m/z 294.0→249.9, 
309.9→265.9, 470.1→192.9, and 356.0→311.8, respectively.  The retention times of 
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DCF, OH-DCF, DCF-AG, and indomethacin were 3.25, 2.84, 2.69, and 3.20 min, 
respectively.  Concentrations of analytes in the samples were determined by comparing 
the peak area ratios (analyte/IS) to those in the standard curve using a linear regression 
model.  The dynamic range was 10 to 5,000 ng/mL for bile, liver homogenate, and 
plasma samples.  The criterion of acceptance for standards was defined to be ±20% of 
nominal concentration. 
Immunohistochemistry.  Slides for immunohistochemistry were deparaffinized by 
xylene, and the xylene was removed by sequentially decreasing concentrations of 
ethanol followed by hydration in water.  After a 30 min heat induced epitope retrieval in 
sodium citrate buffer, endogenous peroxidase activity was blocked with 3% hydrogen 
peroxide for 15 min.  Slides were subsequently treated with an Avidin/Biotin Blocking Kit 
(Vector Laboratories Incorporated, Burlingame, CA) as per the manufacturer’s 
recommendations and incubated with a Dako Serum-free Protein Block (Dako 
Incorporated, Carpinteria, CA) for 30 min.  A rabbit polyclonal primary antibody against 
DCF at a 1:5000 (v/v) dilution was applied for 60 min at room temperature after which 
slides were incubated for 30 min with a 1:300 dilution of a Dako biotinylated swine anti-
rabbit secondary antibody.  The slides were then exposed to streptavidin-horseradish 
peroxidase (BD Biosciences, San Jose, CA) for 30 min.  To develop the chromagen, a 
30 min treatment with a Vector® NovaREDTM Substrate Kit was utilized, and slides were 
counterstained with Mayer’s Hematoxylin (Thermo Fisher Scientific Inc., Grand Island, 
NY).  Finally, slides were dehydrated with ethanol and xylene and cover-slipped using 
Histomount Mounting Solution (Life Technologies).  For negative controls, samples from 
the vehicle-only groups were treated in the same manner as subjects dosed with DCF. 
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Clinical Chemistry.  Plasma samples from the toxicodynamic study were analyzed for 
alanine transaminase (ALT) and blood urea nitrogen (BUN) using kits purchased from 
Thermo Fisher Scientific Incorporated (Grand Island, NY) as per the manufacturer’s 
recommendations.  Positive and negative controls were utilized to assess assay 
functionality.  A BioTek UV/Vis microplate spectrophotometer (BioTek Instruments 
Incorporated, Winooski, VT) was used to measure assay endpoints. 
Histopathology.  Liver & Kidney.  Liver and kidney samples were fixed in 10% neutral-
buffered zinc formalin prior to processing and paraffin embedding.  Tissue sections (5 
μm) were stained with hematoxylin and eosin.  Sections were examined by light 
microscopy for the presence and severity of necrosis and degeneration using an 
established grading system (Ishiguro et al., 2008). 
Gastrointestinal Tract.  The gastrointestinal tract was examined histologically with 
multiple transverse sections of the stomach and large intestine and Swiss Roll sections 
of the small intestine (Moolenbeek and Ruitenberg, 1981).  Histological examination 
used a scoring system adapted from a method described by Krieglstein et al. (2007).   
Briefly, 3 independent parameters were measured for a combined semi quantitative 
injury score; the degree of villus/crypt damage, the severity of inflammation (none, 
minimal, mild, moderate, marked, and severe), and the depth of injury (mucosa with 
epithelium and lamina propria, submucosa, muscularis, and serosa). 
Statistical Analysis.  Data are expressed as mean ± standard error of the mean.  P 
values < 0.05 were considered as statistically significant.  Statistical analysis of data 
was performed using R version 3.2.1 (R Core Team, 2015).  Two groups were 
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compared by Student’s t test, and multiple groups were compared by an analysis of 
variance followed by Tukey’s post hoc test. 
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3.4 Results 
Toxicokinetic Study.  In animals that remained anesthetized for surgical exposure of 
the abdominal cavity and bile duct cannulation, the maximal tolerated dose without 
morbidity was 75 mg/kg.  Plasma concentrations for 75 mg/kg DCF (Figure 3.1A) were 
significantly higher in KO compared to WT, and the increases were generally less than 
40%.  Conversely, OH-DCF concentrations in plasma (Figure 3.1B) were significantly 
higher in WT with a 90% increase observed at 37.5 min.  There was a dramatic disparity 
in plasma concentrations between WT and KO for DCF-AG (Figure 3.1C) with WT 
having nearly 9-fold higher concentrations in plasma compared to KO.  A summary of 
pertinent toxicokinetic parameters is presented in Table 3.1  Both genotypes had similar 
estimated DCF plasma concentrations at time zero (C0).  Though there was a difference 
in the DCF elimination half-life (t1/2) between the 2 genotypes, the DCF plasma 
exposure (AUC0-tlast) for WT and KO was comparable. 
To determine whether the loss of Mrp3 affected the biliary disposition of DCF and the 
two metabolites under consideration, the biliary excretion of DCF and its metabolites 
were quantified.  There was no difference in bile flow between WT and KO (data not 
shown).  The biliary excretion of DCF and its metabolites were equivalent between the 
two genotypes (Figure 3.1D, E, and F).  Of the three analytes, DCF-AG was most 
predominant in bile constituting nearly 10% of the total DCF dose for each genotype, 
whereas DCF and OH-DCF biliary concentrations accounted for 0.2 and 0.1% of total 
DCF dose, respectively, irrespective of genotype.  The limited availability of KO mice 
permitted assessing hepatic concentrations of DCF and its metabolites only at the 
terminal time point of 90 min post-administration.  The KO livers had more DCF though 
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the difference was not statistically significant.  OH-DCF and DCF-AG concentrations in 
KO livers were statistically lower compared to WT (Figure 3.2).  In contrast to bile for 
which the major detected analyte was DCF-AG, unchanged DCF in both genotypes was 
most abundant compared to OH-DCF and DCF-AG. 
Clinical Chemistry.  Having established a role for Mrp3 to modulate systemic exposure 
of DCF-AG in vivo, the next objective was to evaluate to susceptibility of KO to DCF-
induced injury.  For these studies, the DCF dose was increased to 90 mg/kg as that was 
the maximal non-lethal dose in animals that were non-surgerized and freely moving.  
Rather than oral gavage, intraperitoneal administration was used to maximize dose 
absorption and delivery of DCF via portal circulation for immediate uptake into the liver.  
ALT concentrations (Figure 3.3A) were not significantly different between WT and KO 
suggesting no injuries in the liver.  Furthermore, ALT values in all vehicle control and 
DCF-treated groups were less than 40 U/L, which is the upper limit of normal range for 
ALT.  BUN levels (Figure 3.3B) were statistically higher in KO mice compared to WT, 
however the lack of difference between vehicle and DCF treated groups in KO mice 
suggest there was no DCF-induced renal injury. 
Histopathology.  Histopathological examination of liver and kidneys showed no 
obvious injuries at the administered dose confirming the clinical chemistry results (data 
not shown).  The small intestines were also examined and scored according to three 
categories of injury.  WT which received DCF showed a trend of higher injury compared 
to vehicle treated subjects (Figure 3.4), though these differences were not statistically 
significant.  In addition, KO dosed with DCF had significantly greater incidence and 
severity of erosions and ulcers compared to treatment-matched WT mice.  For both WT 
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and KO, ulcers were observed in the jejunal and ileal but not duodenal regions of the 
small intestine.  Thus, the data suggest that the loss of Mrp3 increased the susceptibility 
to intestinal injury from an acute dose of DCF. 
Immunohistochemistry.  Sections of livers, kidneys, and small intestines were 
subjected to immunohistochemistry in order to determine the extent of DCF adduction.  
The rationale for conducting this assay was that reactive intermediates or metabolites of 
DCF are known to covalently bind to proteins.  Thus the goal was to establish possible 
links between covalent binding of reactive DCF products and tissue injury.  Kidneys 
were entirely devoid of DCF adduct staining implying that reactive DCF metabolites 
were not likely to be generated or accumulated by transit in kidneys (data not shown).  
In contrast, WT and KO livers showed strong evidence of DCF adduction after DCF 
administration compared to vehicle controls.  The staining was robust and was 
observed in centrilobular, midzonal, and periportal regions (Figure 3.5B, C, E, and F).  
Vehicle controls did not exhibit staining suggesting that the primary antibody was 
specific for diclofenac adducts (Figure 3.5A and C).  Interestingly, the livers showed 
intense staining for DCF adduct yet this organ did not manifest any apparent signs of 
injury either through clinical chemistry or histopathology.  Lastly, compared to small 
intestines from vehicle controls which were unremarkable (Figure 3.5G and J), the small 
intestines from WT and KO also exhibited positive staining of DCF adducts (Figure 3.5H, 
I, K, L).  The level of adduct staining in the small intestine was notably weaker than that 
observed in the liver as qualitatively assessed by chromagen intensity and the degree of 
scatter.  Adduct formation was detected along the brush border of villi and extended 
inwards towards the basement membrane.  In terms of regiospecificity, staining was 
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scattered throughout the small intestine and did not appear to be confined to any 
particular location. 
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Figure 3.1 Toxicokinetics of DCF and its metabolites in FVB WT and FVB Mrp3-KO 
mice after a single intraarterial dose of 75 mg/kg DCF 
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Figure 3.1 Toxicokinetics of DCF and its metabolites in FVB WT (●) and FVB Mrp3 KO 
(○) mice after a single intraarterial dose of 75 mg/kg DCF.  (A-C) Plasma concentration 
profiles for (A) DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points.  (D-F) Biliary 
excretion profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.  Time points represent 
accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 45-
60, 60-75, and 75-90 min).  All data are expressed as mean ± standard error of the 
mean for 10-12 subjects/group.  * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT. 
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Table 3.1 Summary of DCF toxicokinetic parameters in plasma of FVB WT and 
FVB Mrp3 KO after a single 75 mg/kg DCF dose 
Genotype 
C0 
(µM) 
t1/2 
(min) 
AUC0-tlast 
(µM × min) 
WT 699 ± 31 74.1 ± 12.8 34,600 ± 2,100 
KO 701 ± 38 108 ± 10 35,900 ± 2,500 
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Table 3.1 Summary of DCF toxicokinetic parameters in plasma of FVB WT and FVB 
Mrp3 KO after a single 75 mg/kg DCF dose.  C0 indicates the estimated DCF plasma 
concentration at time zero, t1/2 is the DCF elimination half-life, and AUC0-tlast is the area 
under the plasma concentration versus time curve for DCF from time zero to the last 
collected time point.  Data are expressed as mean ± standard error of the mean for 10-
12 subjects/group. 
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Figure 3.2 Hepatic concentrations of DCF, OH-DCF, and DCF-AG in FVB WT and 
FVB Mrp3 KO mice 
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Figure 3.2 Hepatic concentrations of DCF, OH-DCF, and DCF-AG in FVB WT (■) and 
FVB Mrp3 KO (□) mice.  Mice were injected with 75 mg/kg DCF.  Livers were harvested 
90 min following administration of vehicle or DCF.  Data are expressed as mean ± 
standard error of the mean for 10-12 subjects/group.  * P < 0.05; ** P < 0.01 versus WT. 
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Figure 3.3 Clinical chemistry of WT and KO mice 24 hours after a single dose of 
90 mg/kg DCF 
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Figure 3.3 Clinical chemistry of C57 WT and C57 Mrp3 KO mice 24 hours after a single 
dose of 90 mg/kg DCF.  (A) Plasma alanine aminotransferase (ALT).  (B) Plasma blood 
urea nitrogen (BUN).  Results are expressed as mean ± standard error of the mean for 
3-7 subjects/group.  ** P < 0.01 versus WT. 
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Figure 3.4 Summary of histopathology of small intestines from C57 WT and C57 
Mrp3 KO mice 24 hours after administration of vehicle or 90 mg/kg DCF 
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Figure 3.4 Summary of histopathology of small intestines from C57 WT and C57 Mrp3 
KO mice 24 hours after administration of vehicle or 90 mg/kg DCF.  Results are 
expressed as mean ± standard error of the mean for 3-7 subjects/group.  The overall 
grade was based on the following scheme: 0 = none, 1= minimal, 2 = mild, 3 = 
moderate, 4 = marked, and 5 = severe.  Ulcers and erosions reflect the number of 
findings that were indentified on an entire tissue section.  ** P < 0.01; *** P < 0.001 
versus treatment-matched WT. 
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Figure 3.5 Immunohistochemistry of tissues taken from C57 WT and C57 Mrp3 KO 
mice treated with vehicle or 90 mg/kg DCF 
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Figure 3.5 Immunohistochemistry of tissues taken from C57 WT and C57 Mrp3 KO 
mice treated with vehicle or 90 mg/kg DCF (immunoperoxidase with hematoxylin 
counterstain).  Tissues were harvested 24 hours after administration.  (A-C) Liver 
sections at 4× magnification.  (A) Representative liver section from vehicle treated WT.  
(B and C) WT liver from subjects 3 and 6 after 90 mg/kg. (D) Liver from vehicle treated 
KO. (E and F) KO liver from subjects 4 and 7 after 90 mg/kg.  (G-L) Small intestine 
sections at 15× magnification. (D) Representative small intestine from vehicle treated 
WT. (H and I) WT small intestine from subjects 4 and 6 after 90 mg/kg. (J) Small 
intestine from vehicle treated KO. (K and L) KO small intestine from subjects 2 and 4 
after 90 mg/kg.  The presence of DCF adducts is visualized by the presence of 
red/brown staining. 
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3.5 Discussion 
This work explores the role of Mrp3 on the disposition and acute toxicity of DCF.  DCF 
has high passive permeability, therefore its uptake into tissues should not be limited by 
active transport processes (Huang et al., 2010).  The elevated DCF and lower OH-DCF 
plasma concentrations in KO compared to WT (Figure 3.1A-B) may indicate metabolic 
saturation.  In vitro studies using mouse hepatic S9 fraction did not show differences in 
DCF metabolism as the WT and KO Km values were comparable (Chapter 2 Figure 2.9).  
Further evidence of metabolic saturation comes from the OH-DCF plasma 
concentration-time profile which was relatively flat at 75 mg/kg DCF whereas at lower 
doses plasma OH-DCF was initially high before decreasing by first-order kinetics 
(Chapter 2 Figure 2.4). 
The present DCF-AG data are consistent with low dose studies and demonstrate Mrp3-
mediated DCF-AG efflux (Figure 3.1C).  Our data confirm the observation reported by 
Lagas et al. (2010) that DCF-AG is an in vivo substrate of mouse Mrp3.  KO had DCF-
AG plasma concentrations that were nearly 90% lower compared to WT.  Plasma 
concentrations of several glucuronide metabolites have been reported to be lower in 
Mrp3 KO compared to WT mice (Manautou et al., 2005; Zamek-Gliszczynski et al., 
2006b).  As KO mice were comparable to WT in terms of overall transporter expression 
except for Mrp3, the results indicate that Mrp3 mediates DCF-AG basolateral efflux in 
vivo. 
DCF, OH-DCF, and DCF-AG biliary excretion showed no evident distinction between 
WT and KO.  Because Mrp3 acts as a basolateral efflux pump for bile acids (Zelcer et 
al., 2003c), the bile flow in WT and KO was measured and found to be equal suggesting 
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that Mrp3 deletion and DCF treatment did not affect bile flow.  That DCF-AG biliary 
excretion was similar between WT and KO was unexpected considering the pronounced 
plasma differences.  Other studies in KO mice reported that low plasma or perfusate 
concentrations of glucuronides were inversely correlated with increased glucuronide 
biliary concentrations compared to WT (Manautou et al., 2005; Zamek-Gliszczynski et 
al., 2006b).  Similar to rats, canalicular DCF-AG excretion would likely have been 
mediated by Mrp2 given the 88% protein sequence homology between mouse and rat 
Mrp2 (Altschul et al., 2005).  Another canalicular transporter, breast cancer resistance 
protein (Bcrp, Abcg2), has been also demonstrated to transport DCF (Lagas et al., 
2009).  Exploratory studies in our laboratory with Bcrp-KO mice resulted in slight 
reductions of DCF-AG biliary excretion compared to WT (Chapter 2 Figure 2.1 and 
Figure 2.2). 
To account for other possible DCF metabolites, bile fractions were pooled and infused 
onto the LC/MS/MS for qualitative metabolite profiling.  Peaks corresponding to DCF 
taurine conjugate and diclofenac acyl glucuronide (OH-DCF-AG) were detected in prior 
exploratory studies (Chapter 2 Figure 2.7).  Identification of these metabolites is 
consistent with their formation in rodent (Kenny et al., 2004; Sarda et al., 2012).  
Nonetheless, the OH-DCF-AG signal in KO bile would not have wholly accounted for 
the DCF-AG fraction that was diverted from entering the blood.  Despite the DCF-AG 
mass balance inequity between WT and KO, there are instances in which Mrp3 ablation 
affects basolateral but not canalicular efflux.  Zelcer et al. (2006) noted that 
hyodeoxycholate glucuronide perfusate concentrations were 4-fold greater in WT 
compared to KO while bile concentrations were similar between genotypes.  Moreover, 
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fexofenadine plasma concentrations decreased 50% in Mrp3-KO mice relative to WT, 
yet biliary and hepatic fexofenadine concentrations between the genotypes were the 
same (Tian et al., 2008).  Thus, Mrp3 deletion solely affected DCF-AG basolateral efflux. 
The other aim of this study was to assess the susceptibility of Mrp3-null subjects to 
DCF-induced injury.  Initial studies in FVB 129/Ola mice at a 90 mg/kg DCF dose 
resulted in KO, but not WT, exhibiting greater intestinal injury (data not shown).  As FVB 
129/Ola KO mice were unavailable, further studies were conducted in C57BL/6 KO mice.  
Neither the liver nor kidneys showed any evidence of damage by serum biomarker 
analysis (Figure 3.3).  DCF has been shown to induce nephrotoxicity in ICR mice 
evidenced by a 2.5-fold increase in BUN concentrations 24 hours following an oral 100 
mg/kg dose (Hickey et al., 2001).  The finding in ICR mice likely reflects that strain’s 
higher sensitivity to renal injury since C57BL/6 mice (Figure 3.3B) had no changes in 
BUN concentrations compared to vehicle treatment 24 hours after 90 mg/kg 
intraperitoneal administration.  Regarding the liver, Lagas et al. (2010) reported that a 
25 mg/kg intraperitoneal DCF injection caused ALT concentrations to increase 2-fold 
compared to WT leading the authors to conclude that slight liver toxicity occurred.  
However, the mice used in that study were triple knockouts for Bcrp, Mrp2, and Mrp3 
making it difficult to ascribe which transporter was truly responsible for enhancing the 
toxic effect.  Additionally, ALT, bilirubin, liver weights, and triglycerides were also slightly 
elevated in the triple KO versus WT suggesting that the mice may be more susceptible 
to challenge by a toxicant (Vlaming et al., 2009b).  Though liver and kidney were devoid 
of injury for the present study, the small intestines in both genotypes exhibited damage 
with KO mice sustaining greater injury (Figure 3.4).  The intestinal injury is consistent 
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with published reports on DCF ulcerogenicity (Atchison et al., 2000b; Ramirez-Alcantara 
et al., 2009). 
Reactive DCF metabolites form adducts with a number of hepatic proteins (Seitz et al., 
1998; Sallustio and Holbrook, 2001; Kenny et al., 2004).  Immunohistochemistry 
revealed widespread covalent binding in the liver and small intestine but not in kidneys 
of both WT and KO (Figure 3.5).  Qualitative assessment of the extent of staining did 
not provide meaningful distinction between the two genotypes (data not shown).  DCF 
adduct staining was most intense in the liver, yet this organ did not appear to have any 
obvious histopathological damage.  DCF-AG synthesis would be high in the liver, and it 
is plausible that DCF-AG adducted albumin, which is synthesized in the liver, and/or 
sequestered by thiols (protein and non-protein) that are not critical cellular targets.  
Though staining in small intestines was less robust, histopathology revealed significant 
damage (Figure 3.4).  DCF-AG adduction to enterocytes potentially compromised 
enterocyte function and viability and possibly induced an immune-mediated response.  
Modulation of the immune function within 24 hours of toxicant exposure has previously 
been demonstrated for drugs such as acetaminophen (APAP).  Administration of a toxic 
APAP dose activates hepatic macrophages (i.e., Kupffer cells) to release 
proinflammatory cytokines (Blazka et al., 1995b).  This in turn stimulates the migration 
and infiltration of immune cells into the liver, influencing the ultimate toxic outcome.  The 
role of the immune system in intestinal toxicity following DCF administration was beyond 
the scope of the present work and will be a focus of future studies. 
DCF-AG could adduct enterocyte proteins on the extracellular surface or alternatively 
adduct from within after uptake by various transporters.  Glucuronide conjugates can be 
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transported by organic anion transporting polypeptides (OATPs) of which OATP2B1 
(SLCO2B1) is the predominant isoform in the human intestine (Ishiguro et al., 2008; 
Drozdzik et al., 2014).  It is likely through the mouse Oatp2b1 homologue, which is also 
expressed in the intestines, that DCF-AG uptake occurs (Cheng et al., 2005).  
Nonetheless, the fact that the liver had intense adduct formation without apparent injury 
compared to the intestine which had extensive damage but moderate adduction may 
indicate that protein adducts of DCF metabolite(s) do not necessarily contribute to or 
cause toxicity. 
DCF administration resulted in two diverse outcomes: 1) rapid generation of DCF-AG 
that was excreted into bile or plasma and 2) COX inhibition that decreased local and/or 
systemic prostaglandins that protect the GI mucosa.  Based on the data, we propose 
the following series of events to occur in our model of DCF-induced toxicity.  DCF-AG is 
taken up and covalently binds to targets (plasma membrane, intracellular proteins, etc.) 
compromising the integrity of the enterocyte.  In KO, the DCF-AG basolateral efflux is 
attenuated potentially leading to higher accumulation of intracellular DCF-AG within 
enterocytes compared to WT.  Meanwhile, intestinal mucosal protection is weakened 
due to DCF’s pharmacological inhibition of both COX-1 and COX-2 (Menasse et al., 
1978) causing a decrease in protective prostaglandins.  Simultaneously, the highly 
permeable DCF enters enterocytes and exerts further injury through mitochondrial 
dysfunction leading to apoptosis (Gomez-Lechon et al., 2003a; Lim et al., 2006).  
Unbound DCF-AG may also dissociate into DCF and glucuronic acid intensifying 
diclofenac-induced mitochondrial dysfunction.  Mrp2, which normally confers a measure 
of protection via DCF-AG efflux, could be affected as Mrp2 translocates intracellularly 
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from its apical membrane localization during oxidative stress (Sekine et al., 2006).  The 
proposed events would, in theory, breakdown the overall intactness of the GI tract. 
There are several issues that remain to be addressed: (1) the relationship between 
DCF-AG exposure and developing injury is unclear, (2) determining the DCF-AG 
concentrations in the small intestine that can cause damage, and (3) assessing why the 
small intestines but not liver or kidneys were affected.  It will be necessary to devise 
experiments wherein the mechanism of injury by DCF-AG can be studied with minimal 
interference from its parent or hydroxylated metabolites.  The degree of intestinal COX 
inhibition also warrants examination as a contributing cause for the GI injury observed 
following DCF administration. 
In conclusion, the present work demonstrates that (1) Mrp3 is responsible for DCF-AG 
basolateral efflux during a toxic DCF challenge, (2) hepatic canalicular efflux is not 
perturbed by Mrp3 deletion, (3) KO mice have greater gastrointestinal damage 
compared to WT, and (4) appearance of adducts does not necessarily signify the 
occurrence of injury as certain organs are more sensitive to injury than others. 
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Chapter 4 ELUCIDATION OF THE MECHANISMS THROUGH WHICH THE 
REACTIVE METABOLITE DICLOFENAC ACYL GLUCURONIDE CAN MEDIATE 
TOXICITY 
4.1 Abstract 
We have previously investigated the toxicity of diclofenac (DCF) following a single high 
dose and reported significant intestinal injury in mice lacking the efflux transporter Mrp3.  
One proposed mechanism was that diclofenac acyl glucuronide (DCF-AG), as a 
substrate of Mrp3, played a part in mediating injury.  Thus the goal of the current work 
was to determine the role that DCF-AG had in the observed enteropathy.  Since both 
humans and mice express the uptake transporter OATP2B1 (SCLO2B1) in the 
intestines, this transporter was characterized for DCF-AG uptake.  In vitro assays using 
HEK-OATP2B1 cells demonstrated that DCF-AG was a substrate with a Vmax and Km of 
17.6 ± 1.5 pmol/min/mg and 14.3 ± 0.1 µM, respectively.  It was also determined that 
DCF-AG has low passive diffusion, thus its uptake into cells would be highly dependent 
on active uptake.  Another key finding from our in vitro assays was that DCF-AG was 
not only cytotoxic, but that its cytotoxicity was greater compared to DCF and occurred 
within 1 to 3 hours of exposure.  The potential for DCF-AG to induce reactive oxygen 
species (ROS) was also addressed.  We report that 1 mM DCF-AG caused a 6-fold 
increase in ROS by 3 hours.  Further investigation focused on induction of oxidative 
stress through inhibition of superoxide dismutase (SOD).  We observed that whereas 
DCF increased SOD activity, DCF-AG had 100% inhibition of SOD at the highest tested 
dose of 1 mM.  Taken together, the cytotoxicity, SOD, and ROS results strongly suggest 
DCF-AG induced oxidative stress in our in vitro models.  Lastly, DCF-AG was screened 
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for pharmacologic activity against COX-1 and COX-2 and was found to have IC50 values 
of 0.620 ± 0.105 and 2.91 ± 0.36 µM, respectively.  Despite the weaker potency 
compared to its parent compound, that DCF-AG was able to inhibit the COX enzymes 
constituted a novel finding.  Since COX inhibition can lead to intestinal ulceration, it is 
plausible that DCF-AG can also contribute to enteropathy via COX inhibition.  Taken 
into context, the work presented herein demonstrated the multifactorial pathways by 
which DCF-AG can act as a direct contributor to toxicity following DCF administration. 
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4.2 Introduction 
Prior work on DCF focused on its disposition and the contribution of efflux transporters 
in modulating toxic outcomes.  In one notable report using rats that lacked the efflux 
transporter Mrp2 (Abcc2), these mutant rats exhibited resistance to intestinal injury after 
DCF administration (Seitz and Boelsterli, 1998).  This discovery was followed up by the 
observation that DCF-AG administration led to increased GI ulceration compared to 
DCF administration.  Our own work with efflux transporters demonstrated that Bcrp 
(Abcg2) and Mrp3 (Abcc3) had functional roles with respect to the disposition of DCF 
and DCF-AG (Chapter 2).  Furthermore, toxicodynamic studies conducted in Mrp3 KO 
mice showed conclusively that KO mice developed increased intestinal damage 
compared to WT (Scialis et al., 2015).  Despite the susceptibility differences between 
genotypes, the mechanisms involved in the increased injury remain unclear. 
Our work, as well as that of others, demonstrated that administration of DCF leads to 
the formation of covalent adducts along the intestinal epithelia (Ware et al., 1998; 
Atchison et al., 2000b).  In these instances, adduct formation was detected not only 
along the brush border of the intestinal villi, but was also observed within the enterocyte 
as well.  It is reasonable to assume that adduction on the extracellular surface of 
plasma membrane was followed by internalization of the adducted protein (Boelsterli, 
2003).  Another pathway may involve the active transport of DCF-AG by intestinal 
uptake transporters followed by intracellular adduction.  Indeed, the GI tract expresses a 
number of transporters that have recently been quantified by proteomic analysis using 
LC/MS/MS (Groer et al., 2013).  One of the major uptake transporters is OATP2B1 
(SCLO2B1), a known carrier for conjugated substances (Gao et al., 2012). 
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There exists then a distinct possibility that uptake of DCF-AG by OATP was contributory 
to the enteropathy observed in the aforementioned animal models.  Evidence for uptake 
transporter activity, as a causative means towards injury, has gained recent attention.  
For instance, stably transfected HEK-OATP cells were used to explore toxicity due to 
transporter-mediated uptake of statins in a report by Zhang and colleagues (2013).  For 
that work, active uptake of several compounds in the statin class of drugs by OATP1B1 
(SCLO1B1) was shown to cause a left-shift in cytotoxicity potency compared to the 
toxicity observed in HEK-WT cells.  The Zhang study takes on meaningful significance 
upon consideration that OATP1B1 is a major hepatoselective transporter.  Since 
OATP2B1 intestinal expression is also correlated with uptake activity in the intestines 
(Sai et al., 2006), understanding the relationship between uptake and toxicity should be 
pursued. 
Toxicity from DCF-AG cannot purely arise through its active uptake or decreased 
excretion.  Other processes must occur to account for the increased GI injury attributed 
to DCF-AG compared to parental compound.  A possible modality is involvement of the 
immune system either by activation of liver-specific Kupffer cells or immune response 
caused by covalent adduct recognition (Yano et al., 2012).  The covalent adduct 
immune response hypothesis is difficult to test on an acute basis since the presence of 
antibodies due to covalent adducts does not always result in injury (Vojdani et al., 2015).  
Case in point, there was intense hepatic adduct formation in our DCF toxicodynamic 
study, yet despite the presence of resident macrophages which are known to be 
activated during a cytotoxic challenge, no hepatotoxicity was apparent (Chapter 3). 
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The findings in the liver strongly suggest that DCF-mediated enteropathy is not 
mediated by protein adduction in enterocytes.  Nevertheless, there are alternative 
explanations for how DCF-AG is directly causing injury after DCF administration.  A 
possibility is oxidative stress through inhibition of superoxide dismutase (SOD).  SOD is 
a critical cellular defense mechanism for coping with reactive oxygen species (ROS) 
(Fridovich, 1978).  Precedent of SOD inhibition by xenobiotic metabolites comes from a 
study by Chiou et al. (1999) in which suprofen acyl glucuronide inhibited SOD.  Given 
the structural class similarity between DCF-AG and suprofen acyl glucuronide, DCF-AG 
inhibition of SOD becomes a distinct prospect.  In addition to SOD perturbation, DCF-
AG may induce oxidative stress by generation of ROS just as DCF has been shown to 
incite (Lim et al., 2006). 
Gastrointestinal injury after DCF administration can occur through its pharmacologic 
effects, namely inhibition of cyclooxygenase (COX) enzymes.  COX metabolism of 
arachidonic acid gives rise to a number of physiologically important derivatives such as 
prostaglandin E2 (PGE2) which functions to protect the GI mucosa (Kotani et al., 2006).  
DCF, a non-selective inhibitor of COX-1 and COX-2, promotes GI injury though 
decreased PGE2 signaling.  Inhibition of both COX isoforms is necessary for injury to 
develop.  Toxicity studies wherein a selective COX-1 or COX-2 inhibitor was 
administered to mice failed to show significant GI damage (Tanaka et al., 2001).  Yet, 
when a cocktail of a selective COX-1 and COX-2 inhibitors was given, profound injury 
became evident.  DCF potency for COX-1 and COX-2 is weaker compared to selective 
inhibitors such as SC-560 and DuP-697 (Seibert et al., 1996; Smith et al., 1998a), so its 
ability to provoke injury is a reflection that promiscuity for general COX inhibition, rather 
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than potency against a single COX isoform, is a determining factor.  In that context and 
considering that some DCF metabolites have shown pharmacological activity against 
COX, the capability of DCF-AG to inhibit COX enzymes presents an intriguing avenue 
to explore.  Though conjugated metabolites are normally thought to be devoid of 
pharmacological activity compared to parent compounds, examples exist to the contrary.  
Such cases include morphine-6-glucuronide and mycophenolic acyl glucuronide 
(Osborne et al., 1992; Schutz et al., 1999).  The pharmacologic potencies of those two 
glucuronide metabolites are equivalent to their parent compounds.  In light of this, DCF-
AG may possess enough COX inhibition pharmacology to promote injury. 
Thus the goal of the current work was to identify the various mechanisms that DCF-AG 
can promote injury.  This was accomplished through analysis of uptake by OATPs to 
determine if active uptake of DCF-AG can occur, and by conducting in vitro assays to 
quantify the extent of cytotoxicity as a result of ROS generation or inhibition of COX and 
SOD enzymes. 
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4.3 Materials and Methods 
Chemicals and Reagents.  DCF, DCFDA, DMEM, formic acid, hydrogen peroxide, 
HEPES, indomethacin (used as the IS), MOPS, and SC-560 were purchased from 
Sigma-Aldrich Corporation. (St. Louis, MO).  DCF-AG was purchased from Toronto 
Research Chemicals Incorporated (Toronto, Canada).  AA, COX-1, COX-2, Dup-697, 
and SOD were purchased from Cayman Chemical (Ann Arbor, MI).  Calcein-AM was 
purchased from Thermo Fisher Incorporated (Waltham, MA).  Ethidium homodimer-1 
was purchased from Biotium Inc. (Hayward, CA).  Stably-transfected HEK-OATP2B1 
cells were created at Pfizer Inc (Sandwich, UK) and were previously described 
(Kalgutkar et al., 2013).  All LC/MS/MS solvents were of high analytical grade and were 
purchased from Burdick & Jackson (Muskegon, MI). 
In Vitro Transport.  HEK-WT and HEK-OATP2B1 cells were seeded at 60,000 and 
90,000 cells/well, respectively, in 96-well poly-D-lysine coated microplates.  Cells were 
grown in DMEM containing 10% heat-inactivated fetal bovine serum and 5 mM sodium 
pyrutate.  Plates were kept in an incubator set to 95% relative humidity, 5% CO2, and 
37 °C.  Upon reaching confluency 48 hours after seeding, the growth media was 
discarded, and cells were washed three times with 100 µL uptake buffer at 37 °C.  Two 
types of buffer were used for the studies: 1) HBSS supplemented with 20 mM HEPES 
and titrated to pH 7.4, and 2) HBSS fortified with 20 mM MOPS and titrated to pH 6.0.  
The last wash was left on the cells for 15 min to equilibrate the cells before dosing 
commenced.  After the equilibration period had passed, the last wash was removed and 
cells were dosed with 50 µL uptake buffer containing increasing DCF-AG concentrations.  
Plates were quickly placed on a shaker set to 150 rpm and 37 °C and incubated for 0.1, 
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0.5, 1, and 2 min.  Termination of uptake was performed by quickly removing the uptake 
buffer, and the cells were washed 4 times with 200 µL ice-cold uptake buffer.  
Intracellular DCF-AG was extracted by adding IS in 100 µL ice-cold methanol and 
shaking the cell plates for 15 min at 4 °C.  Cellular extracts were transferred into a clean 
1 mL deep-well microplate and mixed with 100 µL solvent A.  Sample plates were 
vigorously vortex-mixed and injected onto the LC/MS/MS.  A DCF-AG standard curve 
was prepared using naïve cells and extracted using the same process described for 
samples.  The injection volume for all sample types was 10 µL.  Total DCF-AG uptake 
was quantified using the standard curve, and the data were reported as pmol.  Cell 
counts and cell size were measured using a Millipore Scepter device (EMD Millipore, 
Billerica, MA), and total protein was determined using a Pierce BCA kit following the 
manufacturer’s recommendations (Thermo Fisher Scientific Incorporated, Waltham, 
MA).  Concentrations were then normalized to pmol per µL of total cell volume in each 
well. 
Kinetic Modeling.  The DCF-AG uptake data was subsequently analyzed using a 2-
compartamental model previously described for OATP-mediated uptake (Poirier et al., 
2008; Poirier et al., 2009).  Essentially the model is governed by three processes: 1) 
Pdif,in defined as passive diffusion from the media into the cell, 2) Kactive which is active 
transport from the media into the cell, and 3) Pdif,out representing passive diffusion from 
the cell into the media.  A schematic of the model is shown in Figure 4.1.  Each process 
is described using the following equations: 
Equation 4.1 
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Equation 4.2 
        
           
         
 
Equation 4.3 
                    
where Pdif was a passive diffusion constant (µL/min), Cmedia was the DCF-AG 
concentration of the media (µM), Kactive is the saturable OATP2B1-mediated active 
transport that follows Michaelis-Menten kinetics, Vmax is the maximal transport velocity 
(pmol/min), Km is the substrate affinity (µM) at half the Vmax, and Ccell is the intracellular 
DCF-AG concentration (µM).  The Pdif and Vmax parameters noted above were 
normalized by the total cellular protein per well to yield units of µL/min/mg and 
pmol/min/mg, respectively.  The amount of DCF-AG in each compartment was defined 
by: 
Equation 4.4 
                     
Equation 4.5 
                   
where Amedia and Acell were the DCF-AG amounts (pmol), Vmedia was the volume of the 
dosing buffer (50 µL), and Vcell was the total cellular volume per well (µL) that was 
determined during the cell counting procedure using total cell counts and cell diameter.  
Utilizing the previously described relationships, the temporal uptake of DCF-AG into 
cells was based on the following differential equation: 
Equation 4.6 
      
  
                          
The concentrations from the uptake studies were imported into Berkeley Madonna 
software v8.3.18 (Macey et al., 2000).  A fourth order Runge-Kutta integration algorithm 
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was implemented using a proportional error model in which the time course data were 
log transformed.  The software was used to fit the data and determine values for Km, Pdif, 
and Vmax.  Each modeling run consisted of 6 concentrations, 4 time points in duplicate, 
and 2 cell types (HEK-WT and HEK-OATP2B1) giving 96 total data points.  Model 
performance in Berkeley Madonna was assessed by selection of initial guesses and 
parameter ranges that resulted in the lowest root mean square error. 
Cytotoxicity Assay.  HEK-OATP2B1 cells were seeded at 100,000 cells/well in 96-well 
Optilux microplates (BD Gentest, Waltham, MA).  Cells were grown in DMEM containing 
10% heat-inactivated fetal bovine serum and 5 mM sodium pyrutate.  Plates were kept 
overnight in an incubator set to 95% relative humidity, 5% CO2, and 37 °C.  The 
following day, the growth media was discarded, and cells were washed twice with 100 
µL uptake buffer at 37 °C (HBSS, 20 mM HEPES, pH 7.4).  After washing, cells were 
dosed in triplicate with 100 µL vehicle (uptake buffer with organic solvent), DCF, or 
DCF-AG and incubated for 3, 6, or 12 hours at 37°C.  Thirty minutes before the 
incubation period ended, the cells were briefly removed from the incubator, overlaid with 
100 µL of a cocktail containing 2 µM Calcein-AM (CAM) and 4 µM Ethidium 
Homodimer-1 (EthD-1), and placed back in the incubator for a final 30 minutes.  Plates 
were then removed, and fluorescence was measured on a SpectraMax Gemini XPS 
reader (Molecular Devices, Sunnyvale, CA).  The excitation/emission wavelengths for 
CAM were 490/520 nm while the excitation/emission wavelengths for EthD-1 were 
530/620 nm.  Responses for CAM and EthD-1 were normalized against the vehicle 
control cells. 
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ROS Assay.  HEK-OATP2B1 cells were seeded, grown, and washed as detailed in the 
preceding section.  After washing, the cells were dosed in triplicate with 100 µL vehicle 
or increasing concentrations of hydrogen peroxide, DCF, or DCF-AG and incubated for 
1, 2, or 3 hours at 37 °C.  At the end of the incubation period, the cells were removed 
from the incubator, the dosing media carefully aspirated, and the cells were gently 
washed once with 100 µL uptake buffer.  Cells were overlaid with 100 µL of 1 µM CAM 
or 20 µM Dichlorofluorescein diacetate (DCFDA) and were placed back in the incubator 
for an additional 30 minutes at 37 °C.  At the end of the incubation period, plates were 
removed, and fluorescence of the cells was measured on a SpectraMax Gemini XPS 
reader (Molecular Devices, Sunnyvale, CA).  The excitation/emission wavelengths for 
both CAM and DCFDA were 490/530 nm.  Responses for CAM and DCFDA were 
normalized against the vehicle control cells. 
SOD Inhibition Assay.  The SOD assay was conducted using a Cayman Chemical 
SOD kit with minor modifications to the recommended protocol.  Briefly, SOD 
incubations consisted of 198 µL radical detector, 10 µL of copper/zinc SOD, and 2.3 µL 
vehicle or increasing concentration of inhibitor.  Reactions commenced upon the 
addition of 20 µL xanthine oxidase, and the mixtures were shaken at 60 rpm in the dark 
for 30 min at room temperature.  Samples were then read on a BioTek UV/Vis 
microplate spectrophotometer (BioTek Instruments Incorporated, Winooski, VT) at a 
wavelength of 450 nm.  The SOD activity in all samples was compared against a SOD 
standard curve.  Absorption responses were background subtracted, and the 
percentage SOD inhibition was determined by normalizing the inhibitor response to 
vehicle controls. 
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COX Inhibition Assay.  The COX assay was performed using a Cayman Chemical 
COX kit with minor modifications to the recommended protocol.  Briefly, COX 
incubations consisted of 194 µL reaction buffer, 2 µL heme, 2 µL COX (1 or 2) enzyme, 
2 µL of arachidonic acid (AA), and 4 µL of vehicle or increasing concentration of 
inhibitor.  Reactions were conducted for 2 min in duplicate at 37 °C and were quenched 
by the addition of 10 µL 1 M HCl.  A 200 µL aliquot of the quenched reaction was 
transferred into a 1 mL deep-well microplate and diluted with 200 µL ice-cold methanol.  
From the diluted mixture, a 100 µL aliquot was mixed with 100 µL IS in ice-cold 
methanol, vigorously vortex-mixed, and injected onto the LC/MS/MS.  Methodology for 
detecting analytes of interest were modified from Shinde et al. (2012).  The injection 
volume for all sample types was 10 µL.  Rather than merely follow AA depletion, COX 
inhibition was determined by monitoring the appearance of PGE2 (PGE2/IS peak area 
ratio) in all samples and normalizing the inhibitor response to vehicle controls. 
LC/MS/MS Method.  Chromatographic separation of analytes was performed on a 2.6 
µm Kinetex XB-C18 30 × 2 mm column (Phenomenex Incorporated, Torrance, CA).  
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies 
Incorporated, Carrboro, NC), a CBM-20A system controller, two LC20ADvp pumps, and 
a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD).  Analytes of 
interest were eluted using one of two gradient profiles: method 1 (for DCF-AG) began 
with 10% solvent B for the first 0.5 min, which was then increased to 90% solvent B at 
1.25 min using a linear gradient and held at this mixture for 0.25 min before reverting 
back to initial solvent conditions for 0.5 min to re-equilibrate the column, and method 2 
(for PGE2) began with 10% solvent B for the first 0.5 min, which was then increased to 
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95% solvent B at 2.00 min using a linear gradient and held at this mixture for 0.5 min 
before reverting back to initial solvent conditions for 0.5 min to re-equilibrate the column.  
The flow rate for both methods was 0.3 mL/min, and the column effluent was directed to 
waste for the initial 0.5 min before switching to the mass spectrometer.  Analytes were 
detected using an AB Sciex API™ 4000 LC/MS/MS triple quad mass-spectrometer with 
a TurboIonSpray® probe and Analyst version 1.5.2 software (AB Sciex, Framingham, 
MA) that was operated in multiple reaction monitoring mode.  Ion spray voltage was -
4250 V, and the source temperature was set to 400 °C.  The mass transitions in 
negative ion mode for monitoring AA, DCF-AG, PGE2, and indomethacin were m/z 
303.3→259.0, 470.1→192.9, 351.1→271.0, and 356.0→311.8, respectively.  The 
retention times of AA, DCF-AG, PGE2, and indomethacin were 2.46, 1.32, 1.55, and 
1.47 (1.85 for method 2) min, respectively.  Concentrations of analytes in the samples 
were determined by comparing the peak area ratios (analyte/IS) to those in the standard 
curve using a linear regression model.  The criterion of acceptance for standards was 
defined to be ±20% of nominal concentration. 
Statistical Analysis.  Data are expressed as mean ± standard error of the mean.  P 
values < 0.05 were considered as statistically significant.  Statistical analysis of data 
was performed using R version 3.2.1 (R Core Team, 2015).  Two groups were 
compared by Student’s t test, and multiple groups were compared by an analysis of 
variance followed by Tukey’s post hoc test.  GraphPad Prism version 6.0 (GraphPad 
Software Incorporated, La Jolla, CA) was used to calculate the IC50 for COX inhibition 
assays. 
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4.4 Results 
In Vitro Transport.  The uptake of DCF-AG by a major intestinal transporter was 
measured using stably transfected HEK-OATP2B1 cells.  DCF-AG kinetic uptake by 
OATP2B1 was measured at pH 6.0 and 7.4 to reflect the physiological conditions that 
OATP2B1 is exposed to in the intestine and liver, respectively (Fallingborg, 1999).  
DCF-AG was incubated at six concentrations ranging from 1 to 300 µM with time points 
taken at 0.1, 0.5, 1, and 2 min.  The uptake of DCF-AG was both time- and 
concentration-dependent (Figure 4.2).  Concentration versus time data were then 
analyzed using a 2-compartmental model as shown in Figure 4.1.  The model was used 
to estimate transporter kinetic parameters that are summarized in Table 4.1.  The 
kinetic parameters of Vmax, Km, and Pdif at pH 6.0 were 27.8 ± 4.1 pmol/min/mg, 15.2 ± 
0.8 µM, and 0.0522 ± 0.0120 pmol/min/mg, respectively.  It was determined that at pH 
7.4, DCF-AG has Vmax, Km, and Pdif values of 17.6 ± 1.5 pmol/min/mg, 14.3 ± 0.1 µM, 
and 0.0245 ± 0.0030 pmol/min/mg, respectively.  The higher Vmax and Pdif values at pH 
6.0 were found to be statistically significant compared to the parameter estimates at pH 
7.4. 
Cytotoxicity Assay.  Having established a role for OATP2B1-mediated uptake of DCF-
AG, HEK-OATP2B1 cells were incubated with DCF or DCF-AG and monitored over time.  
Cell viability was assessed using two fluorescent dyes that offer different modalities and 
are complementary to each other.  Cell viability measured by CAM, which detects intact 
cells through esterase activity, indicated that as early as 3 hours, cell death by DCF was 
apparent at the 1 mM dose and by 12 hours 29% of the total cells were dead (Figure 
4.3A).  The cell viability was confirmed by EthD-1 that detects cell death by binding to 
155 
 
DNA once the nuclear envelope becomes compromised, and EthD-1 response 
increased by a maximum of 1.3-fold for the 12 hour 1 mM incubation (Figure 4.3C).  
Compared to DCF, DCF-AG induced greater cell death.  After 3 hours, approximately 
61% of cells were dead at the 1 mM dose, and the number of dead cells increased to 
85% by 12 hours for the 1 mM condition. (Figure 4.3B).  EthD-1 in DCF-AG incubations 
corroborated the CAM results.  The EthD-1 response for a 12 hour incubation with 1 
mM DCF increased over 2-fold compared to vehicle control (Figure 4.3D). 
ROS Assay.  Taking into account that DCF had been shown to promote generation of 
reactive oxygen species, we investigated if DCF-AG had a similar potential.  As for the 
cytotoxicity assay, HEK-OATP2B1 cells were exposed to DCF or DCF-AG and 
observed for ROS generation.  Since cytotoxicity was evident by 3 hours, the ROS 
assay was conducted from one to three hours to determine if ROS preceded cell death.  
ROS production was measured with the fluorescent probe DCFDA.  Hydrogen peroxide, 
a known ROS producer, was used as positive control and exhibited an increase in 
DCFDA signal in a dose-dependent manner (Figure 4.4A).  All hydrogen peroxide 
incubations achieved statistical significance compared to vehicle controls.  ROS 
production by DCF was relatively modest by comparison resulting in a statistically 
significant 1-2 fold increase at 3 hours for the 1 mM dose (Figure 4.4B).  DCF ROS 
induction appeared to indicate a dose response at 3 hours.  DCF-AG demonstrated a 
clearer time-dependent ROS production culminating with a 5.5-fold increase at 3 hours 
for the 1 mM dose (Figure 4.4C).  The 500 µM DCF-AG showed trends of increased 
ROS generation, though only for the 3 hour incubation, which yielded a 1.8-fold 
increase versus vehicle that was statistically significant. 
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SOD Inhibition Assay.  The SOD inhibition assay was utilized to explore whether DCF 
or DCF-AG could inhibit SOD enzymatic activity.  SOD incubations were non-cell based 
and consisted of a mixture of substrate, enzymes, inhibitor, and detection reagent.  
Rather than inhibiting SOD activity over the concentration range, DCF caused an 
apparent stimulation with the stimulus becoming statistically significant at the 250 µM 
dose and beyond (Figure 4.5).  DCF-AG had an opposite effect and was associated 
with a dose-dependent decrease in SOD activity such that there was a striking 100% 
inhibition of SOD at the 1 mM dose (Figure 4.5).  Furthermore, a statistically significant 
inhibition of 27% was observed at the 250 µM DCF-AG dose. 
COX Inhibition Assay.  The pharmacology of DCF for COX enzymes has been 
thoroughly evaluated, yet the pharmacology for DCF-AG has not been characterized.  
Hence, the final aspect of our work was to explore DCF-AG inhibition of COX enzymes.  
COX inhibition assays were non-cell based and used isolated COX enzymes that were 
mixed with substrate, co-factor, and inhibitor.  Selective inhibitors of COX-1 and COX-2 
were used as controls.  Inhibition was assessed by measuring the decreased synthesis 
of PGE2 from AA.  A summary of the findings is listed in Table 4.2.  SC-560 and DuP-
691, as selective COX-1 and COX-2 inhibitors, had IC50 values of 0.00166 ± 0.00022 
µM and 0.00714 ± 0.0007 µM, respectively (Figure 4.6A and Figure 4.7A).  DCF, as a 
non-selective COX inhibitor had COX-1 and COX-2 IC50 concentrations of 0.0206 ± 
0.0037 µM and 0.103 ± 0.005 µM, respectively (Figure 4.6B and Figure 4.7B).  OH-DCF 
was more potent against COX-1 than COX-2 and reached an apparent plateau for 
COX-2 inhibition.  The OH-DCF IC50 values were estimated to be 0.375 ± 0.075 µM and 
21.2 ± 0.3 µM for COX-1 and COX-2, respectively (Figure 4.6C and Figure 4.7C).  
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Lastly, DCF-AG was demonstrated to inhibit PGE2 synthesis with COX-1 and COX-2 
IC50 estimates of 0.620 ± 0.105 µM and 2.91 ± 0.36 µM, respectively (Figure 4.6D and 
Figure 4.7D).  COX-1 inhibition potency of DCF-AG was weaker compared to OH-DCF, 
however COX-2 inhibition potency by DCF-AG was more intermediate with respect to 
DCF and OH-DCF. 
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Figure 4.1 Visual representation of a mechanistic 2-compartmental transporter 
model 
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Figure 4.1 Visual representation of a mechanistic 2-compartmental transporter model.  
The movement of DCF-AG in the proposed model is described by three vectorial 
processes: 1) passive diffusion from the buffer into the cell, 2) active transport from the 
buffer into the cell, and 3) passive diffusion from the cell into the buffer.  Active transport 
for this model applies for the OATP2B1-mediated uptake of DCF-AG. 
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Figure 4.2 Concentration versus time profiles of DCF-AG uptake by OATP2B1 
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Figure 4.2 Concentration versus time profiles of DCF-AG uptake by OATP2B1.  HEK-
WT and HEK-OATP2B1 cells were seeded for 48 hours and incubated with increasing 
concentrations of DCF-AG at multiple time points in buffer titrated to either pH 6.0 or 7.4 
at 37 °C.  Intracellular concentrations were determined by LC/MS/MS, and the 
concentrations were modeled in Berkeley Madonna.  (A) and (B) show the uptake of 
DCF-AG by HEK-OATP2B1 cells at pH 6.0 and 7.4, respectively.  Fitted lines from a 2-
compartment model represent the best fit.  Data are the individual replicates from a 
typical study. 
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Table 4.1 Summary of DCF-AG uptake kinetics mediated by OATP2B1 
Media pH 
Vmax 
(pmol/min/mg) 
Km 
(µM) 
Uptake CLint 
(µL/min/mg) 
Pdif 
(µL/min/mg) 
6.0 27.8 ± 4.1* 15.2 ± 0.8 1.82 ± 0.19 0.0522 ± 0.0120* 
7.4 17.6 ± 1.5 14.3 ± 0.1 1.23 ± 0.11 0.0245 ± 0.0030 
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Table 4.1 Summary of DCF-AG uptake kinetics mediated by OATP2B1.  Each value 
represents the mean ± standard error of the mean from 3 studies (n=2 replicates per 
study).  * P < 0.05 for pH 6.0 versus pH 7.4. 
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Figure 4.3 Cytotoxicity of DCF and DCF-AG using HEK cells 
 
 
 
 
 
 
3
h
6
h
1
2
h
0
2 5
5 0
7 5
1 0 0
1 2 5
A : D C F
T re a tm e n t T im e
C
A
M
 R
F
U
 (
%
 c
o
n
tr
o
l)
** *
*
*
* * *
* * ** * * * * *
3
h
6
h
1
2
h
0
2 5
5 0
7 5
1 0 0
1 2 5
B : D C F -A G
T re a tm e n t T im e
C
A
M
 R
F
U
 (
%
 c
o
n
tr
o
l)
* * *
* * *
* * *
* * *
* * *
* * *
* *
3
h
6
h
1
2
h
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
C : D C F
T re a tm e n t T im e
E
th
D
-1
 R
F
U
 (
%
 c
o
n
tr
o
l)
* *
* * * *
*
*
*
* ** *
V e h
1 0 0  µ M
2 5 0  µ M
5 0 0  µ M
1 0 0 0  µ M
3
h
6
h
1
2
h
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
D : D C F -A G
T re a tm e n t T im e
E
th
D
-1
 R
F
U
 (
%
 c
o
n
tr
o
l)
V e h
1 0 0  µ M
2 5 0  µ M
5 0 0  µ M
1 0 0 0  µ M
* * * *
* *
* * *
* * *
* * * *
* * *
* * *
* * *
165 
 
Figure 4.3 Cytotoxicity of DCF and DCF-AG using HEK cells.  HEK-OATP2B1 cells 
were incubated in the absence or presence of increasing concentrations of compound.  
Incubations were conducted for 3, 6, or 12 hours at 37 °C.  Cytotoxicity was assessed 
using Calcein AM (CAM) to determine live cells and Ethidium Homodimer-1 (EthD-1) as 
an indicator of dead cells.  The CAM and EthD-1 responses indicate concentration-
dependent cell death by DCF, and the cytotoxicity was more pronounced for DCF-AG.  
Each bar represents the mean ± the standard deviation of n=3 measurements per 
condition.  * P < 0.05, ** P < 0.01; *** P < 0.001 compound versus its time-matched 
Vehicle incubation. 
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Figure 4.4 Generation of reactive oxygen species by in HEK cells 
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Figure 4.4 Generation of reactive oxygen species by in HEK cells.  HEK-OATP2B1 
cells were incubated in the absence or presence of increasing concentrations of 
compound.  Incubations were conducted for 1, 2, or 3 hours at 37 °C after which ROS 
were detected with the use of DCFDA, which becomes oxidized by ROS to a 
fluorogenic form.  Fluorescence was normalized to vehicle controls and expressed as 
percentage change from vehicle.  Each bar represents the mean ± the standard 
deviation of n=3 measurements per condition.  * P < 0.05, ** P < 0.01; *** P < 0.001 
compound versus its time-matched vehicle incubation. 
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Figure 4.5 Inhibition of superoxide dismutase as an indication of oxidative stress 
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Figure 4.5 Inhibition of superoxide dismutase as an indication of oxidative stress.  
Copper/zinc SOD was incubated in the absence or presence of increasing 
concentrations of DCF (□) or DCF-AG (■) for 30 min at room temperature (ca. 25 °C).  
Vehicle shows assay performance in the presence of the same level of organic solvent 
(DMSO) used in the inhibitor incubations.  Each bar reflects the mean ± standard error 
of the mean from 3 separate studies (n=2 replicates per study).  ** P < 0.01; *** P < 
0.001 inhibitor versus its Vehicle incubation.  # P < 0.05, ### P < 0.001 for DCF versus 
DCF-AG. 
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Figure 4.6 COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG 
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Figure 4.6 COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG.  Recombinant 
COX-1 was incubated in the presence of inhibitors for 2 min at 37 °C, and the formation 
of PGE2 from AA was monitored via LC/MS/MS.  Data reflect the mean ± standard error 
of the mean from 3 separate studies (n=2 replicates per study).  Inhibition data were fit 
with a three parameter model to calculate IC50.  Dotted lines reflect the 95% confidence 
intervals of the fit. 
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Figure 4.7 COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG 
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Figure 4.7 COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG.  Recombinant 
COX-2 was incubated in the presence of inhibitors for 2 min at 37 °C, and the formation 
of PGE2 from arachidonic acid was monitored via LC/MS/MS.  Data reflect the mean ± 
standard error of the mean from 3 separate studies (n=2 replicates per study).  Inhibition 
data were fit with a three parameter model to calculate IC50.  Dotted lines reflect the 
95% confidence intervals of the fit. 
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Table 4.2 Summary of in vitro COX inhibition assays 
Compound 
COX-1 IC50 
(µM) 
COX-2 IC50 
(µM) 
SC-560 (COX-1 selective) 0.00166 ± 0.00022 N.D. 
DuP-697 (COX-2 selective) N.D. 0.00714 ± 0.0007 
DCF 0.0206 ± 0.0037 0.103 ± 0.005 
OH-DCF 0.375 ± 0.075 21.2 ± 0.3 
DCF-AG 0.620 ± 0.105 2.91 ± 0.36 
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Table 4.2 Summary of in vitro COX inhibition assays.  IC50 values reflect the mean ± 
standard error of the mean from 3 experiments (n=2 replicates per experiment).  N.D.: 
not determined. 
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Figure 4.8 Proposed pathways on the disposition and mechanism of intestinal 
toxicity for DCF-AG 
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Figure 4.8 Proposed pathways on the disposition and mechanisms of toxicity for DCF-
AG.  DCF-AG is generated in the liver after DCF (IP or PO) administration where it 
undergoes excretion into bile or blood via ABC transporters.  Luminal DCF-AG is taken 
up by OATPs where it exerts various effects that lead to intestinal injury.  The absence 
of MRP3 exacerbates GI injury from DCF-AG due to the loss of a clearance mechanism 
from enterocytes.  Solid arrows indicate vectorial transport via uptake or efflux 
transporters, or via blood flow.  Dotted arrows signify transport by passive processes.  
Dashed lines demonstrate possible enzymatic reactions such as inhibition of COX, 
generation of ROS, or cleavage by bacterial β-glucuronidases.  The question mark 
denotes uncertainty regarding the efflux pathways for the indicated metabolites. 
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4.5 Discussion 
Our interest in exploring the toxicity attributed to DCF-AG was borne through our initial 
work of characterizing the role that efflux transporters have in modulating toxicity 
following acute administration of DCF.  Our research led to the discovery that mice 
lacking the efflux transporter Mrp3 were more susceptible to intestinal injury compared 
to WT (Scialis et al., 2015).  Though the intestinal toxicity differences between WT and 
KO were unequivocal, the mechanisms behind those differences were uncertain.  
Hence the research presented herein sought to elucidate the probable causes through 
which injury occurred. 
In light of the findings that immunohistochemical staining of intestinal tissues detected 
covalent adducts on the brush border of enterocytes as well as deep within the villi, we 
postulated that DCF-AG, as a causative agent to the covalent adducts, was subjected to 
an active transport process.  The intestines are host to an array of transporters 
(Drozdzik et al., 2014) some of which may be operative with respect to DCF-AG 
transport.  One of the likely candidates for uptake of DCF-AG would be OATP2B1, a 
transporter known to mediate influx of glucuronide conjugates of other compounds (Gao 
et al., 2012; Grosser et al., 2014).  Thus, OATP2B1 was investigated for affinity of DCF-
AG using a stably transfected cell system.  By implementing a mechanistic model 
(Poirier et al., 2008), we were able to define the kinetic parameters describing DCF-AG 
uptake by OATP2B1.  Compartmental modeling is becoming more frequently used due 
to the versatility it offers to define multiple processes in addition to allowing 
simultaneous fitting of several datasets (Poirier et al., 2009; Menochet et al., 2012; De 
Bruyn et al., 2015).  Preliminary studies with transfected cells showed that after six 
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minutes of incubation, OATPs were able to increase intracellular DCF-AG 
concentrations to levels exceeding the initial buffer conditions (Supplement 3).  Based 
on those observations, we investigated the activity of OATP2B1 as a concentrative 
force for DCF-AG uptake. 
We report that OATP2B1 acts an uptake transporter for DCF-AG, and that its affinity for 
DCF-AG varies with extracellular pH.  OATP2B1 transporter clearance for DCF-AG was 
1.82 µL/min/mg at pH 6.0 while the transport clearance at pH 7.4 was 1.23 µL/min/mg 
(Table 4.1).  These findings are relevant in that they indicate OATP2B1 activity is 
greater at pH 6.0 which is a typical pH in the intestines (Evans et al., 1988).  The 
differential affinity is not surprising given that pravastatin uptake by OATP2B1 was also 
found to be sensitive to pH. (Varma et al., 2011).  The transporter clearance values at 
pH 7.4 would be applicable for hepatic OATP-mediated uptake of DCF-AG as several 
OATPs, including OATP2B1, are expressed on the basolateral membrane in the liver 
(Hagenbuch and Meier, 2003; Wang et al., 2015).  The mechanistic modeling permitted 
estimation of the passive diffusion clearance for DCF-AG.  We determined that DCF-AG 
had a passive uptake clearance that was nearly 2.1-fold greater at pH 6.0 compared to 
pH 7.4 (0.0522 versus 0.0242 µL/min/mg, respectively).  The OATP-dependent uptake 
of the two positive controls that are known to be OATP2B1 substrates, estrone-3-sulfate 
and rosuvastatin, were similarly increased at pH 6 compared to pH 7.4 (data not shown).  
A study by Ming and colleagues likewise indicated that fexofenadine uptake at pH 6.0 
was increased compared to pH 7.4 transport (Ming et al., 2011).  The increase in DCF-
AG passive permeability can be explained through analysis of its structure.  The 
carboxylic acid moiety on the glucuronide ring of DCF-AG has an apparent pKa of 2.7 
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that becomes less ionized at acidic pH (ACD/Labs).  Thus the increased passive 
diffusion at pH 6.0 was driven by increased flux of unionized DCF-AG.  This rationale 
has been used to explain the tissue distribution of ionized and neutral species at various 
pH using OATP-mediated uptake (Ghosh et al., 2014).  The same cells used by Ghosh 
and colleagues were implemented for DCF-AG uptake, hence the two findings are 
comparable.  Despite the increased passive diffusion at pH 6.0, DCF-AG uptake would 
be dominated by active uptake as the intrinsic uptake clearance by OATP2B1 was 35-
fold greater than passive diffusion.  This categorizes DCF-AG as an ECCS class 3b 
compound making it dependent on active uptake to attain meaningful intracellular 
concentrations (Varma et al., 2015).  DCF, in contrast, as a smaller molecule with high 
passive uptake, has no such limitations and can more freely enter cells (Huang et al., 
2010).  Though OATP2B1 is a human transporter, there exists a mouse homologue 
Oatp2b1 that has been shown to be expressed in the intestinal tract (Cheng et al., 
2005).  Overall, the OATP2B1 studies provide insight as to how the intracellular 
covalent adducts observed in our previous mouse studies (Chapter 3 Figure 3.5) may 
have arisen. 
Having established a potential role for OATP2B1-mediated uptake of DCF-AG, we next 
theorized that toxicity from DCF-AG could be enhanced due to OATP2B1 transport.  To 
that end, we conducted cytotoxicity assays with HEK-OATP2B1 cells.  Our studies 
indicated that DCF-AG is indeed cytotoxic, and that cytotoxicity can manifest within 3 
hours of exposure (Figure 4.3B).  Furthermore, the cytotoxicity by DCF-AG was found to 
be greater than that of the parent compound.  The DCF-AG concentrations chosen for 
the cytotoxicity assays were physiologically relevant in that they are in the same range 
181 
 
as the biliary concentrations detected in mice after an IA administration of 75 mg/kg 
DCF (Chapter 3 Figure 3.2).  In our toxicodynamic studies with 90 mg/kg diclofenac, we 
were only able to observe intestinal injury 24-hours post-administration since that was 
the sole time point chosen for tissue harvesting (Chapter 3 Figure 3.4).  The cytotoxicity 
data here indicate that injury, in terms of cell death, may occur with early onset.  Cell 
death by DCF reached a maximum of 29% by 12 hours at 1 mM compared to nearly 
62% cell death for DCF-AG by 3 hours at 1 mM with a maximal cell death of 85% 
reached after 12 hours.  DCF can cause higher cytotoxicity than what was observed in 
our assays.  These data substantiate the findings reported in TR- rats wherein 
administration of bile containing DCF-AG elicited greater intestinal injury compared to 
an equimolar dose of DCF (Seitz and Boelsterli, 1998).  It is conceivable that Oatp-
mediated uptake of DCF-AG in our mouse model, along with the cytotoxicity potential of 
DCF-AG, may have contributed to the increased enteropathy in Mrp3 KO mice since 
those mice had reduced capacity to eliminate DCF-AG compared to WT. 
Oxidative stress is another means by which cell toxicity can occur.  Specifically, 
generation of reactive oxygen species may overwhelm a cell’s ability to maintain 
homeostatic redox levels.  For instance, the pesticide rotenone is a known inducer of 
ROS, and exposure to rotenone results in cell death (Tamilselvam et al., 2013).  
Accordingly, we conducted ROS assays with DCF and DCF-AG to determine their ROS 
activity.  The positive control in the assay, hydrogen peroxide, increased ROS in a 
dose-dependent manner (Figure 4.4A) verifying its role as a ROS-inducting agent (Alia 
et al., 2005).  DCF ROS induction was relatively weak, yet ROS production was 
significantly increased after 2 hours of exposure (Figure 4.4B).  The modest ROS 
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increase by DCF in our assay was less than a nearly 6-fold increase in ROS caused by 
DCF after a 30 hour exposure in a hepatocyte model of cytotoxicity (Lim et al., 2006).  
DCF-AG exhibited a dose-dependent increase in ROS with a maximal increase of 5.5-
fold after 3 hours (Figure 4.4).  Given that the ROS assay was carried out from 1-3 
hours compared to the cytotoxicity assay time frame of 3-12 hours, an argument can be 
made that DCF-AG ROS production is a contributing factor to the observed cell death in 
our assays.  As to how ROS production promotes cell death, possible pathways are 
through inhibition of ATPases, oxidation of DNA, perturbation of the mitochondrial 
permeability transition pore, or protein inactivation (Cantoni et al., 1989; Martinez-Reyes 
and Cuezva, 2014). 
Oxidative stress can come about through means other than generation of ROS.  For 
instance, administration of high doses of acetaminophen promotes oxidative stress in 
the liver through depletion of hepatic glutathione due to the formation of a reactive 
intermediate NAPQI that immediately reacts with glutathione (van de Straat et al., 1987).  
Glutathione depletion following DCF exposure has been shown to occur using an in 
vitro hepatotoxicity model (Pourahmad et al., 2011).  Nonetheless, oxidative stress via 
other pathways remained a possibility.  One such route is the inhibition of superoxide 
dismutase, an important part of the cell’s antioxidant response system (Fukui and Zhu, 
2010).  Therefore, we conducted SOD inhibition assays using the same concentrations 
of DCF and DCF-AG as applied in the aforementioned in vitro assays.  The SOD assay 
was not cell-based hence incubations were executed within a relatively short time span 
since inhibitor uptake was not necessary.  DCF failed to yield any inhibition and 
surprisingly appeared to stimulate SOD activity (Figure 4.5).  The nature of this 
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stimulation is unknown to us.  A striking observation was the clear dose-dependent 
inhibition of SOD by DCF-AG, so much so that at the highest tested DCF-AG 
concentration of 1 mM, SOD activity was reduced to non-detectable levels (Figure 4.5).  
Prior evidence for SOD inhibition by an NSAID metabolite was reported by Chiou and 
colleagues (1999).  In their study, 5 mM of suprofen acyl glucuronide reduced SOD 
activity by 88% after a 14-day treatment using a non-cell based in vitro model.  In the 
same study, 5 mM suprofen decreased SOD activity by 5% after a 14-day incubation.  
Our data show that DCF-AG can elicit as great an inhibition but at lower doses and 
within a shorter time scale.  Taken into context, the SOD inhibition along with ROS 
generation by DCF-AG may lead to sustained oxidative stress, culminating in cell death. 
A last part of our research focused on the inherent pharmacology of DCF-AG.  DCF was 
developed as a treatment for inflammation and pain, and it is through its ability to inhibit 
COX enzymes that pharmacologic efficacy is achieved.  Hydroxylated metabolites of 
DCF have been tested for COX inhibition, but there has been no investigation of DCF-
AG’s pharmacology.  Hence, we sought to identify if DCF-AG possessed COX inhibitory 
activity.  Our inhibition assays with COX-1 and COX-2 led to a novel finding.  DCF-AG 
had apparent COX-1 and COX-2 IC50 values of 0.620 ± 0.105 µM and 2.91 ± 0.36 µM, 
respectively (Figure 4.6, Figure 4.7, Table 4.2).  The COX inhibition potency by DCF-AG 
was notably weaker compared to DCF for which we determined IC50 values of 0.0206 ± 
0.0037 µM and 0.103 ± 0.005 µM for COX-1 and COX-2, respectively, values that are in 
line with published findings (Johnson et al., 1995). 
The IC50 concentrations determined in the COX inhibition assays take on greater 
meaning when considering that the inhibition values are physiologically relevant both in 
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terms of circulating plasma concentrations that were observed in our mouse 
toxicokinetic studies as well as human plasma levels (professional communiqué, 
publication pending).  Furthermore, the inhibition assays were performed with the intent 
to monitor formation of PGE2 which has several important physiological functions such 
as immune system modulation (Nicolaou et al., 2014).  Critically, PGE2 is responsible 
for the protection of the GI mucosa, and deficiencies in PGE2 signaling were associated 
with increased GI injury (Takeuchi, 2014).  There is a deeper significance to the COX 
inhibition findings.  Mere inhibition of COX-1 or COX-2 is not sufficient as a causal factor 
of gastrointestinal injury.  As an example, administration to rats of the selective COX-1 
inhibitor SC-560 or the selective COX-2 inhibitor rofecoxib, which was recalled as a 
marketed drug, did not induce any gastrointestinal damage (Tanaka et al., 2001).  
However, when SC-560 and rofecoxib were co-administered, extensive damage was 
observed implying that inhibition of the two isoforms of COX is essential to injury 
formation.  Using the same model, administration of non-selective COX inhibitors 
(diclofenac, indomethacin, and naproxen) resulted in gastrointestinal injury.  
Furthermore, studies with COX-1 or COX-2 KO mice demonstrated that COX-1 activity 
promotes intestinal intactness while COX-2 activity is necessary for healing of ulcers 
(Schmassmann et al., 2006).  That DCF-AG, like its parent compound, can inhibit both 
COX enzymes represents a novel finding and offers a possible cause during 
enteropathy associated with exposure to DCF-AG. 
The results from the in vitro assays in the preceding sections can be interwoven into a 
mechanistic paradigm for injury directly attributable to DCF-AG.  In Figure 4.8 we 
propose a tox model describing the multiplicity of transporters, pharmacologic, and 
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inhibitory activities that capture our current and past investigations.  The model is 
predicated on the transfer of DCF into the liver after administration (the route of 
administration is not a defining factor at this point) whereupon it undergoes extensive 
biotransformation.  The metabolite DCF-AG can be excreted into the blood via MRP3 or 
alternatively transported into the bile by BCRP or MRP2.  In our toxicokinetic studies, 
we determined that the biliary concentration of DCF-AG were between 1.3 to 4.0 mM 
(Chapter 3).  Any remaining DCF-AG in the liver may undergo adduct formation either to 
albumin or sequestration by glutathione (Grillo et al., 2003).  In addition, we have 
characterized DCF-AG stability and determined that its half-life in the presence of S9 
esterases was approximately 15 min (Supplement 1), setting up a scenario where 
residual hepatic DCF-AG reverts to parent compound reinitializing another round of 
metabolism.  It is important to note that this proposed injury model does not apply to the 
liver since the in vivo studies (Chapter 3) showed no hepatotoxicity by DCF.  Biliary 
DCF-AG traverses the common bile duct and enters the small intestine at the proximal 
duodenal region.  The acidic environment of the intestinal lumen acts as a stabilizing 
force on DCF-AG decreasing the rate of non-enzymatic hydrolysis (Supplement 2).  
Once in the GI lumen, DCF-AG may undergo conversion back to parent compound by 
the activity of bacterial β-glucuronidase present in the gut microflora (Louis et al., 2014).  
Free DCF-AG may also take one of two steps: 1) covalent adduction to the outside of 
the enterocytes, or 2) active uptake by OATP2B1.  Once inside the cell, DCF-AG can 
induce cytotoxicity either through ROS generation or SOD inhibition ultimately leading to 
oxidative stress.  DCF-AG may be cleared from enterocytes if MRP3 is present and 
functional.  However, lack of MRP3 (as in the null mice) may result in greater DCF-AG 
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retention and more aggravated damage by the aforementioned mechanisms.  The tox 
mechanistic model also includes the inhibitory attributes of DCF-AG against COX 
enzymes.  COX-mediated inhibition by DCF-AG may potentiate enteropathy via loss of 
PGE2 protection as well as interference of COX-2 directed wound healing.  Lastly, DCF 
is expected to contribute to intestinal injury in conjunction to DCF-AG via similar 
pathways of COX inhibition, oxidative stress, and ROS generation. 
It may not be clear which of the proposed mechanisms are dominant and which have 
minor roles.  Nonetheless, our results lay the foundation of a novel multifactorial 
process of intestinal injury attributable directly to DCF-AG.  The in vitro assays detailed 
in the current work along with our previous findings offer potential explanations and 
insight that have not been previously explored.  In conclusion, we believe we have 
made a rational argument of the potential for DCF-AG to directly mediate toxicity and 
have provided credible mechanistic leads that could explain this toxicity. 
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Chapter 5 THE MODULATION OF TRANSCRIPTIONAL EXPRESSION AND 
INHIBITION OF MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4 (MRP4) BY 
ANALGESICS AND THEIR PRIMARY METABOLITES 
5.1 Abstract 
During the course of a toxic challenge, changes in gene expression can manifest such 
as induction of metabolizing enzymes as a compensatory detoxification response.  We 
currently report that a single 400 mg/kg IP APAP dose to C57BL/6J mice led to an 
increase in Mrp4 (Abcc4) mRNA 12 hours after administration.  Alanine 
aminotransferase, as a marker of liver injury, was also elevated indicating hepatotoxicity 
had occurred.  Therefore, induction of Mrp4 mRNA was likely attributable to APAP-
induced liver injury.  Mrp4 has been shown to be upregulated during oxidative stress, 
and it is well-established that APAP overdose causes oxidative stress due to depletion 
of glutathione.  Given the importance of Mrp4 induction as an adaptive response during 
cholestatic and oxidative liver injury, we next investigated the extent by which human 
Mrp4 can be inhibited by the analgesics, APAP, DCF, and their metabolites.  Using an 
in vitro assay with inside out human MRP4 vesicles, we determined that APAP-cysteine 
inhibited MRP4-mediated transport of leukotriene C4 with an apparent IC50 of 125 µM.  
APAP-glutathione also attenuated MRP4 activity though it achieved only 28% inhibition 
at 300 µM.  DCF-AG inhibited MRP4 transport by 34% at 300 µM.  The MRP4 in vitro 
inhibition occurs at APAP-cysteine and DCF-AG concentrations seen in vivo after a 
toxic dose of APAP or DCF in mice, hence the findings are important given the role that 
Mrp4 serves as a compensatory response during oxidative stress following toxic 
challenge. 
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5.2 Introduction 
Injury following overdose with analgesics is relatively common and can result in 
extensive damage to multiple organs that may ultimately lead to death in severe cases 
(Jones, 2002).  Mild to moderate toxicity may induce changes vis-à-vis regulation of 
genes.  Such changes involve modulation of transcription factors or induction of 
transporters as a compensatory response (Blazka et al., 1995a; Barnes et al., 2007).  
Intoxication with APAP, for example, has been demonstrated to result in upregulation of 
the efflux transporter Mrp4 (Campion et al., 2008) as well as the metabolic enzyme 
flavin containing monooxygenase 3 (Rudraiah et al., 2014a), a particularly novel finding 
given that Fmo3 was previously thought to be non-inducible (Cashman and Zhang, 
2002).  The mechanism of Mrp4 induction has been demonstrated to be linked to 
activation of nuclear factor erythroid 2-like 2 (Nrf2, Nfe2l2) as evidenced by lack of Mrp4 
upregulation in Nrf2 knockout mice (Ghanem et al., 2015).  Furthermore, Mrp4 induction 
by APAP was found to be dependent on Kupffer cell activation (Campion et al., 2008).  
Mrp4 expression also was induced after administration of clofibrate via activation of 
peroxisome proliferator-activated receptor α (Moffit et al., 2006).  In a mouse model, the 
elevated expression of Mrp4 after an initial toxic APAP insult results in mice becoming 
refractory to injury following subsequent toxic doses, an effect termed autoprotection 
(Aleksunes et al., 2008a). 
In the previously cited work by Campion and colleagues, protein induction became 
evident two to three days after administration of toxic doses of APAP.  Measurement of 
ALT as an indicator of hepatocellular injury has been utilized in human and rodents 
(McGill et al., 2012; Singhal et al., 2012), and there is a clear relationship between ALT 
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and manifestations of injury.  Furthermore, Rudraiah and colleagues (2014b) reported 
elevations in ALT and Fmo3 mRNA following toxic APAP treatment leading the authors 
to conclude that induction of Fmo3 was likely a protective mechanism in response to 
APAP-induced hepatotoxicity.  To date, transporter expression as a function of ALT has 
not been thoroughly investigated. 
As expected, administration of xenobiotics results in the generation of metabolites that 
can be eliminated through biliary or urinary excretion.  Work from our group has 
previously shown that metabolites of APAP and DCF (Figure 5.1) can be generated in 
high concentrations, with respect to the parent compound, after toxic doses (Chen et al., 
2003; Manautou et al., 2005; Scialis et al., 2015).  Though metabolite disposition has 
been characterized, and in some instances the affinity for a transporter to mediate 
metabolite clearance quantified (Zelcer et al., 2003b; Zamek-Gliszczynski et al., 2006c), 
there has not been systematic examination as to the potential for these metabolites to 
interfere with normal transporter function. 
Thus the goals of our current work were to first assess the relationship, if one exists, 
between elevations in ALT and transcriptional regulation of Mrp4.  To accomplish this 
objective, a toxic dose of APAP will be given to C57BL/6J mice with measurement of 
ALT and Mrp4 mRNA at several time points post-administration.  The second aspect of 
our inquiry focuses on the inhibition of MRP4 by APAP, DCF, and their primary 
metabolites.  The MRP4 inhibition assays were conducted using APAP and DCF 
metabolite concentrations that reflect those observed during in vivo studies from our 
laboratory. 
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Figure 5.1 Structures of APAP, DCF, and their major metabolites 
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Figure 5.1 Structures of APAP, DCF, and their major metabolites.  The various 
conjugated metabolites of APAP as the result of Phase II metabolism or spontaneous 
adduction to the CYP450-mediated reactive intermediate NAPQI.  APAP: 
acetaminophen, APAP-CYS: acetaminophen cysteine, APAP-GLU: acetaminophen 
glucuronide, APAP-GSH: acetaminophen glucuronide, APAP-NAC: acetaminophen N-
acetylcysteine, APAP-SUL: acetaminophen sulfide, DCF: diclofenac, 4ʹ-OH-DCF: 4ʹ-
hydroxy diclofenac, DCF-AG: diclofenac acyl glucuronide. 
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5.3 Materials and Methods 
Chemicals and Reagents.  APAP, AMP, ATP, DCF, formic acid, indomethacin (used 
as the IS), KCl, MgCl2, MOPS, OH-DCF, and Tris-HCl, were purchased from Sigma-
Aldrich Corporation. (St. Louis, MO).  DCF-AG was purchased from Toronto Research 
Chemicals Incorporated (Toronto, Canada).  APAP metabolites were obtained from 
McNeil-PPC Incorporated (Fort Washington, PA).  Leukotriene C4 and MK-571 were 
purchased from Santa Cruz Biotechnology (Dallas, TX).  MRP4 vesicles were 
purchased from GenoMembrane Corporation (Kanazawa, Japan).  All LC/MS/MS 
solvents were of high analytical grade and were purchased from Burdick & Jackson 
(Muskegon, MI). 
Animals.  Male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, 
ME).  Mice were housed in an American Animal Associations Laboratory Animal Care 
accredited facility at the University of Connecticut under a standard temperature-, light-, 
and humidity-controlled environment.  Mice had free access to Harlan Teklad 2018 
chow (Harlan, Madison, WI) and drinking water.  All animal studies were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals using protocols 
reviewed and approved by the local Institutional Animal Care and Use Committee at the 
University of Connecticut. 
In Vivo Studies.  Mice were used at 2-3 months of age.  The mice received a single IP 
dose of 400 mg/kg APAP in 0.9% saline.  Mice were sacrificed by decapitation at 6, 12, 
and 24 hours after APAP administration.  Blood samples were collected and 
subsequently centrifuged at 1,200 × g for 15 min to yield plasma.  Livers were harvested, 
rinsed in ice-cold saline, and quickly frozen in liquid nitrogen prior to storage at -80 °C. 
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RNA Isolation and RT-PCR.  Total liver RNA was extracted using TRIzol reagent 
(Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol.  The 
concentration of total RNA in each sample was quantified spectrophotometrically at 260 
nm, and the integrity was evaluated by agarose gel electrophoresis.  RNA (1 µg) was 
reverse transcribed to cDNA using a M-MLV Reverse Transcriptase kit (Thermo Fisher 
Scientific). mRNA expression of Abcc4 and was quantified using specific primers (Table 
5.1) by the CT method and normalized to the housekeeping gene Actb.  Primer pairs 
were synthesized by Integrated DNA Technologies (Coralville, IA).  Amplification was 
performed using an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo 
Fisher Scientific) and carried out in a 20 µL reaction volume containing diluted cDNA, 
Fast SYBR Green PCR Master Mix (Thermo Fisher Scientific), and 1 µM of each primer. 
Clinical Chemistry.  Plasma samples were analyzed for alanine aminotransferase 
(ALT) using a kit purchased from Thermo Fisher Scientific as per the manufacturer’s 
recommendations.  A BioTek UV/Vis microplate spectrophotometer (BioTek Instruments 
Incorporated, Winooski, VT) was used to measure assay endpoints. 
In Vitro Transport.  Commercially available MRP4 inside-out vesicles from 
GenoMembrane were quickly thawed from storage and placed on ice.  Incubation 
reactions consisted of uptake buffer at pH 7.0 (50 mM MOPS-Tris, 70 mM KCl, and 7.5 
mM MgCl2), 25 µg vesicle protein, 5 mM of AMP or ATP, and 2.5 mM GSH.  After a 5 
min pre-incubation period of reaction mixture, incubations were commenced by addition 
of increasing concentrations of LTC4 for substrate studies.  For inhibition studies, the 
concentration of LTC4 was fixed while increasing concentrations of inhibitor was added.  
Incubations were conducted at 37 °C in a total volume of 75 µL.  Reactions were 
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quenched by the addition of 100 µL ice-cold stopping buffer (40 mM MOPS-Tris and 70 
mM KCl), and the quenched mixtures were quickly transferred to a 96-well glass-fiber 
filter plate (EMD Millipore, Billerica, MA). The plate was subjected to vacuum filtration 
followed by 5 rapid washes of 100 µL/well ice-cold stopping buffer.  The filter plate was 
allowed to dry before extraction of samples.  Once the filter plate was dry, LTC4 was 
extracted by filling each well of the filter plate with 200 µL of 80:20 (v/v) methanol: water.  
Plates were shaken for 15 min on ice, and the filtrate was collected via centrifugation at 
3,000 × g for 10 min and 4 °C.  The filtrate was evaporated to dryness under warm N2 at 
40 °C.  The resulting residue was reconstituted with 100 µL water and 100 µL IS in 
methanol, vigorously vortex-mixed, and injected onto the LC/MS/MS.  The accumulation 
of LTC4 was quantified against a standard curve, and the data were expressed as pmol 
uptake normalized to mg vesicle protein. 
LC/MS/MS Method.  Chromatographic separation of analytes was performed on a 2.6 
µm Kinetex XB-C18 30 × 2 mm column (Phenomenex Incorporated, Torrance, CA).  
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies 
Incorporated, Carrboro, NC), a CBM-20A system controller, two LC20ADvp pumps, and 
a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD).  Analytes of 
interest were eluted using a gradient program that began with 10% solvent B for the first 
0.5 min, which was then increased to 90% solvent B at 1.25 min using a linear gradient 
and held at this mixture for 0.25 min before reverting back to initial solvent conditions for 
0.5 min to re-equilibrate the column.  The flow rate for was 0.3 mL/min, and the column 
effluent was directed to waste for the initial 0.5 min before switching to the mass 
spectrometer.  Analytes were detected using an AB Sciex API™ 4000 LC/MS/MS triple 
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quad mass-spectrometer with a TurboIonSpray® probe and Analyst version 1.5.2 
software (AB Sciex, Framingham, MA) that was operated in multiple reaction monitoring 
mode.  Ion spray voltage was -4250 V, and the source temperature was set to 400 °C.  
The mass transitions in negative ion mode for monitoring LTC4 and IS were m/z 
626.4→189.5 and 356.0→311.8, respectively.  The retention times of LTC4 and IS were 
1.33 and 1.47 min, respectively. Concentrations of analytes in the samples were 
determined by comparing the peak area ratios (analyte/IS) to those in the standard 
curve using a linear regression model.  The criterion of acceptance for standards was 
defined to be ±20% of nominal concentration. 
Data Analysis.  Where IC50 estimates could be determined for Mrp4 inhibition, Ki 
values for the inhibitors were calculated according to the following equation (Cheng and 
Prusoff, 1973): 
Equation 5.1 
   
    
  
   
  
 
where Ki is the affinity of the inhibitor, IC50 is the inhibitor concentration producing 50% 
inhibition, [S] is the substrate concentration in the incubation, and Km is the Michaelis 
constant representing substrate affinity for the transporter. 
Statistical Analysis.  Data are expressed as mean ± standard error of the mean.  P 
values < 0.05 were considered as statistically significant.  Statistical analysis of data 
was performed using R version 3.2.1 (R Core Team, 2015).  Two groups were 
compared by Student’s t test, and multiple groups were compared by an analysis of 
variance followed by Tukey’s post hoc test.  GraphPad Prism version 6.0 (GraphPad 
196 
 
Software Incorporated, La Jolla, CA) was used to calculate kinetic parameters (Vmax and 
Km) as well as the IC50 inhibition parameter. 
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Table 5.1 Primer sequences for quantitative RT-PCR 
Gene (Protein) Primer Sequence 
Actb (β-actin) 
Forward: 5′-GCA ACG AGC GGT TCCG-3′ 
Reverse: 5′-GCA GAC AGC CAA GGA GCC CAA AGA CC-3′ 
Abcc4 (Mrp4) 
Forward: 5′-ACC TCT GCT CGC GCG TGT TCT-3′ 
Reverse: 5′-CCA GTA CCG TTG AAG CTC CTC TCC-3′ 
Reverse: 5′-CTC AGC ATG ATG GAC TTG GA-3′ 
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5.4 Results 
In Vivo Study.  C57BL/6J male mice were administered a single IP dose of 400 mg/kg 
APAP in 0.9% saline.  Animals were sacrificed 6, 12, and 24 hours post administration, 
and livers were harvested.  Plasma was used to assess liver injury using ALT as a 
marker.  The mean ALT values at 6, 12, and 24 hours were, 930, 1,080, and 1,750 U/L, 
respectively (Figure 5.2).  Transcriptional changes of Mrp4 were assessed at the same 
time points used for ALT analysis.  An increase in Mrp4 mRNA was observed at 12 
hours, and this increase was statistically significant (P < 0.05).  Taken together, the data 
suggest that APAP-induced liver injury, evidenced by high ALT values, resulted in the 
induction of Mrp4 mRNA. 
LTC4 Kinetics.  Human MRP4 was characterized for transport of LTC4 prior to 
conducting inhibition studies.  The linearity of MRP4-mediated transport for 0.1 µM LTC4 
was evaluated and determined to be time-dependent (Figure 5.3A).  The dynamic 
response reached a maximal value of 19-fold (ATP response divided by AMP response) 
by 20 minutes.  Next, LTC4 was characterized for concentration-dependent transport.  
Kinetic parameters of Vmax and Km for MRP4 LTC4 transport were determined to be 245 
pmol/min/mg and 4.25 µM, respectively (Figure 5.3B).  Kinetic data were fitted using a 
single Km model without assuming cooperativity. 
MRP4 Inhibition.  The potential for MRP4 inhibition was carried out in the presence of 
parent compounds and their metabolites.  MK-571 was used as inhibitor control yielding 
an IC50 of 14.2 µM (Figure 5.4), a value that is close to its reported IC50 against other 
probes (Reid et al., 2003a; Rius et al., 2003).  APAP, APAP-SUL, APAP-GLU, and 
APAP-NAC did not manifest any significant inhibition.  APAP-CYS inhibited transport 
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with an IC50 of 125 µM.  APAP-GSH decreased MRP4 transport, but only at the two 
highest doses resulting in 29% inhibition at 300 µM.  DCF and its metabolites likewise 
inhibited MRP4, with DCF-AG showing the greatest inhibition reaching a maximal 
inhibition of 34% at the highest tested concentration of 300 µM.  The apparent Ki values 
using Equation 5.1 for MK-571 and APAP-CYS were calculated to be 13.9 and 122 µM, 
respectively. 
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Figure 5.2 Relationship between ALT values and Mrp4 gene expression following 
acute exposure to APAP 
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Figure 5.2 Relationship between ALT values and Mrp4 gene expression following acute 
exposure to APAP.  Male C57BL/6J mice were administered 400 mg/kg APAP and 
sacrificed 6, 12, or 24 hours after administration.  ALT was determined from plasma 
while Mrp4 mRNA expression was determined via RT-PCR using RNA extracted from 
whole liver homogenate.  Data are expressed as the mean ± standard error of the mean 
for n=5-7 subjects/group.  The vertical dotted line reflects the ALT upper limit of normal 
value of 40 U/L. 
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Figure 5.3 Time-dependent and concentration-dependent transporter kinetics of 
LTC4 with MRP4 vesicles 
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Figure 5.3 Time-dependent and concentration-dependent transporter kinetics of LTC4 
with MRP4 vesicles.  MRP4 vesicles were incubated with LTC4 in the presence of either 
AMP or ATP.  (A) The time-dependent transport of 0.1 µM LTC4 in the presence of 5 
mM AMP (○) or 5 mM ATP (●) at 37 °C.  The dotted line represents the nonlinear fit of 
LTC4 active transport and was calculated by subtracting the AMP values (background 
and passive uptake) from the ATP response.  (B) The concentration-dependent 
transport of LTC4 at 37 °C.  The fitted line indicates the ATP-dependent transport 
assuming typical Michaelis-Menten kinetics.  Insert: Eadie-Hofstee plot.  Each data 
point reflects the mean ± the standard error of the mean for n=3 measurements per time 
point or concentration. 
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Figure 5.4 Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF 
metabolites 
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Figure 5.4 Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF 
metabolites.  In vitro inhibition was conducted using MRP4 vesicles with 0.1 µM LTC4 in 
the presence of 5 mM ATP at 37 °C for 5 min.  The ATP-dependent transport of LTC4 in 
the absence of inhibitor was set to 100%.  Inhibition data were fit with a three parameter 
model to calculate IC50.  Dotted lines reflect the 95% confidence intervals of the fit.  
Each data point reflects individual values (n=2 per inhibitor concentration). 
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5.5 Discussion 
The objective of our current work was to evaluate the regulation and function of Mrp4 
following a toxic challenge by APAP.  Analysis of major hepatic transporters in 
untreated C57BL/6J mouse livers showed that Mrp4 has one of the lowest expression 
levels in a comparative profile panel of uptake and efflux transporters (Supplement 4).  
Despite its seemingly low hepatic expression during homeostatic conditions, Mrp4 is 
quite inducible and plays a major role after intoxication by xenobiotics.  As an example, 
work by Campion et al. (2008)  showed that among the Mrp class of transporters, Mrp4 
was the most inducible after a 500 mg/kg IP APAP dose to C57BL/6J mice, and its 
protein expression increased 10- and 33-fold by 48 and 72 hours, respectively.  
Furthermore, the mechanism of induction was shown to be dependent on the functional 
presence of hepatic macrophages known as Kupffer cells.  Loss of Kupffer cell viability, 
via targeted cell death by the agent clodronate, resulted in loss of Mrp4 induction.  
Moreover, induction of Mrp4 following APAP challenge was found to be dependent on 
the transcription factor Nrf2 as mice lacking Nrf2 did not show any changes to Mrp4 
mRNA or protein levels after a toxic APAP dose (Aleksunes et al., 2008b).  During the 
course of our current study, we observed that Mrp4 mRNA was significantly upregulated 
12 hours after a 400 mg/kg APAP challenge (Figure 5.2).  Curiously, the Mrp4 mRNA 
levels were essentially the same at 6 and 24 hours.  Given the prior protein expression 
data, we postulate that the transcriptional upregulation at 12 hours was sufficient to be 
the driving factor for Mrp4 protein levels to reach maximal expression at 48 hours. 
We next sought to draw correlation between liver injury and Mrp4 mRNA.  Serum ALT 
has been used a reliable indicator for liver injury, and we detected ALT levels that were 
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consistent with APAP toxicity (Figure 5.2).  ALT levels were elevated at all the time 
points examined, while Mrp4 mRNA reached maximal induction 12 hours post-dose.  
Ghanem et al. (2015) similarly reported that ALT and Mrp4 mRNA levels were 
significantly increased 24 hours following toxic challenge by APAP.  Rudraiah and 
colleagues (2014b) observed an association between ALT and flavin containing 
monooxygenase-3 (Fmo3) mRNA where both reached maximal values 48 hours after a 
400 mg APAP dose.  Thus the results suggest that liver injury following toxic APAP 
administration may have lead to the induction of Mrp4 mRNA. 
Given the importance Mrp4 has as a compensatory response during APAP toxicity, we 
investigated the potential for Mrp4 inhibition by APAP and its metabolites.  The rationale 
for investigating Mrp4 inhibition is based on the finding that Mrp4 is upregulated as a 
compensatory mechanism during oxidative stress (Xu et al., 2010).  Considering APAP 
metabolism can cause oxidative stress that can lead to hepatotoxicity, inhibition of Mrp4 
by APAP or its metabolites may further exacerbate liver injury.  In lieu of mouse Mrp4, 
we chose to use vesicles containing human MRP4 as a surrogate.  Our first course of 
action was to characterize the assay for performance.  Among the substrates for MRP4 
are estradiol-17β-glucuronide, ferosemide, and methotrexate (Chen et al., 2001; Chen 
et al., 2002; Hasegawa et al., 2007).  The choice of estradiol-17β-glucuronide as a 
probe can result in potentially misleading findings as it was shown to be stimulated by 
several compounds that were able to inhibit the vesicular transport for other substrates 
(Kidron et al., 2012).  Hence, we decided to use Leukotriene C4 as our probe based on 
the work of Rius et al. (2008) that identified LTC4 as a substrate for MRP4.  LTC4 as a 
measure of MRP4 activity is advantageous since it is a naturally occurring derivative of 
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arachidonic acid and plays a role during pro-inflammatory responses (Dahlen et al., 
1983; Zipser et al., 1987).  Using inside-out MRP4 vesicles, we determined that the 
transport of LTC4 was time-dependent (Figure 5.3A).  Furthermore, the transport of 
LTC4 was concentration-dependent with a Vmax and Km of 253 pmol/min/mg and 4.25 
µM, respectively (Figure 5.3B). 
We next proceeded to conduct MRP4 inhibition assays, and expanded our assay to 
include two analgesics and their metabolites.  Our results show that APAP has no effect 
on MRP4, and neither did APAP-SUL, APAP-GLU or APAP-NAC.  However, we 
observed that APAP-CYS had concentration-dependent inhibition of MRP4 with an 
apparent IC50 of 125 µM.  Based on the in vitro parameters from our assays, we 
calculate a Ki of 122 µM for APAP-CYS.  Bearing in mind the low LTC4 substrate 
concentration relative to its Km and ratio of IC50 to Ki, it is likely the inhibition of MRP4 by 
APAP-CYS was of a competitive nature (Burlingham and Widlanski, 2003).  That APAP-
NAC did not manifest inhibition was surprising considering the structural resemblance it 
shares with APAP-CYS (Figure 5.1).  Yet, APAP-GSH, which has a longer side chain 
compared to APAP-NAC and would potentially have greater steric hindrance, was able 
to inhibit LTC4 transport by 29% inhibition at 300 µM.  The results show the high 
specificity and discretionary recognition by MRP4 of closely related chemical entities.  
Inhibition by APAP-GSH is intriguing in light of the fact that it is a major metabolite 
stemming from sequestration of the highly reactive APAP intermediate NAPQI (Mitchell 
et al., 1973; Moore et al., 1985). 
Akin to APAP-GSH, DCF and two of its main metabolites produced inhibition of MRP4 
with DCF-AG achieving 34% inhibition.  The DCF inhibition was not surprising as a 
209 
 
previous investigation established that DCF was able to inhibit the MRP4-mediated 
uptake of methotrexate (El-Sheikh et al., 2007).  In that study, DCF was found to 
possess a two-site affinity with IC50 values of 326 and 0.006 µM for the high and low site, 
respectively.  Since DCF only achieved 22% for the current study, the difference in 
potency is likely reflective of substrate selection.  MRP4 inhibition by DCF parent and 
metabolites may have physiological ramifications.  Studies point to MRP4 being an 
efflux transporter for PGE2 (Reid et al., 2003b).  In light of PGE2’s role in promoting cell 
survival and repair (Takeuchi, 2014), abrogation of its efflux could interfere with 
localized signaling in response to DCF-induced injury.  It should be noted that the 
concentrations chosen for the in vitro inhibition were physiologically relevant as they 
reflect the in vivo metabolite concentrations observed in prior animal studies (Chen et 
al., 2003; Manautou et al., 2005; Scialis et al., 2015). 
To summarize our findings, we report that Mrp4 mRNA expression was induced after a 
single toxic dose of APAP, and that induction was maximal at 12 hours.  ALT, as a 
marker of hepatic injury, was also elevated.  Also, we show that human MRP4 function 
was inhibited by APAP metabolites with APAP-CYS achieving an apparent IC50 that is 
physiologically relevant.  We believe these findings demonstrate the intricate balance 
between compensatory transporter upregulation due to xenobiotic intoxication and the 
possible deleterious effects that xenobiotics continue to exert in the form of their 
circulating metabolites. 
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Chapter 6 SUMMARY 
DCF is a non-steroidal anti-inflammatory drug that has been used for the past several 
decades to treat a variety of conditions such as arthritis, pain, and migraine (Novartis, 
2011; Depomed, 2014).  In the United States, DCF is available only by prescription, and 
it is normally tolerated by a majority of patients.  However, patient compliance with DCF 
treatment can become problematic owing to ADRs such as gastrointestinal bleeding, 
perforation, and ulceration.  In these cases, patients are alternatively prescribed a 
combination of DCF with misoprostol which can significantly lessen the occurrence of GI 
injury (Reyes-Garcia et al., 2007; Pfizer, 2014). 
DCF has been extensively studied for its pharmacology, pharmacokinetics, and 
metabolism (Menasse et al., 1978; Riess et al., 1978; Tang et al., 1999; Kenny et al., 
2004).  DCF has nearly 100% absorption after oral dosing due to its high passive 
uptake (Kalgutkar and Daniels, 2010).  DCF undergoes extensive first-pass hepatic 
metabolism resulting in approximately 50% bioavailability in humans.  Among the 
primary metabolites generated by the liver are hydroxylated metabolites (4ʹ-OH-DCF, 5-
OH-DCF, 4ʹ,5-(OH)2-DCF, 3ʹ-OH-DCF, 3ʹ,4ʹ-(OH)2-DCF) and conjugated metabolites 
(acyl glucuronides, ether glucuronides, hydroxylated acyl glucuronides, sulfated 
conjugates, and taurine conjugates).  Many of these metabolites have been 
characterized using animal models (Stierlin and Faigle, 1979; Stierlin et al., 1979; 
Pickup et al., 2012; Sarda et al., 2012).  Despite the notion that metabolism serves to 
detoxify the body of xenobiotics, in the case of DCF, biotransformation leads to the 
creation of reactive metabolites that can potentially cause injury.  The 4ʹ-OH-DCF and 5-
OH-DCF metabolites undergo rearrangement to form quinone imines which can adduct 
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proteins via covalent binding.  These quinone imines can be neutralized by 
sequestration with glutathione that is present in millimolar concentrations in the liver 
(Kaplowitz, 1981).  In general, depletion of hepatic glutathione without subsequent 
replenishment may result in oxidative stress and hepatocellular damage (Grewal and 
Racz, 1993; Rafeiro et al., 1994; Hinson et al., 2010).  Biotransformation of DCF also 
results in production of the reactive metabolite diclofenac acyl glucuronide which was a 
major focus of the work presented herein. 
The reactive nature of DCF-AG has been the subject of intense investigation.  DCF-AG 
had been previously shown to covalently adduct to a number of hepatic proteins and 
enzymes such as albumin, Mg2+-ATPase, and dipeptidyl peptidase IV (Hargus et al., 
1995; Sallustio and Holbrook, 2001; Kenny et al., 2004), an enzyme that has emerged 
as a pharmacological target in the treatment of diabetes (Rohrborn et al., 2015).  An 
early study reported that though DCF-AG can covalently bind to hepatic proteins, DCF-
AG itself did not appear to contribute to hepatotoxicity in vitro (Kretz-Rommel and 
Boelsterli, 1993).  In contrast, a follow-up study indicated DCF-AG could directly 
mediate intestinal injury in vivo.  Specifically, rats that were administered DCF-AG 
exhibited greater intestinal damage, in terms of ulcer number and length, compared to 
rats that received an equimolar dose of DCF (Seitz and Boelsterli, 1998).  In that same 
study, it was determined that mutant rats lacking the efflux transporter Mrp2 had less 
intestinal injury compared to rats that expressed Mrp2.  The reduction in intestinal injury 
was from reduced canalicular excretion of DCF-AG from the liver into bile, a transport 
process mediated by Mrp2 (Seitz et al., 1998).  These studies were significant as they 
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demonstrated that transporters were able to modulate toxicity after exposure to a single 
DCF dose. 
Based on the earlier work with mutant Mrp2 rats, we chose to investigate if other efflux 
transporters were operative in the transport of DCF or its metabolites.  Our preliminary 
studies used mouse models in which either breast cancer resistance protein (Bcrp) or 
Mrp3 was genetically knocked out (Chapter 2).  Whereas the loss of Bcrp led to a 
reduction in DCF biliary excretion in KO mice compared to WT, there was no 
concomitant increase in KO plasma DCF concentrations.  On the other hand, a marginal 
decrease of biliary DCF-AG excretion in KO led to increased DCF-AG plasma in KO 
relative to WT, and this trend was observed at two subtoxic doses of DCF (Figure 2.1 
and Figure 2.2).  Overall the data conclusively indicate that both DCF and DCF-AG are 
Bcrp substrates with perhaps OH-DCF also being a Bcrp substrate based on the results 
from the 10 mg/kg DCF dose.  The results from the Mrp3 study were more profound.  
Mrp3 KO mice had reduced DCF-AG plasma concentrations compared to WT mice, yet 
there were no differences in the DCF-AG biliary excretions between WT and KO (Figure 
2.4 and Figure 2.5).  Neither DCF nor OH-DCF had any differences between WT and 
KO in plasma concentrations or biliary excretion signifying that neither are Mrp3 
substrates.  Analysis of terminal liver concentrations did not reveal any accumulation of 
DCF-AG in WT, Bcrp KO, or Mrp3 KO mice (Figure 2.6).  Whereas loss of the 
canalicular efflux transporter Bcrp affected both biliary and plasma disposition of DCF-
AG, the deletion of the basolateral efflux transporter Mrp3 impacted only plasma DCF-
AG concentrations.  Taken together, our results were consistent with the published 
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findings of Bcrp- and Mrp3-mediated transport of DCF-AG (Lagas et al., 2009; Lagas et 
al., 2010). 
That Bcrp and Mrp3 were carriers of DCF-AG was not surprising given their roles in 
mediating the efflux of glucuronide conjugates derived from other compounds 
(Kawabata et al., 2001; Nakatomi et al., 2001; Manautou et al., 2005; Zamek-
Gliszczynski et al., 2009).  While loss of Mrp3 resulted in decreased plasma 
concentrations of acetaminophen glucuronide and 4-methylumbelliferyl glucuronide 
along with increased biliary excretion for those two respective glucuronides (Manautou 
et al., 2005; Zamek-Gliszczynski et al., 2006b), there was no corresponding elevation in 
KO biliary levels for DCF-AG despite WT mice having nearly 10-fold higher plasma 
concentrations compared to KO.  Our data with Mrp3 implied that only basolateral 
excretion of DCF-AG was affected by Mrp3 deletion, and that the function or expression 
of Mrp3 did not affect biliary disposition of DCF-AG.  Our finding is not an anomaly in 
light of the evidence provided for the Mrp3 substrates fexofenadine and hydeoxycholate 
glucuronide for which only basolateral excretion was significantly decreased in Mrp3 KO 
animals while biliary efflux was comparable between WT and KO for both fexofenadine 
and hydeoxycholate glucuronide (Zelcer et al., 2006; Tian et al., 2008). 
As our studies provided evidence that Mrp3 can modulate DCF-AG disposition in vivo 
with mouse knockout models, we next sought to determine the affinity of DCF-AG for 
human MRP3.  For these studies, we used commercially available MRP3 inside-out 
vesicles where substrate affinity was measured by quantifying the transport of probe 
into the vesicles and subsequently compared to the transport activity of human MRP2 
vesicles.  The comparison to MRP2 was important as MRP2 has been shown to 
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modulate DCF-induced toxicity as well as DCF-AG disposition in humans and rodents.  
For instance, human subjects with reduced MRP2 expression were associated with 
greater hepatotoxicity during DCF treatment while rats lacking hepatic Mrp2 were 
refractory to intestinal injury following treatment with DCF (Seitz and Boelsterli, 1998; 
Daly et al., 2007).  We observed that MRP3 has an apparent high affinity and low 
affinity binding site for DCF-AG (Figure 2.11).  The low affinity site exhibited comparable 
transporter kinetics as calculated for the MRP2-mediated transport of DCF-AG.  The 
high affinity MRP3 site implies that at low DCF-AG concentrations, transport of DCF-AG 
is likely to be dominated by MRP3 relative to MRP2.  To summarize this part of our work, 
the mouse in vivo studies and human in vitro experiments indicated that MRP3/Mrp3 
has a major role in the disposition of DCF-AG. 
With Mrp3 transport of DCF-AG firmly established, our next aim was to find out whether 
deletion of Mrp3 leads to increased hepatocellular or intestinal injury (Chapter 3).  To 
accomplish our goals, we used WT and Mrp3 KO mice and administered a single toxic 
dose of 90 mg/kg DCF.  The selected dose was the highest tolerated DCF dose that did 
not result in morbidity.  Clinical chemistry analysis using serum markers of liver injury 
did not reveal any obvious damage to either WT or KO livers (Figure 3.3).  In contrast to 
our results, Lagas et al. (2010) reported elevated ALT levels suggestive of mild hepatic 
injury after a 25 mg/kg DCF dose.  The difference between our study and that of Lagas 
is likely due to the triple knockout mouse model (Bcrp/Mrp2/Mrp3) they used, which is 
expected to be more susceptible to injury due to a heavily compromised hepatobiliary 
transport capacity (Kock and Brouwer, 2012).  Histopathological examination in our 
studies showed no gross hepatic injury despite the presence of intense covalent DCF 
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adducts (Figure 3.5).  The lack of hepatocellular injury in our mouse in vivo studies may 
be explained by less oxidative metabolism of DCF in mouse compared to human.  Our 
toxicokinetic experiment showed that hydroxylated metabolites accounted for a small 
fraction of overall DCF metabolism (Figure 3.1), with DCF-AG and other conjugates 
being the predominant metabolites identified in the bile (Figure 2.7 and Figure 2.8).  
Hepatotoxicity in human hepatocytes following DCF exposure was revealed to be 
dependent on CYP450-mediated generation of 5-OH-DCF and N,5-(OH)2-DCF (Bort et 
al., 1999b).  In addition, repeated dosing may be necessary for immune-mediated 
hepatic injury following DCF exposure.  The rationale for this argument stems from the 
work by Aithal et al. (2004) in which antibodies taken from human patients presenting 
with hepatotoxicity as a result of DCF treatment recognized the hepatic covalent 
adducts in rats that received daily dosing of 30 mg/kg DCF.  However, the same human 
antisera failed to recognize hepatic adducts in rats that were given a single 200 mg/kg 
DCF dose.  We conclude therefore that Mrp3 deletion does not lead to increased 
hepatotoxicity following acute exposure to DCF. 
As Mrp3 is also expressed in the mouse gastrointestinal tract (Zelcer et al., 2006), we 
examined the extent of GI injury after a toxic DCF dose.  Compared to WT mice, the 
intestines of KO mice exhibited profound damage in terms of ulcer count and overall 
inflammation (Figure 3.4.).  Interestingly, the level of covalent adduction in KO intestines 
determined through immunohistochemistry was not commensurate with injury.  In fact, 
both WT and KO appeared to have the same level of intestinal covalent adducts despite 
the finding that KO mice had more injury compared to WT (Figure 3.5).  The apparent 
disconnect between injury and adduct formation led us to the conclusion that covalent 
216 
 
adducts of xenobiotics merely indicate the presence of reactive species, and that their 
presence and intensity is not a direct indicator of the degree in tissue damage.  In short, 
covalent adduction is just a byproduct of metabolism and not an overt contributor to 
injury on an acute basis.  Disregarding the covalent adduct aspect for a moment, the 
functional expression of Mrp3 served to protect the GI supported by the mild injury 
observed in WT mice while the loss of Mrp3 was met by significant injury in KO animals.  
Given the preponderance of data linking DCF-AG to Mrp3-mediated transport, we 
believe that the increased intestinal injury in KO mice was due to altered DCF-AG 
disposition and that DCF-AG was contributory toward intestinal enteropathy.  Since 
MRP3 is known to be expressed along the human GI tract (Groer et al., 2013; Drozdzik 
et al., 2014), the presumed protection afforded by Mrp3 in our mouse model may be 
applicable to humans as well.  Permutation to MRP3 function or expression due to 
genetic polymorphisms, of which many are known to exist for MRP3 (Kobayashi et al., 
2008; Sasaki et al., 2011), may render certain patient populations more susceptible to 
GI injury during the course of treatment with DCF. 
The intense covalent adducts detected in mouse livers is understandable given that the 
liver was the primary site of DCF-AG synthesis.  Adduct formation in the GI tract was 
more intriguing.  Certainly brush border adduction would be likely to occur given that 
DCF-AG would naturally come into contact with that part of the villi during transit in the 
gut lumen.  The brush border staining we observed was consistent with what was 
reported in rats that were administered DCF (Atchison et al., 2000b).  We became 
curious how adducts could form so deep in the villi.  Endocytosis of adducted plasma 
membrane protein was a possibility, though our investigation lead us to the belief that 
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active uptake of DCF-AG was also an option.  To examine if this could be the case, we 
used stably transfected cells to characterize DCF-AG uptake by a major intestinal 
transporter (Chapter 4).  Based on the expression of likely uptake transporter 
candidates, we focused our efforts on OATP2B1 which is expressed both in the human 
GI tract as well as mice intestines (Hagenbuch and Meier, 2004; Cheng et al., 2005). 
To determine the extent of OATP2B1-mediated uptake of DCF-AG, a two-
compartmental model was used.  This same approach was also used to characterize 
OATP-mediated uptake in transfected cells and primary hepatocytes (Poirier et al., 
2008; Menochet et al., 2012; Pfeifer et al., 2013).  The advantage to using such a model 
is that it allows for estimates of active and passive processes, and the models can be 
adapted to utilize and fit data over a range of time rather than be limited to a single time 
point as used in traditional transporter kinetic studies.  Our studies indicated that DCF-
AG uptake by OATP2B1 was concentration-dependent and that uptake activity was 
higher at pH 6.0 compared to pH 7.4 (Figure 4.2).  The acidic nature of the intestinal 
lumen would partially stabilize DCF-AG, which hydrolyzes more readily at pH 7.4 
(Supplement 2), and potentially enhance its uptake by OATP2B1 at pH 6.0.  With DCF-
AG uptake into enterocytes plausibly explained by OATP2B1 activity, we next 
determined the potential for DCF-AG to directly induce injury. 
Our cytotoxicity studies with DCF-AG demonstrated that not only could DCF-AG cause 
cell death, but that it induced greater cell death compared to an equimolar concentration 
of DCF (Figure 4.3).  The cytotoxicity results were in line with the observations of Seitz 
and Boelsterli (1998) who reported that DCF-AG elicited greater GI injury than DCF in 
vivo.  Furthermore, cell death was brought on fairly early and occurred within 3 hours of 
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exposure to DCF-AG.  To resolve the mechanism of the cytotoxicity, we examined the 
potential for DCF-AG to induce reactive oxygen species and found that DCF-AG indeed 
caused ROS to increase in a dose-dependent manner with onset occurring after 1 hour 
(Figure 4.4).  In comparison, DCF was reported to promote ROS generation at much 
later time points (Lim et al., 2006).  The presence of ROS was important as it indicated 
that DCF-AG could create a state of oxidative stress.  As suprofen acyl glucuronide was 
purported to inhibit superoxide dismutase (Chiou et al., 1999), a key cellular defense 
against oxidative stress, we examined if DCF-AG also inhibits SOD.  We report that 
DCF-AG exemplified a clear dose-dependent inhibition of SOD whereas DCF showed 
either no effect or stimulation of SOD (Figure 4.5).  Lastly, we examined if DCF-AG had 
inherent pharmacology against cyclooxygenases as this has not been fully explored.  
Our in vitro assays repeatedly demonstrated that DCF-AG possesses the ability to 
inhibit both COX-1 and COX-2, and that the inhibition leads to decreased synthesis of 
prostaglandin E2 from arachidonic acid.  Considering the role PGE2 has in protecting the 
GI tract and that inhibition of both COX enzymes is necessary for intestinal injury to 
develop (Tanaka et al., 2001; Sigthorsson et al., 2002; Hoshino et al., 2003; Kotani et 
al., 2006), DCF-AG modulation of COX activity may have exacerbated the GI injury 
normally ascribed to DCF.  Ostensibly, we believe our studies demonstrate that DCF-
AG directly contributed to enteropathy in our in vivo models via active uptake by mouse 
Oatp2b1 resulting in enhanced cytotoxicity in Mrp3 KO animals, due to decreased 
basolateral excretion (and greater enterocyte retention) from the combined effects of 
ROS generation, SOD inhibition, and attenuation of the PGE2-derived protection of the 
intestinal tract. 
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The last aspect of our work focused on the upregulation of Mrp4 during oxidative stress 
and the potential for inhibition of human MRP4 by analgesics and/or their metabolites 
(Chapter 5).  Induction of Mrp4 was shown to occur after toxic doses of APAP were 
given to mice (Aleksunes et al., 2008b; Campion et al., 2008).  Mrp4 transcriptional 
regulation appeared to be causally linked to hepatic injury, as assessed by serum ALT 
levels, after toxic APAP administration in mice (Figure 5.2).  MRP4 activity in the 
presence of APAP, APAP metabolites, DCF, and DCF metabolites was characterized 
using human MRP4 inside-out vesicles.  Our study indicated that APAP-CYS and DCF-
AG were able to significantly inhibit MRP4 activity, with APAP-CYS having an IC50 of 
125 µM and DCF-AG achieving 34% inhibition at 300 µM (Figure 5.4).  The inhibition of 
these two metabolites is physiologically relevant in that both metabolites are present, 
following toxic doses of their respective parent compounds, at concentrations matching 
their inhibitory potencies (Chen et al., 2003; Manautou et al., 2005; Scialis et al., 2015).  
Since Mrp4 is upregulated in response to oxidative stress, which can occur following 
toxic challenge by APAP or DCF (Moore et al., 1985; Lim et al., 2006), inhibition of 
MRP4/Mrp4 may further promote injury by limiting the ability to excrete toxic agents. 
In conclusion, our collective work offers conclusive evidence that the disposition of 
DCF-AG is modulated not only by MRP2/Mrp2, but also by MRP3/Mrp3, Bcrp, and 
OATP2B1.  Furthermore, we determined that Mrp3 serves a protective role against 
injury by DCF-AG, and that loss of Mrp3 results in increased susceptibility to GI damage.  
The enteropathy observed in our mouse studies was the result of the multi-factorial 
mechanisms through which DCF-AG can induce harm, namely induction of oxidative 
stress through generation of ROS, inhibition of SOD, cell death, and the combined 
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effects of COX-1 and COX-2 inhibition resulting in the diminished protection by PGE2.  
We also demonstrate that DCF-AG can inhibit MRP4, which is normally upregulated in 
response to oxidative stress and is involved in PGE2 signaling.  The results of our 
studies represent novel findings and offer insight into the roles that DCF-AG has in 
enteropathy.  Subsequent studies should focus on identifying patient populations at risk 
of GI injury from DCF-AG as a result of diminished MRP3 function so that alternative 
treatment can be prescribed. 
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Chapter 7 APPENDIX 
Supplement 1 Stability of DCF-AG in mouse S9 fraction without co-factors at 
37 °C 
 
The metabolic stability of 1 µM DCF-AG in the presence of 1 mg/mL mouse S9 fraction 
at pH 7.4 is shown.  Incubations were conducted at 37 °C using S9 without NADPH, 
GSH, or UDPGA.  Loss of DCF-AG is reflective by spontaneous hydrolysis as well as 
the activity of endogenous hepatic esterases.  The estimated t1/2 was 14.5 ± 0.6 min.  
Dotted lines reflect the 95% confidence intervals of the fit (solid line).  Each point 
reflects the mean ± standard error of the mean of n=4 measurements from two separate 
experiments. 
 
 
 
 
0 1 0 2 0 3 0 4 0
2 .0
2 .5
3 .0
3 .5
4 .0
4 .5
5 .0
T im e  (m in )
ln
(%
 R
e
m
a
in
in
g
)
222 
 
Supplement 2 Stability of DCF-AG at various pH levels 
 
The aqueous stability of 1 µM DCF-AG at various pH levels and 37 °C is shown.  The 
pH values reflect the conditions utilized for several of the in vitro assays described 
throughout the thesis.  The pH value of 2.7 represents the acidity in 0.1% formic acid 
that was used for sample preparation and LC/MS/MS analysis.  The lines reflect the 
best fit for the indicated pH.  Each point reflects the mean ± standard error of the mean 
from n=2 measurements from two separate studies. 
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Supplement 3 Time-dependent uptake of DCF-AG by HEK-OATP cells 
 
The time-dependent uptake of 10 µM DCF-AG from media by stably-transfected HEK 
cells is shown.  The dashed line reflects the initial buffer DCF-AG concentration of 10 
µM and demonstrates that OATPs can increase intracellular DCF-AG concentrations to 
levels greater than initial buffer conditions.  Each point reflects the mean ± standard 
error of the mean of n=3 measurements. 
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Supplement 4 Basal transporter expression in C57BL/6J male mouse liver 
 
The basal transporter expression in the livers of male C57BL/6J mice is shown.  
Expression profiles were detected using a bDNA assay.  Data are expressed as relative 
light units (RLU) per 10 µg RNA.  Each bar reflects the mean ± standard error of the 
mean of n=4 subjects. 
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